PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 7/02, 7/04, 15/48, C12Q 1/68, 1/70, A61K 39/21

A1

(11) International Publication Number: WO 95/21912

(43) International Publication Date: 17 August 1995 (17.08.95)

(21) International Application Number: PCT/AU95/00063

(22) International Filing Date: 14 February 1995 (14.02.95)

(30) Priority Data:

PM 3864	14 February 1994 (14.02.94)	AU
PM 4002	21 February 1994 (21.02.94)	AU
PN 0284	23 December 1994 (23.12.94)	AU

(71) Applicants *(for all designated States except US)*: THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH LIMITED [AU/AU]; Yarra Bend Road, Fairfield, VIC 3078 (AU). AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION) [AU/AU]; 153 Clarence Street, Sydney, NSW 2000 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DEACON, Nicholas, John [AU/AU]; 51 Elliott Avenue, Balwyn, VIC 3105 (AU). LEARMONT, Jennifer, Catherine [AU/AU]; 88 Patongo Street, Patongo, NSW 2256 (AU). McPHEE, Dale, Alan [AU/AU]; 14 Freeman Street, Fitzroy, VIC 3065 (AU). CROWE, Suzanne [AU/AU]; 1 Palermo Street, South Yarra, VIC 3141 (AU). COOPER, David [AU/AU]; 7 Carrington Avenue, Bellvue Hill, NSW 2023 (AU).

(74) Agents: HUGHES, E. John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.

(54) Title: NON-PATHOGENIC STRAINS OF HIV-1



(57) Abstract

The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular regions of the HIV-1 genome.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgystan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LI	Liechtenstein
LK	Sri Lanka
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SI	Slovenia
SK	Slovakia
SN	Senegal
TD	Chad
TG	Togo
TJ	Tajikistan
TT	Trinidad and Tobago
UA	Ukraine
US	United States of America
UZ	Uzbekistan
VN	Viet Nam

BNSDOCID: <WO___9521912A1_I_>

NON-PATHOGENIC STRAINS OF HIV-1

The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular regions of the HIV-1 genome.

Bibliographic details of the publications referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Genomic nucleotide sequences of HIV-1 strains referred to herein are represented by their corresponding DNA sequence.

Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the PHLS Centre for Applied Microbiology and Research, European Collection of Animal Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4 OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession Number V941031169. Viral isolate "C54" was deposited at ECACC on 14 February, 1995 under Provisional Accession Number _____.

A summary of particular deletion mutants of HIV-1 of the present invention referred to herein is given in Figure 11.

Acquired Immune Deficiency Syndrome (AIDS) and AIDS related disorders are the clinical result of infection by Human Immunodeficiency Virus type I (HIV-1) (Barre-Sinoussi *et al*, 1983). Infection by HIV-1 is generally characterised by progressive immune system damage (Teeuwsen *et al*, 1990; Clerici *et al*, 1989) leading to opportunistic infections, malignancies or wasting syndrome that constitute clinically-defined AIDS (Busch *et al*, 1991; Klaslow *et al*, 1990).

The high mortality rate of individuals infected with HIV-1 together with the social and economic consequences of the continuing HIV-1 epidemic has created an urgent need for a safe and effective treatment and/or prophylaxis against the devastating effects of AIDS. However, despite over a decade of high level scientific research into the pathogenesis of HIV-1 and the clinical manifestations of the disease, together with a detailed molecular analysis of the virus, there has been little success in the development of an effective vaccine. To date, the most effective therapy is treatment with zidovudine (AZT) which delays the onset of full blown AIDS and alleviates to some extent the symptoms of HIV-1 infection. However, AZT is not an innocuous compound and AZT, metabolic products thereof or impurities therein can cause a number of side effects which limit long term treatment with the drug. Furthermore, AZT resistant isolates have been reported during treatment. Clearly, therefore, a need exists to develop alternative strategies in preventing and treating HIV-1 infection.

The initial phases of HIV-1 infection are summarised by Levy (1993) as involving attachment, fusion and nucleocapsid entry. These phases have been the traditional foci in research into development of antiviral strategies. The molecular events at the virus genomic level have also been the subject of intense scientific research with an aim being the development of a live attenuated vaccine as a possible approach for the treatment or prophylaxis of HIV-1 infection.

BNSDOCID: <WO___9521912A1_I_>

There is a high variable rate of progression from initial HIV-1 infection to AIDS which reflects a rapidly changing pathogen and variable immune response of the host to infection (Sheppard *et al*, 1993). With regards to the latter, HIV-1 can be considered as a heterogenous group of viruses differing at the genetic level with concomitant variable pathogenicity. For example, HIV-1 strains can differ in their capacity to kill cells. Furthermore, it appears that HIV-1 strains evolve in a host after infection and that the evolution varies depending on the tissues infected by the virus. The major sites in the genome apparently responsible for biological and pathological variation are the highly variable envelope region (Cheng-Mayer *et al*, 1991; Shioda *et al*, 1992; Hwang, *et al* 1991; Sullivan *et al*, 1993; Groenink *et al*, 1993) and the viral regulatory regions such as *tat* (Leguern *et al*, 1993). The genetic complexity of the HIV-1 group of viruses together with their variable pathogenicity, are major difficulties in the development of live vaccines, genetic vaccines or component vaccines.

Notwithstanding the highly pathogenic nature of HIV-1, there are some reports of long term survival of subjects infected with the virus (Learmont *et al*, 1992; Levy, 1993; Sheppard *et al*, 1993; Lifson *et al* 1991). It is not always clear, however, whether a benign course following HIV-1 infection is due to host factors, viral factors or other unknown factors. There are reports that most infected people have at least laboratory evidence of progressive immune system damage in the form of CD4+ cell loss (Lang *et al*, 1989) and defective immune responses (Clerici *et al*, 1989).

Although simian monkeys have been used as an *in vivo* model for HIV and Simian Immunodeficiency Virus (SIV) infection, a major handicap in AIDS research has been the absence of suitable *in vivo* models to study the pathogenesis of the disease and, in particular, to study the viruses involved in benign infection. The need for a suitable *in vivo* model is heightened by the fact that results obtained *in vitro* cannot necessarily be extrapolated to what occurs *in vivo*. This was clearly observed by Mosier *et al* (1993) where conflicting results were obtained in animals compared to cell cultures.

Despite the absence of suitable *in vivo* models, considerable scientific research has been directed to attenuating HIV-1 strains by mutagenesis of the virus genome. Deletions in the *nef* gene have been implicated in attenuated strains of SIV and their use in providing protective effects in monkeys (Daniel *et al*, 1992). However, there are conflicting reports on the possible negative influence the *nef* gene product has on the rate or extent of virus replication (Terwilliger *et al*, 1986; Luciw *et al*, 1987; Niederman *et al*, 1989; Kim *et al*, 1989; Hammes *et al*, 1989). In fact, Kim *et al* (1989) found that *nef* did not affect HIV-1 replication or HIV-1 long terminal repeat (LTR)-driven CAT expression. Kestler III *et al* (1991) found that the *nef* gene is required for full pathogenic potential in SIV. However, such is the complexity of the HIV-1 group of viruses and the variability of immune responses between individuals let alone different species, that it is far from clear whether *nef* deleted strains of HIV-1 would behave similarly to *nef* deleted strains of SIV-I. There is a need, therefore, in order to investigate the possibility of *nef* deleted HIV-1 strain as a vaccine candidate, to identify individuals infected with such modified viruses.

Learmont *et al* (1992) reported that a cohort of five persons infected with blood products from a single HIV-1 infected donor have remained asymptomatic from up to about 10-14 years after infection. Subsequently, a sixth person has been identified as being part of the cohort. Both the donor and recipients were HIV-1 seropositive but with no indications of clinical symptoms of HIV-1 related disease and CD4+ cell number and β_2-microglobulin levels have remained in the normal range. The identification of this cohort of benignly infected individuals provides a unique *in vivo* model in which the pathogenesis of HIV-1 infection can be studied at the clinical and molecular biological levels.

However, it has not always possible using conventional isolation procedures to routinely and reproducibly isolate viral strains from the above mentioned donor or recipients which has frustrated efforts to investigate the cause of the asymptomatic individuals. In accordance with the present invention, methods have now been established to isolate viruses from the above individuals. It has been determined, in accordance with the

BNSDOCID: <WO___9521912A1_I_>

present invention, that the six individuals of the cohort are infected by non-pathogenic strains of HIV-1. Furthermore, the non-pathogenic strains of HIV-1 carry one or more nucleotide mutations. The non-pathogenic strains of the present invention enable the generation of a range of therapeutic, diagnostic and targeting agents against HIV-1 infection. The present invention also enables the attenuation of previously pathogenic strains of HIV-1.

Accordingly, one aspect of the present invention contemplates a non-pathogenic isolate of HIV-1 or a component, part, fragment or derivative thereof.

In a related embodiment, there is provided a novel isolate of HIV-1 or a component, part, fragment or derivative thereof wherein said HIV-1 isolate is capable of stimulating in a human or primate subject an immune response such as a humoral immune response to at least one HIV-1 glycoprotein such as but not limited to gp41-45, gp120 and/or gp160 while not substantially reducing in said human or primate subject proliferative responses and cytokine production to a mitogen, alloantigen and/or recall antigen compared to a healthy, non-infected human or primate subject. Preferably, the cytokine is IL-2. Preferably, the mitogen is ConA or PHA and the recall antigen is influenza or tetanus toxoid. Preferably, the HIV-1 isolate is non-pathogenic.

More particularly, the present invention relates to an isolated HIV-1 strain which:

(i) is substantially non-pathogenic in human subjects; and

(ii) carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one pathogenic HIV-1-derived polypeptide or protein.

Even more particularly, the present invention provides an isolated HIV-1 strain which:

(i) is substantially non-pathogenic in human subjects; and

(ii) carries a mutation in the *nef* gene and/or a long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

Still even more particularly, the present invention is directed to an isolated virus which:

(i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1;

(ii) is substantially non-pathogenic in human subjects;

(iii) carries one or more deletion mutations in a region of its genome corresponding to a *nef* gene in said pathogenic strain of HIV-1; and

(iv) optionally carries a mutation in one or both LTR regions.

In a related embodiment, there is provided an isolated virus which:

(i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1;

(ii) is substantially non-pathogenic in human subjects;

(iii) carries one or more deletion mutations in an LTR region of its genome; and

(iv) optionally carries a mutation in a region corresponding to a *nef* gene in said pathogenic strain of HIV-1.

In a further related embodiment, there is provided an isolated virus which:

(i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1;

(ii) is substantially non-pathogenic in human subjects; and

(iii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains *nef* coding sequences and LTR nucleotide sequences.

In a particularly preferred embodiment, the present invention provides non-pathogenic HIV-1 isolate C18 deposited at the ECACC on 17 October, 1994 under Provisional Accession Number V94101706.

In a related embodiment, the present invention provides non-pathogenic HIV-1 isolate C98 deposited at the ECACC on 31 October, 1994 under Provisional Accession Number V941031169.

In another embodiment, the present invention provides non-pathogenic HIV-1 isolate C54 deposited at ECACC on 14 February, 1995 under Provisional Accession No. _____.

Although pathogenicity is a relative term, it is used herein in relation to the capacity of a strain of HIV-1 to induce AIDS or AIDS-related disorders in an individual over time. Accordingly, a "non-pathogenic" strain of HIV-1 is a strain which, at the clinical level, does not lead to the development of AIDS, at least within the median time of 6-10 years following infection with HIV-1. At the laboratory level, a non-pathogenic strain of HIV-1 is considered not to alter CD4+ cell counts or β_2-microglobulin concentrations. In addition, a non-pathogenic strain of HIV-1 may not alter CD8+ and CD3+ cell counts and would not alter lymphocyte counts. CD4+:CD8+ ratios also remain unchanged relative to normal non-infected individuals. Furthermore, generally, a non-pathogenic strain of HIV-1 does not induce p24 antigenaemia. A non-pathogenic HIV-1 of the present invention is generally still infectious but individuals infected with the virus remain free of symptoms for at least 6-10 years after infection.

A laboratory classified non-pathogenic strain of HIV-1 may be determined at any time after infection. The term "non-pathogenic" is not to be considered as a strain that is never pathogenic under any conditions as this might depend on the host individual, the level of immune responsiveness in that individual and the extent or otherwise of other, for example, immune comprising disorders. Accordingly, a "non-pathogenic" HIV-1 isolate of the present invention may also be considered a "low virulent" strain of the virus. A non-pathogenic strain of HIV-1 as contemplated herein may be isolated from an asymptomatic individual or may be derived from a pathogenic strain by mutation. Although the present invention is not to be limited to any particular pathogenic strain of HIV-1, for reference purposes, an example of a pathogenic strain is HIV-1 NL4-3 strain as described by Myers *et al* (1992).

The non-pathogenic nature of the HIV-1 of the present invention is conveniently evidenced by the cohort of seven individuals comprising one donor and six recipients which have remained free of symptoms or signs of HIV-1 infection for greater than the median time of 6-10 years. However, the individuals of the cohort are seropositive for

HIV-1 following infection with the virus as determined by Western blot analysis and genetic analysis (e.g. using PCR techniques). A seropositive individual is one showing reactivity to at least one HIV-1 glycoprotein (such as but not limited to gp 41-45, gp120, gp160) and at least three other virus-specific bands.

In accordance with the present invention, a non-pathogenic HIV-1 isolate is also a strain of HIV-1 which:

(i) induces an immune response in a human or primate subject; and

(ii) does not substantially reduce proliferative responses or cytokine production to a mitogen, alloantigen and/or recall antigen relative to a healthy, non-infected subject.

Preferably, the immune response such as to a glycoprotein, for example gp41-45, gp120 and/or gp160. Preferably, the cytokine monitored is an interleukin, such as IL-2. Preferably, the recall antigen is influenza or tetanus toxoid. A non-pathogenic HIV-1 isolate is also one which:

(iii) does not substantially alter proliferative responses or cytokine production to allorgeneic mononuclear cells.

The genomes or complementary DNA therefrom of the non-pathogenic HIV-1 isolates of the present invention are capable of hybridising under medium stringency conditions to the corresponding genome or complementary DNA of a pathogenic strain of HIV-1 (e.g. HIV-1 strain NL4-3). The ability to hybridise to a pathogenic strain of HIV-1 only applies to a comparison of the entire genome/complementary DNA of a non-pathogenic strain or a fragment which includes genetic material corresponding to a region in the genome 3′ of the *nef* gene in a pathogenic strain of HIV-1.

For the purposes of reference only, a suitable genomic nucleotide sequence from a pathogenic HIV-1 strain is set forth in SEQ ID NO: 1 from HIV-1 strain NL4-3 (Myers *et al*, 1992):

```
  1 TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGG
 51 ATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGG
101 GCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTAC
```

```
 151 CAGTTGAACCAGAGCAAGTAGAAGAGGCCAAATAAGGAGAGAAGAACAGC
 201 TTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCGGAGGGAGAAGT
 251 ATTAGTGTGGAAGTTTGACAGCCTCCTAGCATTTCGTCACATGGCCCGAG
 301 AGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAG
 351 GGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTGG
 401 GGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGT
 451 ACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA
 501 ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCA
 551 AAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
 601 AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGG
 651 GACTTGAAAGCGAAAGTAAAGCCAGAGGAGATCTCTCGACGCAGGACTCG
 701 GCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTA
 751 CGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAG
 801 AGCGTCGGTATTAAGCGGGGGAGAATTAGATAAATGGGAAAAAATTCGGT
 851 TAAGGCCAGGGGGAAAGAAACAATATAAACTAAAACATATAGTATGGGCA
 901 AGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTTTTAGAGACATC
 951 AGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAG
1001 GATCAGAAGAACTTAGATCATTATATAATACAATAGCAGTCCTCTATTGT
1051 GTGCATCAAAGGATAGATGTAAAAGACACCAAGGAAGCCTTAGATAAGAT
1101 AGAGGAAGAGCAAAACAAAAGTAAGAAAAAGGCACAGCAAGCAGCAGCTG
1151 ACACAGGAAACAACAGCCAGGTCAGCCAAAATTACCCTATAGTGCAGAAC
1201 CTCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGC
1251 ATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTAATACCCA
1301 TGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAATACCATG
1351 CTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGAC
1401 CATCAATGAGGAAGCTGCAGAATGGGATAGATTGCATCCAGTGCATGCAG
1451 GGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCA
1501 GGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACACATAATCC
1551 ACCTATCCCAGTAGGAGAAATCTATAAAAGATGGATAATCCTGGGATTAA
1601 ATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAA
1651 GGACCAAAGGAACCCTTTAGAGACTATGTAGACCGATTCTATAAAACTCT
1701 AAGAGCCGAGCAAGCTTCACAAGAGGTAAAAAATTGGATGACAGAAACCT
1751 TGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTTAAAAGCATTG
1801 GGACCAGGAGCGACACTAGAAGAAATGATGACAGCATGTCAGGGAGTGGG
1851 GGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAA
1901 CAAATCCAGCTACCATAATGATACAGAAAGGCAATTTTAGGAACCAAAGA
1951 AAGACTGTTAAGTGTTTCAATTGTGGCAAAGAAGGGCACATAGCCAAAAA
2001 TTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGAC
```

2051 ACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATC
2101 TGGCCTTCCCACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAGA
2151 GCCAACAGCCCCACCAGAAGAGAGCTTCAGGTTTGGGGAAGAGACAACAA
2201 CTCCCTCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAGCT
2251 TCCCTCAGATCACTCTTTGGCAGCGACCCCTCGTCACAATAAAGATAGGG
2301 GGGCAATTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATT
2351 AGAAGAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAA
2401 TTGGAGGTTTTATCAAAGTAGGACAGTATGATCAGATACTCATAGAAATC
2451 TGCGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAA
2501 CATAATTGGAAGAAATCTGTTGACTCAGATTGGCTGCACTTTAAATTTTC
2551 CCATTAGTCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGAT
2601 GGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATT
2651 AGTAGAAATTTGTACAGAAATGGAAAAGGAAGGAAAAATTTCAAAAATTG
2701 GGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGAC
2751 AGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAAC
2801 TCAAGATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAA
2851 AACAGAAAAAATCAGTAACAGTACTGGATGTGGGCGATGCATATTTTTCA
2901 GTTCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAG
2951 TATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCAC
3001 AGGGATGGAAAGGATCACCAGCAATATTCCAGTGTAGCATGACAAAAATC
3051 TTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTCATCTATCAATACAT
3101 GGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAA
3151 AAATAGAGGAACTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCA
3201 GACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT
3251 CCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAGGACA
3301 GCTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAATTGGGCA
3351 AGTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAAACTTCTTAG
3401 GGGAACCAAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGC
3451 TAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCGGTACATGGAGTG
3501 TATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCA
3551 AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAA
3601 CAGGAAAATATGCAAGAATGAAGGGTGCCCACACTAATGATGTGAAACAA
3651 TTAACAGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGG
3701 AAAGACTCCTAAATTTAAATTACCCATACAAAAGGAAACATGGGAAGCAT
3751 GGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTC
3801 AATACCCCTCCCTTAGTGAAGTTATGGTACCAGTTAGAGAAAGAACCCAT
3851 AATAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCCAATAGGGAAACTA
3901 AATTAGGAAAAGCAGGATATGTAACTGACAGAGGAAGACAAAAAGTTGTC

3951 CCCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCT
4001 AGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAAT
4051 ATGCATTGGGAATCATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTA
4101 GTCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAAGTCTACCTGGC
4151 ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATGGGT
4201 TGGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAG
4251 GCCCAAGAAGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAG
4301 TGATTTTAACCTACCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTG
4351 ATAAATGTCAGCTAAAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGC
4401 CCAGGAATATGGCAGCTAGATTGTACACATTTAGAAGGAAAAGTTATCTT
4451 GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTAATTCCAG
4501 CAGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGAAGA
4551 TGGCCAGTAAAAACAGTACATACAGACAATGGCAGCAATTTCACCAGTAC
4601 TACAGTTAAGGCCGCCTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCA
4651 TTCCCTACAATCCCCAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAA
4701 TTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGAC
4751 AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGA
4801 TTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGAC
4851 ATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCG
4901 GGTTTATTACAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGC
4951 TCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGACATA
5001 AAAGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTATGGAAAACA
5051 GATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAACACA
5101 TGGAAAAGATTAGTAAAACACCATATGTATATTTCAAGGAAAGCTAAGGA
5151 CTGGTTTTATAGACATCACTATGAAAGTACTAATCCAAAAATAAGTTCAG
5201 AAGTACACATCCCACTAGGGGATGCTAAATTAGTAATAACAACATATTGG
5251 GGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCAT
5301 AGAATGGAGGAAAAAGAGATATAGCACACAAGTAGACCCTGACCTAGCAG
5351 ACCAACTAATTCATCTGCACTATTTTGATTGTTTTTCAGAATCTGCTATA
5401 AGAAATACCATATTAGGACGTATAGTTAGTCCTAGGTGTGAATATCAAGC
5451 AGGACATAACAAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAA
5501 TAAAACCAAAACAGATAAAGCCACCTTTGCCTAGTGTTAGGAAACTGACA
5551 GAGGACAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCA
5601 TACAATGAATGGACACTAGAGCTTTTAGAGGAACTTAAGAGTGAAGCTGT
5651 TAGACATTTTCCTAGGATATGGCTCCATAACTTAGGACAACATATCTATG
5701 AAACTTACGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTG
5751 CAACAACTGCTGTTTATCCATTTCAGAATTGGGTGTCGACATAGCAGAAT
5801 AGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGA

5851 CTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAA
5901 TTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATGACAA
5951 AAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGA
6001 GCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATCAAAGCAGTAAGT
6051 AGTACATGTAATGCAACCTATAATAGTAGCAATAGTAGCATTAGTAGTAG
6101 CAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGG
6151 AAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAATAGA
6201 AAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAGTATCAGCACTTG
6251 TGGAGATGGGGGTGGAAATGGGGCACCATGCTCCTTGGGATATTGATGAT
6301 CTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTG
6351 TGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCA
6401 TATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCAC
6451 AGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTA
6501 ACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGT
6551 TTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGT
6601 TAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTA
6651 GCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAAT
6701 ATCAGCACAAGCATAAGAGATAAGGTGCAGAAAGAATATGCATTCTTTTA
6751 TAAACTTGATATAGTACCAATAGATAATACCAGCTATAGGTTGATAAGTT
6801 GTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCA
6851 ATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAA
6901 TAATAAGACGTTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTAC
6951 AATGTACACATGGAATCAGGCCAGTAGTATCAACTCAACTGCTGTTAAAT
7001 GGCAGTCTAGCAGAAGAAGATGTAGTAATTAGATCTGCCAATTTCACAGA
7051 CAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATT
7101 GTACAAGACCCAACAACAATACAAGAAAAAGTATCCGTATCCAGAGGGGA
7151 CCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGC
7201 ACATTGTAACATTAGTAGAGCAAAATGGAATGCCACTTTAAAACAGATAG
7251 CTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAG
7301 CAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGG
7351 AGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGT
7401 TTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGAC
7451 ACAATCACACTCCCATGCAGAATAAAACAATTTATAAACATGTGGCAGGA
7501 AGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTT
7551 CATCAAATATTACTGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC
7601 AATGGGTCCGAGATCTTCAGACCTGGAGGAGGCGATATGAGGGACAATTG
7651 GAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAG
7701 TAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCA

7751 GTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCAC
7801 TATGGGCTGCACGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGT
7851 CTGATATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAA
7901 CAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAACAGCTCCAGGCAAG
7951 AATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTT
8001 GGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCT
8051 AGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATAACATGACCTGGAT
8101 GGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAA
8151 TTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAA
8201 TTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCT
8251 GTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAA
8301 GAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATAT
8351 TCACCATTATCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAG
8401 GCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCA
8451 TTCGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCGGAGC
8501 CTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAAC
8551 GAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATT
8601 GGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTT
8651 AACTTGCTCAATGCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGT
8701 TATAGAAGTATTACAAGCAGCTTATAGAGCTATTCGCCACATACCTAGAA
8751 GAATAAGACAGGGCTTGGAAAGGATTTTGCTATAAGATGGGTGGCAAGTG
8801 GTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAATGAGAC
8851 GAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAA
8901 AAACATGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTG
8951 TGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACAC
9001 CTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGC
9051 CACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAG
9101 AAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCC
9151 CTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACC
9201 TTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGA
9251 GGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATG
9301 GAATGGATGACCCTGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGC
9351 CTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAA
9401 CTGCTGACATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAG
9451 GGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGC
9501 ATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGA
9551 TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT
9601 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTG

9651 TGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAA
9701 TCTCTAGCA

However, for the purposes of comparing the nucleotide sequences of non-pathogenic HIV-1 strains including the ability to hybridise to a reference strain, the present invention extends to a genomic nucleotide sequence from any pathogenic strain of HIV-1.

Accordingly, in a particularly preferred embodiment, there is provided a viral isolate which:

(i) carries a genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1; and

(ii) carries a deletion mutation in a region corresponding to the *nef* gene and/or in an LTR region. Generally, such an HIV-1 isolate is non-pathogenic as hereinbefore defined.

In a related embodiment, there is provided an isolated virus which:

(i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1; and

(ii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains *nef* coding sequences and LTR nucleotide sequences.

For the purposes of defining the level of stringency, reference can conveniently be made to Maniatis *et al* (1982) at pages 387-389 which is herein incorporated by reference where the washing steps disclosed are considered high stringency. A low stringency is defined herein as being in 1-3X SSC/0.1-0.5% w/v SDS at 37-50°C for 2-3 hours. Depending on the source and concentration of nucleic acid involved in the hybridisation, alternative conditions of stringency may be employed such as medium stringent conditions which are considered herein to be 0.1-1X SSC/0.25-0.5% w/v SDS at ≥ 45°C for 2-3 hours or high stringent conditions considered herein to be 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours.

In a particularly preferred embodiment of the present invention, the non-pathogenic strain of HIV-1 carries a mutation in the *nef* gene and/or LTR region of the genome.

A "mutation" is considered herein to include a single or multiple nucleotide substitution, deletion and/or addition. Most preferred mutations are single or multiple deletions of at least one, most preferably at least ten and even more preferably at least twenty contiguous nucleotides from a region corresponding to the *nef* gene and/or the LTR region. When the non-pathogenic virus carries a mutation in the LTR region, this generally occurs 5′ of the Sp1 sites.

According to a preferred aspect of the present invention, there is provided a viral isolate which:

(i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gp120 and/or gp160;

(ii) is substantially non-pathogenic in human subjects; and

(iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the *nef* gene and/or LTR region of a pathogenic strain of HIV-1.

In another embodiment, there is provided a viral isolate which:

(i) is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*;

(ii) is substantially non-pathogenic in human subjects; and

(iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the *nef* gene and/or LTR region of a pathogenic strain of HIV-1.

Preferably, in respect of the latter embodiment, the immune response is an antibody or a cell mediated response. In a most preferred embodiment, the immune response is a humoral immune response.

The nucleotide sequence of the *nef* gene in HIV-1 NL4-3 is defined in SEQ ID NO: 650:

ATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAAT
GAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAAC
ATGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAA

GCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAAT
GACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAG
GGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAA
GGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGAC
CTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATA
AAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAG
AGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGA
GCTGCATCCGGAGTACTTCAAGAACTGCTGA

The present invention extends to any or all single or multiple nucleotide deletions to a contiguous series of at least ten nucleotides from the *nef* gene which render the strain avirulent. The deletions may encompass the entire gene or parts thereof and may represent a single deletion or two or more deletions. Put in alternative terms, the non-pathogenic HIV-1 isolates of the present invention comprise a nucleotide sequence at the corresponding *nef* gene region non-identifiable to SEQ ID NO: 650, said non-identity comprising at least 5%, more preferably at least 10% and even more preferably at least 20% variation thereon.

In a preferred embodiment, therefore, the present invention contemplates a viral isolate which:

(i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gp120 and/or gp160;

(ii) carries a genome or a part or fragment thereof capable of hybridising under medium stringency conditions to a nucleotide sequence as set forth in SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1;

(iii) carries a deletion of at least ten nucleotides in a region corresponding to the *nef* gene in HIV-1 NL4-3; and

wherein said deletion encompasses one or more of the following decanucleotides from the *nef* gene of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1:

ATGGGTGGCA(SEQ ID NO: 2); TGGGTGGCAA(SEQ ID NO: 3);
GGGTGGCAAG(SEQ ID NO: 4); GGTGGCAAGT(SEQ ID NO: 5);
GTGGCAAGTG(SEQ ID NO: 6); TGGCAAGTGG(SEQ ID NO: 7);

GGCAAGTGGT(SEQ ID NO: 8); GCAAGTGGTC(SEQ ID NO: 9);
CAAGTGGTCA(SEQ ID NO: 10); AAGTGGTCAA(SEQ ID NO: 11);
AGTGGTCAAA(SEQ ID NO: 12); GTGGTCAAAA(SEQ ID NO: 13);
TGGTCAAAAA(SEQ ID NO: 14); GGTCAAAAAG(SEQ ID NO: 15);
GTCAAAAAGT(SEQ ID NO: 16); TCAAAAAGTA(SEQ ID NO: 17);
CAAAAAGTAG(SEQ ID NO: 18); AAAAAGTAGT(SEQ ID NO: 19);
AAAAGTAGTG(SEQ ID NO: 20); AAAGTAGTGT(SEQ ID NO: 21);
AAGTAGTGTG(SEQ ID NO: 22); AGTAGTGTGA(SEQ ID NO: 23);
GTAGTGTGAT(SEQ ID NO: 24); TAGTGTGATT(SEQ ID NO: 25);
AGTGTGATTG(SEQ ID NO: 26); GTGTGATTGG(SEQ ID NO: 27);
TGTGATTGGA(SEQ ID NO: 28); GTGATTGGAT(SEQ ID NO: 29);
TGATTGGATG(SEQ ID NO: 30); GATTGGATGG(SEQ ID NO: 31);
ATTGGATGGC(SEQ ID NO: 32); TTGGATGGCC(SEQ ID NO: 33);
TGGATGGCCT(SEQ ID NO: 34); GGATGGCCTG(SEQ ID NO: 35);
GATGGCCTGC(SEQ ID NO: 36); ATGGCCTGCT(SEQ ID NO: 37);
TGGCCTGCTG(SEQ ID NO: 38); GGCCTGCTGT(SEQ ID NO: 39);
GCCTGCTGTA(SEQ ID NO: 40); CCTGCTGTAA(SEQ ID NO: 41);
CTGCTGTAAG(SEQ ID NO: 42); TGCTGTAAGG(SEQ ID NO: 43);
GCTGTAAGGG(SEQ ID NO: 44); CTGTAAGGGA(SEQ ID NO: 45);
TGTAAGGGAA(SEQ ID NO: 46); GTAAGGGAAA(SEQ ID NO: 47);
TAAGGGAAAG(SEQ ID NO: 48); AAGGGAAAGA(SEQ ID NO: 49);
AGGGAAAGAA(SEQ ID NO: 50); GGGAAAGAAT(SEQ ID NO: 51);
GGAAAGAATG(SEQ ID NO: 52); GAAAGAATGA(SEQ ID NO: 53);
AAAGAATGAG(SEQ ID NO: 54); AAGAATGAGA(SEQ ID NO: 55);
AGAATGAGAC(SEQ ID NO: 56); GAATGAGACG(SEQ ID NO: 57);
AATGAGACGA(SEQ ID NO: 58); ATGAGACGAG(SEQ ID NO: 59);
TGAGACGAGC(SEQ ID NO: 60); GAGACGAGCT(SEQ ID NO: 61);
AGACGAGCTG(SEQ ID NO: 62); GACGAGCTGA(SEQ ID NO: 63);
ACGAGCTGAG(SEQ ID NO: 64); CGAGCTGAGC(SEQ ID NO: 65);
GAGCTGAGCC(SEQ ID NO: 66); AGCTGAGCCA(SEQ ID NO: 67);
GCTGAGCCAG(SEQ ID NO: 68); CTGAGCCAGC(SEQ ID NO: 69);
TGAGCCAGCA(SEQ ID NO: 70); GAGCCAGCAG(SEQ ID NO: 71);
AGCCAGCAGC(SEQ ID NO: 72); GCCAGCAGCA(SEQ ID NO: 73);
CCAGCAGCAG(SEQ ID NO: 74); CAGCAGCAGA(SEQ ID NO: 75);
AGCAGCAGAT(SEQ ID NO: 76); GCAGCAGATG(SEQ ID NO: 77);
CAGCAGATGG(SEQ ID NO: 78); AGCAGATGGG(SEQ ID NO: 79);
GCAGATGGGG(SEQ ID NO: 80); CAGATGGGGT(SEQ ID NO: 81);
AGATGGGGTG(SEQ ID NO: 82); GATGGGGTGG(SEQ ID NO: 83);

ATGGGGTGGG(SEQ ID NO: 84); TGGGGTGGGA(SEQ ID NO: 85);
GGGGTGGGAG(SEQ ID NO: 86); GGGTGGGAGC(SEQ ID NO: 87);
GGTGGGAGCA(SEQ ID NO: 88); GTGGGAGCAG(SEQ ID NO: 89);
TGGGAGCAGT(SEQ ID NO: 90); GGGAGCAGTA(SEQ ID NO: 91);
GGAGCAGTAT(SEQ ID NO: 92); GAGCAGTATC(SEQ ID NO: 93);
AGCAGTATCT(SEQ ID NO: 94); GCAGTATCTC(SEQ ID NO: 95);
CAGTATCTCG(SEQ ID NO: 96); AGTATCTCGA(SEQ ID NO: 97);
GTATCTCGAG(SEQ ID NO: 98); TATCTCGAGA(SEQ ID NO: 99);
ATCTCGAGAC(SEQ ID NO: 100); TCTCGAGACC(SEQ ID NO: 101);
CTCGAGACCT(SEQ ID NO: 102); TCGAGACCTA(SEQ ID NO: 103);
CGAGACCTAG(SEQ ID NO: 104); GAGACCTAGA(SEQ ID NO: 105);
AGACCTAGAA(SEQ ID NO: 106); GACCTAGAAA(SEQ ID NO: 107);
ACCTAGAAAA(SEQ ID NO: 108); CCTAGAAAAA(SEQ ID NO: 109);
CTAGAAAAAC(SEQ ID NO: 110); TAGAAAAACA(SEQ ID NO: 111);
AGAAAAACAT(SEQ ID NO: 112); GAAAAACATG(SEQ ID NO: 113);
AAAAACATGG(SEQ ID NO: 114); AAAACATGGA(SEQ ID NO: 115);
AAACATGGAG(SEQ ID NO: 116); AACATGGAGC(SEQ ID NO: 117);
ACATGGAGCA(SEQ ID NO: 118); CATGGAGCAA(SEQ ID NO: 119);
ATGGAGCAAT(SEQ ID NO: 120); TGGAGCAATC(SEQ ID NO: 121);
GGAGCAATCA(SEQ ID NO: 122); GAGCAATCAC(SEQ ID NO: 123);
AGCAATCACA(SEQ ID NO: 124); GCAATCACAA(SEQ ID NO: 125);
CAATCACAAG(SEQ ID NO: 126); AATCACAAGT(SEQ ID NO: 127);
ATCACAAGTA(SEQ ID NO: 128); TCACAAGTAG(SEQ ID NO: 129);
CACAAGTAGC(SEQ ID NO: 130); ACAAGTAGCA(SEQ ID NO: 131);
CAAGTAGCAA(SEQ ID NO: 132); AAGTAGCAAT(SEQ ID NO: 133);
AGTAGCAATA(SEQ ID NO: 134); GTAGCAATAC(SEQ ID NO: 135);
TAGCAATACA(SEQ ID NO: 136); AGCAATACAG(SEQ ID NO: 137);
GCAATACAGC(SEQ ID NO: 138); CAATACAGCA(SEQ ID NO: 139);
AATACAGCAG(SEQ ID NO: 140); ATACAGCAGC(SEQ ID NO: 141);
TACAGCAGCT(SEQ ID NO: 142); ACAGCAGCTA(SEQ ID NO: 143);
CAGCAGCTAA(SEQ ID NO: 144); AGCAGCTAAC(SEQ ID NO: 145);
GCAGCTAACA(SEQ ID NO: 146); CAGCTAACAA(SEQ ID NO: 147);
AGCTAACAAT(SEQ ID NO: 148); GCTAACAATG(SEQ ID NO: 149);
CTAACAATGC(SEQ ID NO: 150); TAACAATGCT(SEQ ID NO: 151);
AACAATGCTG(SEQ ID NO: 152); ACAATGCTGC(SEQ ID NO: 153);
CAATGCTGCT(SEQ ID NO: 154); AATGCTGCTT(SEQ ID NO: 155);
ATGCTGCTTG(SEQ ID NO: 156); TGCTGCTTGT(SEQ ID NO: 157);
GCTGCTTGTG(SEQ ID NO: 158); CTGCTTGTGC(SEQ ID NO: 159);

TGCTTGTGCC(SEQ ID NO: 160); GCTTGTGCCT(SEQ ID NO: 161);
CTTGTGCCTG(SEQ ID NO: 162); TTGTGCCTGG(SEQ ID NO: 163);
TGTGCCTGGC(SEQ ID NO: 164); GTGCCTGGCT(SEQ ID NO: 165);
TGCCTGGCTA(SEQ ID NO: 166); GCCTGGCTAG(SEQ ID NO: 167);
CCTGGCTAGA(SEQ ID NO: 168); CTGGCTAGAA(SEQ ID NO: 169);
TGGCTAGAAG(SEQ ID NO: 170); GGCTAGAAGC(SEQ ID NO: 171);
GCTAGAAGCA(SEQ ID NO: 172); CTAGAAGCAC(SEQ ID NO: 173);
TAGAAGCACA(SEQ ID NO: 174); AGAAGCACAA(SEQ ID NO: 175);
GAAGCACAAG(SEQ ID NO: 176); AAGCACAAGA(SEQ ID NO: 177);
AGCACAAGAG(SEQ ID NO: 178); GCACAAGAGG(SEQ ID NO: 179);
CACAAGAGGA(SEQ ID NO: 180); ACAAGAGGAG(SEQ ID NO: 181);
CAAGAGGAGG(SEQ ID NO: 182); AAGAGGAGGA(SEQ ID NO: 183);
AGAGGAGGAA(SEQ ID NO: 184); GAGGAGGAAG(SEQ ID NO: 185);
AGGAGGAAGA(SEQ ID NO: 186); GGAGGAAGAG(SEQ ID NO: 187);
GAGGAAGAGG(SEQ ID NO: 188); AGGAAGAGGT(SEQ ID NO: 189);
GGAAGAGGTG(SEQ ID NO: 190); GAAGAGGTGG(SEQ ID NO: 191);
AAGAGGTGGG(SEQ ID NO: 192); AGAGGTGGGT(SEQ ID NO: 193);
GAGGTGGGTT(SEQ ID NO: 194); AGGTGGGTTT(SEQ ID NO: 195);
GGTGGGTTTT(SEQ ID NO: 196); GTGGGTTTTC(SEQ ID NO: 197);
TGGGTTTTCC(SEQ ID NO: 198); GGGTTTTCCA(SEQ ID NO: 199);
GGTTTTCCAG(SEQ ID NO: 200); GTTTTCCAGT(SEQ ID NO: 201);
TTTTCCAGTC(SEQ ID NO: 202); TTTCCAGTCA(SEQ ID NO: 203);
TTCCAGTCAC(SEQ ID NO: 204); TCCAGTCACA(SEQ ID NO: 205);
CCAGTCACAC(SEQ ID NO: 206); CAGTCACACC(SEQ ID NO: 207);
AGTCACACCT(SEQ ID NO: 208); GTCACACCTC(SEQ ID NO: 209);
TCACACCTCA(SEQ ID NO: 210); CACACCTCAG(SEQ ID NO: 211);
ACACCTCAGG(SEQ ID NO: 212); CACCTCAGGT(SEQ ID NO: 213);
ACCTCAGGTA(SEQ ID NO: 214); CCTCAGGTAC(SEQ ID NO: 215);
CTCAGGTACC(SEQ ID NO: 216); TCAGGTACCT(SEQ ID NO: 217);
CAGGTACCTT(SEQ ID NO: 218); AGGTACCTTT(SEQ ID NO: 219);
GGTACCTTTA(SEQ ID NO: 220); GTACCTTTAA(SEQ ID NO: 221);
TACCTTTAAG(SEQ ID NO: 222); ACCTTTAAGA(SEQ ID NO: 223);
CCTTTAAGAC(SEQ ID NO: 224); CTTTAAGACC(SEQ ID NO: 225);
TTTAAGACCA(SEQ ID NO: 226); TTAAGACCAA(SEQ ID NO: 227);
TAAGACCAAT(SEQ ID NO: 228); AAGACCAATG(SEQ ID NO: 229);
AGACCAATGA(SEQ ID NO: 230); GACCAATGAC(SEQ ID NO: 231);
ACCAATGACT(SEQ ID NO: 232); CCAATGACTT(SEQ ID NO: 233);
CAATGACTTA(SEQ ID NO: 234); AATGACTTAC(SEQ ID NO: 235);

ATGACTTACA(SEQ ID NO: 236); TGACTTACAA(SEQ ID NO: 237);
GACTTACAAG(SEQ ID NO: 238); ACTTACAAGG(SEQ ID NO: 239);
CTTACAAGGC(SEQ ID NO: 240); TTACAAGGCA(SEQ ID NO: 241);
TACAAGGCAG(SEQ ID NO: 242); ACAAGGCAGC(SEQ ID NO: 243);
CAAGGCAGCT(SEQ ID NO: 244); AAGGCAGCTG(SEQ ID NO: 245);
AGGCAGCTGT(SEQ ID NO: 246); GGCAGCTGTA(SEQ ID NO: 247);
GCAGCTGTAG(SEQ ID NO: 248); CAGCTGTAGA(SEQ ID NO: 249);
AGCTGTAGAT(SEQ ID NO: 250); GCTGTAGATC(SEQ ID NO: 251);
CTGTAGATCT(SEQ ID NO: 252); TGTAGATCTT(SEQ ID NO: 253);
GTAGATCTTA(SEQ ID NO: 254); TAGATCTTAG(SEQ ID NO: 255);
AGATCTTAGC(SEQ ID NO: 256); GATCTTAGCC(SEQ ID NO: 257);
ATCTTAGCCA(SEQ ID NO: 258); TCTTAGCCAC(SEQ ID NO: 259);
CTTAGCCACT(SEQ ID NO: 260); TTAGCCACTT(SEQ ID NO: 261);
TAGCCACTTT(SEQ ID NO: 262); AGCCACTTTT(SEQ ID NO: 263);
GCCACTTTTT(SEQ ID NO: 264); CCACTTTTTA(SEQ ID NO: 265);
CACTTTTTAA(SEQ ID NO: 266); ACTTTTTAAA(SEQ ID NO: 267);
CTTTTTAAAA(SEQ ID NO: 268); TTTTTAAAAG(SEQ ID NO: 269);
TTTTAAAAGA(SEQ ID NO: 270); TTTAAAAGAA(SEQ ID NO: 271);
TTAAAAGAAA(SEQ ID NO: 272); TAAAAGAAAA(SEQ ID NO: 273);
AAAAGAAAAG(SEQ ID NO: 274); AAAGAAAAGG(SEQ ID NO: 275);
AAGAAAAGGG(SEQ ID NO: 276); AGAAAAGGGG(SEQ ID NO: 277);
GAAAAGGGGG(SEQ ID NO: 278); AAAAGGGGGG(SEQ ID NO: 279);
AAAGGGGGGA(SEQ ID NO: 280); AAGGGGGGAC(SEQ ID NO: 281);
AGGGGGGACT(SEQ ID NO: 282); GGGGGGACTG(SEQ ID NO: 283);
GGGGGACTGG(SEQ ID NO: 284); GGGGACTGGA(SEQ ID NO: 285);
GGGACTGGAA(SEQ ID NO: 286); GGACTGGAAG(SEQ ID NO: 287);
GACTGGAAGG(SEQ ID NO: 288); ACTGGAAGGG(SEQ ID NO: 289);
CTGGAAGGGC(SEQ ID NO: 290); TGGAAGGGCT(SEQ ID NO: 291);
GGAAGGGCTA(SEQ ID NO: 292); GAAGGGCTAA(SEQ ID NO: 293);
AAGGGCTAAT(SEQ ID NO: 294); AGGGCTAATT(SEQ ID NO: 295);
GGGCTAATTC(SEQ ID NO: 296); GGCTAATTCA(SEQ ID NO: 297);
GCTAATTCAC(SEQ ID NO: 298); CTAATTCACT(SEQ ID NO: 299);
TAATTCACTC(SEQ ID NO: 300); AATTCACTCC(SEQ ID NO: 301);
ATTCACTCCC(SEQ ID NO: 302); TTCACTCCCA(SEQ ID NO: 303);
TCACTCCCAA(SEQ ID NO: 304); CACTCCCAAA(SEQ ID NO: 305);
ACTCCCAAAG(SEQ ID NO: 306); CTCCCAAAGA(SEQ ID NO: 307);
TCCCAAAGAA(SEQ ID NO: 308); CCCAAAGAAG(SEQ ID NO: 309);
CCAAAGAAGA(SEQ ID NO: 310); CAAAGAAGAC(SEQ ID NO: 311);

AAAGAAGACA(SEQ ID NO: 312); AAGAAGACAA(SEQ ID NO: 313);
AGAAGACAAG(SEQ ID NO: 314); GAAGACAAGA(SEQ ID NO: 315);
AAGACAAGAT(SEQ ID NO: 316); AGACAAGATA(SEQ ID NO: 317);
GACAAGATAT(SEQ ID NO: 318); ACAAGATATC(SEQ ID NO: 319);
CAAGATATCC(SEQ ID NO: 320); AAGATATCCT(SEQ ID NO: 321);
AGATATCCTT(SEQ ID NO: 322); GATATCCTTG(SEQ ID NO: 323);
ATATCCTTGA(SEQ ID NO: 324); TATCCTTGAT(SEQ ID NO: 325);
ATCCTTGATC(SEQ ID NO: 326); TCCTTGATCT(SEQ ID NO: 327);
CCTTGATCTG(SEQ ID NO: 328); CTTGATCTGT(SEQ ID NO: 329);
TTGATCTGTG(SEQ ID NO: 330); TGATCTGTGG(SEQ ID NO: 331);
GATCTGTGGA(SEQ ID NO: 332); ATCTGTGGAT(SEQ ID NO: 333);
TCTGTGGATC(SEQ ID NO: 334); CTGTGGATCT(SEQ ID NO: 335);
TGTGGATCTA(SEQ ID NO: 336); GTGGATCTAC(SEQ ID NO: 337);
TGGATCTACC(SEQ ID NO: 338); GGATCTACCA(SEQ ID NO: 339);
GATCTACCAC(SEQ ID NO: 340); ATCTACCACA(SEQ ID NO: 341);
TCTACCACAC(SEQ ID NO: 342); CTACCACACA(SEQ ID NO: 343);
TACCACACAC(SEQ ID NO: 344); ACCACACACA(SEQ ID NO: 345);
CCACACACAA(SEQ ID NO: 346); CACACACAAG(SEQ ID NO: 347);
ACACACAAGG(SEQ ID NO: 348); CACACAAGGC(SEQ ID NO: 349);
ACACAAGGCT(SEQ ID NO: 350); CACAAGGCTA(SEQ ID NO: 351);
ACAAGGCTAC(SEQ ID NO: 352); CAAGGCTACT(SEQ ID NO: 353);
AAGGCTACTT(SEQ ID NO: 354); AGGCTACTTC(SEQ ID NO: 355);
GGCTACTTCC(SEQ ID NO: 356); GCTACTTCCC(SEQ ID NO: 357);
CTACTTCCCT(SEQ ID NO: 358); TACTTCCCTG(SEQ ID NO: 359);
ACTTCCCTGA(SEQ ID NO: 360); CTTCCCTGAT(SEQ ID NO: 361);
TTCCCTGATT(SEQ ID NO: 362); TCCCTGATTG(SEQ ID NO: 363);
CCCTGATTGG(SEQ ID NO: 364); CCTGATTGGC(SEQ ID NO: 365);
CTGATTGGCA(SEQ ID NO: 366); TGATTGGCAG(SEQ ID NO: 367);
GATTGGCAGA(SEQ ID NO: 368); ATTGGCAGAA(SEQ ID NO: 369);
TTGGCAGAAC(SEQ ID NO: 370); TGGCAGAACT(SEQ ID NO: 371);
GGCAGAACTA(SEQ ID NO: 372); GCAGAACTAC(SEQ ID NO: 373);
CAGAACTACA(SEQ ID NO: 374); AGAACTACAC(SEQ ID NO: 375);
GAACTACACA(SEQ ID NO: 376); AACTACACAC(SEQ ID NO: 377);
ACTACACACC(SEQ ID NO: 378); CTACACACCA(SEQ ID NO: 379);
TACACACCAG(SEQ ID NO: 380); ACACACCAGG(SEQ ID NO: 381);
CACACCAGGG(SEQ ID NO: 382); ACACCAGGGC(SEQ ID NO: 383);
CACCAGGGCC(SEQ ID NO: 384); ACCAGGGCCA(SEQ ID NO: 385);
CCAGGGCCAG(SEQ ID NO: 386); CAGGGCCAGG(SEQ ID NO: 387);

AGGGCCAGGG(SEQ ID NO: 388); GGGCCAGGGG(SEQ ID NO: 389);
GGCCAGGGGT(SEQ ID NO: 390); GCCAGGGGTC(SEQ ID NO: 391);
CCAGGGGTCA(SEQ ID NO: 392); CAGGGGTCAG(SEQ ID NO: 393);
AGGGGTCAGA(SEQ ID NO: 394); GGGGTCAGAT(SEQ ID NO: 395);
GGGTCAGATA(SEQ ID NO: 396); GGTCAGATAT(SEQ ID NO: 397);
GTCAGATATC(SEQ ID NO: 398); TCAGATATCC(SEQ ID NO: 399);
CAGATATCCA(SEQ ID NO: 400); AGATATCCAC(SEQ ID NO: 401);
GATATCCACT(SEQ ID NO: 402); ATATCCACTG(SEQ ID NO: 403);
TATCCACTGA(SEQ ID NO: 404); ATCCACTGAC(SEQ ID NO: 405);
TCCACTGACC(SEQ ID NO: 406); CCACTGACCT(SEQ ID NO: 407);
CACTGACCTT(SEQ ID NO: 408); ACTGACCTTT(SEQ ID NO: 409);
CTGACCTTTG(SEQ ID NO: 410); TGACCTTTGG(SEQ ID NO: 411);
GACCTTTGGA(SEQ ID NO: 412); ACCTTTGGAT(SEQ ID NO: 413);
CCTTTGGATG(SEQ ID NO: 414); CTTTGGATGG(SEQ ID NO: 415);
TTTGGATGGT(SEQ ID NO: 416); TTGGATGGTG(SEQ ID NO: 417);
TGGATGGTGC(SEQ ID NO: 418); GGATGGTGCT(SEQ ID NO: 419);
GATGGTGCTA(SEQ ID NO: 420); ATGGTGCTAC(SEQ ID NO: 421);
TGGTGCTACA(SEQ ID NO: 422); GGTGCTACAA(SEQ ID NO: 423);
GTGCTACAAG(SEQ ID NO: 424); TGCTACAAGC(SEQ ID NO: 425);
GCTACAAGCT(SEQ ID NO: 426); CTACAAGCTA(SEQ ID NO: 427);
TACAAGCTAG(SEQ ID NO: 428); ACAAGCTAGT(SEQ ID NO: 429);
CAAGCTAGTA(SEQ ID NO: 430); AAGCTAGTAC(SEQ ID NO: 431);
AGCTAGTACC(SEQ ID NO: 432); GCTAGTACCA(SEQ ID NO: 433);
CTAGTACCAG(SEQ ID NO: 434); TAGTACCAGT(SEQ ID NO: 435);
AGTACCAGTT(SEQ ID NO: 436); GTACCAGTTG(SEQ ID NO: 437);
TACCAGTTGA(SEQ ID NO: 438); ACCAGTTGAG(SEQ ID NO: 439);
CCAGTTGAGC(SEQ ID NO: 440); CAGTTGAGCC(SEQ ID NO: 441);
AGTTGAGCCA(SEQ ID NO: 442); GTTGAGCCAG(SEQ ID NO: 443);
TTGAGCCAGA(SEQ ID NO: 444); TGAGCCAGAT(SEQ ID NO: 445);
GAGCCAGATA(SEQ ID NO: 446); AGCCAGATAA(SEQ ID NO: 447);
GCCAGATAAG(SEQ ID NO: 448); CCAGATAAGG(SEQ ID NO: 449);
CAGATAAGGT(SEQ ID NO: 450); AGATAAGGTA(SEQ ID NO: 451);
GATAAGGTAG(SEQ ID NO: 452); ATAAGGTAGA(SEQ ID NO: 453);
TAAGGTAGAA(SEQ ID NO: 454); AAGGTAGAAG(SEQ ID NO: 455);
AGGTAGAAGA(SEQ ID NO: 456); GGTAGAAGAG(SEQ ID NO: 457);
GTAGAAGAGG(SEQ ID NO: 458); TAGAAGAGGC(SEQ ID NO: 459);
AGAAGAGGCC(SEQ ID NO: 460); GAAGAGGCCA(SEQ ID NO: 461);
AAGAGGCCAA(SEQ ID NO: 462); AGAGGCCAAT(SEQ ID NO: 463);

GAGGCCAATA(SEQ ID NO: 464); AGGCCAATAA(SEQ ID NO: 465);
GGCCAATAAA(SEQ ID NO: 466); GCCAATAAAG(SEQ ID NO: 467);
CCAATAAAGG(SEQ ID NO: 468); CAATAAAGGA(SEQ ID NO: 469);
AATAAAGGAG(SEQ ID NO: 470); ATAAAGGAGA(SEQ ID NO: 471);
TAAAGGAGAG(SEQ ID NO: 472); AAAGGAGAGA(SEQ ID NO: 473);
AAGGAGAGAA(SEQ ID NO: 474); AGGAGAGAAC(SEQ ID NO: 475);
GGAGAGAACA(SEQ ID NO: 476); GAGAGAACAC(SEQ ID NO: 477);
AGAGAACACC(SEQ ID NO: 478); GAGAACACCA(SEQ ID NO: 479);
AGAACACCAG(SEQ ID NO: 480); GAACACCAGC(SEQ ID NO: 481);
AACACCAGCT(SEQ ID NO: 482); ACACCAGCTT(SEQ ID NO: 483);
CACCAGCTTG(SEQ ID NO: 484); ACCAGCTTGT(SEQ ID NO: 485);
CCAGCTTGTT(SEQ ID NO: 486); CAGCTTGTTA(SEQ ID NO: 487);
AGCTTGTTAC(SEQ ID NO: 488); GCTTGTTACA(SEQ ID NO: 489);
CTTGTTACAC(SEQ ID NO: 490); TTGTTACACC(SEQ ID NO: 491);
TGTTACACCC(SEQ ID NO: 492); GTTACACCCT(SEQ ID NO: 493);
TTACACCCTG(SEQ ID NO: 494); TACACCCTGT(SEQ ID NO: 495);
ACACCCTGTG(SEQ ID NO: 496); CACCCTGTGA(SEQ ID NO: 497);
ACCCTGTGAG(SEQ ID NO: 498); CCCTGTGAGC(SEQ ID NO: 499);
CCTGTGAGCC(SEQ ID NO: 500); CTGTGAGCCT(SEQ ID NO: 501);
TGTGAGCCTG(SEQ ID NO: 502); GTGAGCCTGC(SEQ ID NO: 503);
TGAGCCTGCA(SEQ ID NO: 504); GAGCCTGCAT(SEQ ID NO: 505);
AGCCTGCATG(SEQ ID NO: 506); GCCTGCATGG(SEQ ID NO: 507);
CCTGCATGGA(SEQ ID NO: 508); CTGCATGGAA(SEQ ID NO: 509);
TGCATGGAAT(SEQ ID NO: 510); GCATGGAATG(SEQ ID NO: 511);
CATGGAATGG(SEQ ID NO: 512); ATGGAATGGA(SEQ ID NO: 513);
TGGAATGGAT(SEQ ID NO: 514); GGAATGGATG(SEQ ID NO: 515);
GAATGGATGA(SEQ ID NO: 516); AATGGATGAC(SEQ ID NO: 517);
ATGGATGACC(SEQ ID NO: 518); TGGATGACCC(SEQ ID NO: 519);
GGATGACCCT(SEQ ID NO: 520); GATGACCCTG(SEQ ID NO: 521);
ATGACCCTGA(SEQ ID NO: 522); TGACCCTGAG(SEQ ID NO: 523);
GACCCTGAGA(SEQ ID NO: 524); ACCCTGAGAG(SEQ ID NO: 525);
CCCTGAGAGA(SEQ ID NO: 526); CCTGAGAGAG(SEQ ID NO: 527);
CTGAGAGAGA(SEQ ID NO: 528); TGAGAGAGAA(SEQ ID NO: 529);
GAGAGAGAAG(SEQ ID NO: 530); AGAGAGAAGT(SEQ ID NO: 531);
GAGAGAAGTG(SEQ ID NO: 532); AGAGAAGTGT(SEQ ID NO: 533);
GAGAAGTGTT(SEQ ID NO: 534); AGAAGTGTTA(SEQ ID NO: 535);
GAAGTGTTAG(SEQ ID NO: 536); AAGTGTTAGA(SEQ ID NO: 537);
AGTGTTAGAG(SEQ ID NO: 538); GTGTTAGAGT(SEQ ID NO: 539);

TGTTAGAGTG(SEQ ID NO: 540); GTTAGAGTGG(SEQ ID NO: 541);
TTAGAGTGGA(SEQ ID NO: 542); TAGAGTGGAG(SEQ ID NO: 543);
AGAGTGGAGG(SEQ ID NO: 544); GAGTGGAGGT(SEQ ID NO: 545);
AGTGGAGGTT(SEQ ID NO: 546); GTGGAGGTTT(SEQ ID NO: 547);
TGGAGGTTTG(SEQ ID NO: 548); GGAGGTTTGA(SEQ ID NO: 549);
GAGGTTTGAC(SEQ ID NO: 550); AGGTTTGACA(SEQ ID NO: 551);
GGTTTGACAG(SEQ ID NO: 552); GTTTGACAGC(SEQ ID NO: 553);
TTTGACAGCC(SEQ ID NO: 554); TTGACAGCCG(SEQ ID NO: 555);
TGACAGCCGC(SEQ ID NO: 556); GACAGCCGCC(SEQ ID NO: 557);
ACAGCCGCCT(SEQ ID NO: 558); CAGCCGCCTA(SEQ ID NO: 559);
AGCCGCCTAG(SEQ ID NO: 560); GCCGCCTAGC(SEQ ID NO: 561);
CCGCCTAGCA(SEQ ID NO: 562); CGCCTAGCAT(SEQ ID NO: 563);
GCCTAGCATT(SEQ ID NO: 564); CCTAGCATTT(SEQ ID NO: 565);
CTAGCATTTC(SEQ ID NO: 566); TAGCATTTCA(SEQ ID NO: 567);
AGCATTTCAT(SEQ ID NO: 568); GCATTTCATC(SEQ ID NO: 569);
CATTTCATCA(SEQ ID NO: 570); ATTTCATCAC(SEQ ID NO: 571);
TTTCATCACG(SEQ ID NO: 572); TTCATCACGT(SEQ ID NO: 573);
TCATCACGTG(SEQ ID NO: 574); CATCACGTGG(SEQ ID NO: 575);
ATCACGTGGC(SEQ ID NO: 576); TCACGTGGCC(SEQ ID NO: 577);
CACGTGGCCC(SEQ ID NO: 578); ACGTGGCCCG(SEQ ID NO: 579);
CGTGGCCCGA(SEQ ID NO: 580); GTGGCCCGAG(SEQ ID NO: 581);
TGGCCCGAGA(SEQ ID NO: 582); GGCCCGAGAG(SEQ ID NO: 583);
GCCCGAGAGC(SEQ ID NO: 584); CCCGAGAGCT(SEQ ID NO: 585);
CCGAGAGCTG(SEQ ID NO: 586); CGAGAGCTGC(SEQ ID NO: 587);
GAGAGCTGCA(SEQ ID NO: 588); AGAGCTGCAT(SEQ ID NO: 589);
GAGCTGCATC(SEQ ID NO: 590); AGCTGCATCC(SEQ ID NO: 591);
GCTGCATCCG(SEQ ID NO: 592); CTGCATCCGG(SEQ ID NO: 593);
TGCATCCGGA(SEQ ID NO: 594); GCATCCGGAG(SEQ ID NO: 595);
CATCCGGAGT(SEQ ID NO: 596); ATCCGGAGTA(SEQ ID NO: 597);
TCCGGAGTAC(SEQ ID NO: 598); CCGGAGTACT(SEQ ID NO: 599);
CGGAGTACTT(SEQ ID NO: 600); GGAGTACTTC(SEQ ID NO: 601);
GAGTACTTCA(SEQ ID NO: 602); AGTACTTCAA(SEQ ID NO: 603);
GTACTTCAAG(SEQ ID NO: 604); TACTTCAAGA(SEQ ID NO: 605);
ACTTCAAGAA(SEQ ID NO: 606); CTTCAAGAAC(SEQ ID NO: 607);
TTCAAGAACT(SEQ ID NO: 608); TCAAGAACTG(SEQ ID NO: 609);
CAAGAACTGC(SEQ ID NO: 610); AAGAACTGCT(SEQ ID NO: 611);
AGAACTGCTG(SEQ ID NO: 612); GAACTGCTGA(SEQ ID NO: 613).

Generally, the subject HIV-1 isolate is non-pathogenic as hereinbefore defined. Additionally, reference herein to "a deletion" includes reference to a contiguous or non-contiguous series of two or more deletions.

The non-pathogenic isolate may carry a single decanucleotide deletion or may carry more than one decanucleotide deletion. Where it carries multiple deletions these may all correspond to a contiguous sequence or be from different parts of the *nef* gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above. It is emphasised that the present invention extends to analogous sequences from other pathogenic strains of HIV-1 which might carry *nef* genes with a slightly altered sequence relative to HIV-1 strain NL4-3.

In a most preferred embodiment of the present invention, there is provided a non-pathogenic strain of HIV-1 carrying a nucleotide sequence in its genome as set forth in SEQ ID No. 614:

GAAGAGATTTGGGAGAACATGACCTGGATGCAGTGGGAAAAAGAAATTCACAATCACAC
AAAATACATATACTCCTTACTTGAAAAATCGCAGAACCAACAAGAAAAGAATGAACAAG
AACTATTGGAATTGGATCAATGGGCAAGTTTGTGGAATTGGTTTGACATAACAAAATGG
CTGTGGTATATAAAAATATTCATAATGGTAGTAGGAGGCTTGATAGGTTTAAGAATAGT
TTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCGTTTC
AGACCCTCCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGAAGGT
GGAGAGAGAGACAGAGACAGATCCACTCGATTAGTACACGGATTCTTAGCACTTTTCTG
GGACGACCTGAGGAGCCTGTGCCTCTTCCTCTACCACCACTTGAGAGACTTACTCTTGA
TTGTAACAAGGATTGTGGAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATATTGG
TGGAACCTCCTAAAGTATTGGAGCCAGGAACTGCAGAAGAGTGCTGTTATCTTGCTCAA
TGCCACCGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTTTAGAAGTATTACAAAGAG
CTTATAGAGCTATCCTCCACATACCTAGAAGAATAAGACAGGGCCTCGAAATGGCTTTG
CTATAAAATGGGTGGCAAGTGAGCAAAAAGTAGTGTAGTCAGATAGCATGCATCATAAG
GGGTGGGGGCCAACAACTAACAATGCTGATCGTGCCTGGCTAGAAGCACAAGAGAAGGA
AGAAGCGGGTTTTCCAGTCAAACCTCAGGTAGCTGTAGATCTTAGCCACTTTTTAAAAG
AAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATACACAGTGCTGC
AAACTATTACCAGTGGAGTCAGCGAAGATAGAAGAGGCCAATGGAGGAGAAAACCACAG
ATTGTTCTGTTGGGGACTTTCCATCCGTTGGGGACTTTCCAAGGCGGCGTGGCCTGGGT
GACTAGTTCCGGTGGGGACTTTCCAAGAAGGCGCGGCCTGGGCGGGACTGGGGAGTGGC
GAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGCTGTTACTGGGTCTCTCGGGTT

AGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTC
AATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT
ATCTAGA;

and/or SEQ ID NO: 615:

GAAACAATTTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGACAATTACAC
AAACATAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAAAATGAACTAG
AATTATTGGAATTGGATAAATGGGCAAATTTGTGGAATTGGTTTAGTATATCAAACTGG
CTATGGTATATAAAATTATTCATAATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGT
TTTTACTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCGTTTC
AGACCCACCTCCCAACCCCGAAGGGACCCGACAGGCCAGAAGGAATCGAAGAAGAAGGT
GGAGAGAGAGACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCTTAGCACTTTTCTG
GGACGACCTGAGGAGTCTGTGCCTCTTCAGCTACCACCACTTGAGAGACTTACTCTTGA
TTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATACTGG
TGGAATCTCCTGCAGTATTGGAGGCAGGAACTACAGAAGAGTGCTGTTAGCTTGTTCAA
TGGCACGGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGCTTTACGAAGGG
CTTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAAGGGCTTTG
CTATAAAATGGGTGGCAAGTGGTCAGAAAGTAGTGTGGTTAGAAGGCATGTACCTTTAA
GACAAGGCAGCTATAGATCTTAGCCGCTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCT
AATTCACTCACAGAGAAGATCAGTTGAACCAGAAGAAGATAGAAGAGGCCATGAAGAAG
AAAACAACAGATTGTTCCGTTTGTTCCGTTGGGGACTTTCCAGGAGACGTGGCCTGAGT
GATAAGCCGCTGGGGACTTTCCGAAGAGGCGTGACGGGACTTTCCAAGGCGACGTGGCC
TGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGC
CTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAG
GGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCC
CGTCTGTTGTGTGACTCTGGTATCTAGA.

The present invention, however, extends to HIV-1 isolates which are non-pathogenic; carry genomes capable of hybridising under low stringency conditions to SEQ ID NO: 614 or SEQ ID NO: 615; and which do not direct the synthesis of a full length *nef* gene product.

In a further embodiment the present invention contemplates a viral isolate which:

(i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gp120 and/or gp160;

(ii) carries a genome or a part or fragment thereof capable of hybridising under

medium stringency conditions to a nucleotide sequence as set forth in SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1;

(iii) carries a deletion of at least ten nucleotides in a region corresponding to the LTR region in HIV-1 NL4-3; and

wherein said deletion encompasses one or more of the following decanucleotides from the LTR region of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1:

GCTTTTTGCC (SEQ ID NO: 652); CTTTTTGCCT (SEQ ID NO: 653);
TTTTTGCCTG (SEQ ID NO: 654); TTTTGCCTGT (SEQ ID NO: 655);
TTTGCCTGTA (SEQ ID NO: 656); TTGCCTGTAC (SEQ ID NO: 657);
TGCCTGTACT (SEQ ID NO: 658); GCCTGTACTG (SEQ ID NO: 659);
CCTGTACTGG (SEQ ID NO: 660); CTGTACTGGG (SEQ ID NO: 661);
TGTACTGGGT (SEQ ID NO: 662); GTACTGGGTC (SEQ ID NO: 663);
TACTGGGTCT (SEQ ID NO: 664); ACTGGGTCTC (SEQ ID NO: 665);
CTGGGTCTCT (SEQ ID NO: 666); TGGGTCTCTC (SEQ ID NO: 667);
GGGTCTCTCT (SEQ ID NO: 668); GGTCTCTCTG (SEQ ID NO: 669);
GTCTCTCTGG (SEQ ID NO: 670); TCTCTCTGGT (SEQ ID NO: 671);
CTCTCTGGTT (SEQ ID NO: 672); TCTCTGGTTA (SEQ ID NO: 673);
CTCTGGTTAG (SEQ ID NO: 674); TCTCTGGTTA (SEQ ID NO: 675);
CTGGTTAGAC (SEQ ID NO: 676); TGGTTAGACC (SEQ ID NO: 677);
GGTTAGACCA (SEQ ID NO: 678); GTTAGACCAG (SEQ ID NO: 679);
TTAGACCAGA (SEQ ID NO: 680); TAGACCAGAT (SEQ ID NO: 681);
AGACCAGATC (SEQ ID NO: 682); GACCAGATCT (SEQ ID NO: 683);
ACCAGATCTG (SEQ ID NO: 684); CCAGATCTGA (SEQ ID NO: 685);
CAGATCTGAG (SEQ ID NO: 686); AGATCTGAGC (SEQ ID NO: 687);
GATCTGAGCC (SEQ ID NO: 688); ATCTGAGCCT (SEQ ID NO: 689);
TCTGAGCCTG (SEQ ID NO: 690); CTGAGCCTGG (SEQ ID NO: 691);
TGAGCCTGGG (SEQ ID NO: 692); GAGCCTGGGA (SEQ ID NO: 693);
AGCCTGGGAG (SEQ ID NO: 694); GCCTGGGAGC (SEQ ID NO: 695);
CCTGGGAGCT (SEQ ID NO: 696); CTGGGAGCTC (SEQ ID NO: 697);
TGGGAGCTCT (SEQ ID NO: 698); GGGAGCTCTC (SEQ ID NO: 699);
GGAGCTCTCT (SEQ ID NO: 700); GAGCTCTCTG (SEQ ID NO: 701);
AGCTCTCTGG (SEQ ID NO: 702); GCTCTCTGGC (SEQ ID NO: 703);
CTCTCTGGCT (SEQ ID NO: 704); TCTCTGGCTA (SEQ ID NO: 705);

CTCTGGCTAA (SEQ ID NO: 706); TCTGGCTAAC (SEQ ID NO: 707);
CTGGCTAACT (SEQ ID NO: 708); TGGCTAACTA (SEQ ID NO: 709);
GGCTAACTAG (SEQ ID NO: 710); GCTAACTAGG (SEQ ID NO: 711);
CTAACTAGGG (SEQ ID NO: 712); TAACTAGGGA (SEQ ID NO: 713);
AACTAGGGAA (SEQ ID NO: 714); ACTAGGGAAC (SEQ ID NO: 715);
CTAGGGAACC (SEQ ID NO: 716); TAGGGAACCC (SEQ ID NO: 717);
AGGGAACCCA (SEQ ID NO: 718); GGGAACCCAC (SEQ ID NO: 719);
GGAACCCACT (SEQ ID NO: 720); GAACCCACTG (SEQ ID NO: 721);
AACCCACTGC (SEQ ID NO: 722); ACCCACTGCT (SEQ ID NO: 723);
CCCACTGCTT (SEQ ID NO: 724); CCACTGCTTA (SEQ ID NO: 725);
CACTGCTTAA (SEQ ID NO: 726); ACTGCTTAAG (SEQ ID NO: 727);
CTGCTTAAGC (SEQ ID NO: 728); TGCTTAAGCC (SEQ ID NO: 729);
GCTTAAGCCT (SEQ ID NO: 730); CTTAAGCCTC (SEQ ID NO: 731);
TTAAGCCTCA (SEQ ID NO: 732); TAAGCCTCAA (SEQ ID NO: 733);
AAGCCTCAAT (SEQ ID NO: 734); AGCCTCAATA (SEQ ID NO: 735);
GCCTCAATAA (SEQ ID NO: 736); CCTCAATAAA (SEQ ID NO: 737);
CTCAATAAAG (SEQ ID NO: 738); TCAATAAAGC (SEQ ID NO: 739);
CAATAAAGCT (SEQ ID NO: 740); AATAAAGCTT (SEQ ID NO: 741);
ATAAAGCTTG (SEQ ID NO: 742); TAAAGCTTGC (SEQ ID NO: 743);
AAAGCTTGCC (SEQ ID NO: 744); AAGCTTGCCT (SEQ ID NO: 745);
AGCTTGCCTT (SEQ ID NO: 746); GCTTGCCTTG (SEQ ID NO: 747);
CTTGCCTTGA (SEQ ID NO: 748); TTGCCTTGAG (SEQ ID NO: 749);
TGCCTTGAGT (SEQ ID NO: 750); GCCTTGAGTG (SEQ ID NO: 751);
CCTTGAGTGC (SEQ ID NO: 752); CTTGAGTGCT (SEQ ID NO: 753);
TTGAGTGCTT (SEQ ID NO: 754); TGAGTGCTTC (SEQ ID NO: 755);
GAGTGCTTCA (SEQ ID NO: 756); AGTGCTTCAA (SEQ ID NO: 757);
GTGCTTCAAG (SEQ ID NO: 758); TGCTTCAAGT (SEQ ID NO: 759);
GCTTCAAGTA (SEQ ID NO: 760); CTTCAAGTAG (SEQ ID NO: 761);
TTCAAGTAGT (SEQ ID NO: 762); TCAAGTAGTG (SEQ ID NO: 763);
CAAGTAGTGT (SEQ ID NO: 764); AAGTAGTGTG (SEQ ID NO: 765);
AGTAGTGTGT (SEQ ID NO: 766); GTAGTGTGTG (SEQ ID NO: 767);
TAGTGTGTGC (SEQ ID NO: 768); AGTGTGTGCC (SEQ ID NO: 769);
GTGTGTGCCC (SEQ ID NO: 770); TGTGTGCCCG (SEQ ID NO: 771);
GTGTGCCCGT (SEQ ID NO: 772); TGTGCCCGTC (SEQ ID NO: 773);
GTGCCCGTCT (SEQ ID NO: 774); TGCCCGTCTG (SEQ ID NO: 775);
GCCCGTCTGT (SEQ ID NO: 776); CCCGTCTGTT (SEQ ID NO: 777);
CCGTCTGTTG (SEQ ID NO: 778); CGTCTGTTGT (SEQ ID NO: 779);
GTCTGTTGTG (SEQ ID NO: 780); TCTGTTGTGT (SEQ ID NO: 781);

CTGTTGTGTG (SEQ ID NO: 782); TGTTGTGTGA (SEQ ID NO: 783);
GTTGTGTGAC (SEQ ID NO: 784); TTGTGTGACT (SEQ ID NO: 785);
TGTGTGACTC (SEQ ID NO: 786); GTGTGACTCT (SEQ ID NO: 787);
TGTGTGACTC (SEQ ID NO: 788); GTGTGACTCT (SEQ ID NO: 789);
TGTGACTCTG (SEQ ID NO: 790); GTGACTCTGG (SEQ ID NO: 791);
TGACTCTGGT (SEQ ID NO: 792); GACTCTGGTA (SEQ ID NO: 793);
ACTCTGGTAA (SEQ ID NO: 794); CTCTGGTAAC (SEQ ID NO: 795);
TCTGGTAACT (SEQ ID NO: 796); CTGGTAACTA (SEQ ID NO: 797);
TGGTAACTAG (SEQ ID NO: 798); GGTAACTAGA (SEQ ID NO: 799).

The non-pathogenic isolate may carry a single decanucleotide deletion in the LTR region or may carry multiple deletions in the same region or in the LTR region and another region such as the *nef* gene. In particular, the mutation may be in the LTR/*nef* overlap region. Where it carries multiple deletions, these may correspond to a contiguous sequence or be from different parts of the LTR region and/or *nef* gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above.

Yet another aspect of the present invention provides an infectious molecular clone comprising genetic sequences derived from the non-pathogenic HIV-I isolates as hereinbefore described and includes genetic sequences encoding major structural proteins such as *gag, env* and *pol*. Infectious molecular clones are particularly useful as genetic compositions capable of "infecting" host cells without need of viral coat. The infectious molecular clones of the present invention may also be derived from pathogenic HIV-1 strains rendered non-pathogenic as hereindescribed.

According to this latter embodiment, there is contemplated a method of attenuating a pathogenic strain of HIV-1, said method comprising inducing a mutation in the *nef* gene and/or an LTR region to generate a non-pathogenic HIV-1 strain as hereinbefore described. Preferred mutations are deletions of at least ten nucleotides such as one or more of the decanucleotides as hereinbefore described. The mutations may also constitute substitutions and/or insertions of heterologous nucleic acid molecules in the *nef* and/or LTR regions such as the incorporation of a sense (i.e. co-suppression) antisense or ribozyme molecule (see below).

In still yet another embodiment of the present invention, there is provided an isolated, non-pathogenic strain of HIV-1 comprising a deletion in its genome of at least 10 nucleotide within the region of nucleotide 8787 and 9709 and more particularly within the region 8800 and 9700 and even more preferably within the region 8800 and 9410, using the nucleotide numbering of HIV-1 NL4-3.

In one embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

In another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

In yet another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

In still yet another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3):

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

The above embodiments including any combinations thereof or functional equivalents thereof. Most preferred variants of HIV-1 are defined in Table 3.

Reference herein to the non-pathogenic HIV-1 strains of the present invention includes reference to components, parts, fragments and derivatives thereof including both genetic and non-genetic material. Furthermore, the non-pathogenic HIV-1 strains may be in isolated form or resident in peripheral blood mononuclear cells (PBMCs) or other like cells where the genome of the HIV-1 strains is integrated as DNA from said HIV-1 strains such as proviral DNA. In addition, the present invention extends to recombinant virus such as from (or resident in) prokaryotes or eukaryotes as well as in the form of infectious molecular clones.

Accordingly, the present invention provides for the non-pathogenic HIV-1 isolate, genomic material therefrom, complementary proviral DNA, molecular infectious clones, recombinant viral particles or genetic sequences therefrom or cells expressing same or blood cells carrying proviral DNA or to any mutants, derivatives, components, fragments, parts, homologues or analogues of the foregoing.

The non-pathogenic HIV-1 strains of the present invention are particularly useful in the development of therapeutic compositions, therapeutic molecules and/or diagnostic reagents. With regards to the former, the non-pathogenic HIV-1 strain may be considered as a live attenuated vaccine where individuals carrying DNA derived from said non-pathogenic HIV-1 strain such as proviral DNA in target cells are protected from infection by a corresponding pathogenic strain. The term "vaccine" is used in its broadest sense as a therapeutic composition or molecule which prevents or reduces HIV-1 infection or risk of infection or which ameliorates the symptoms of infection. It may involve the stimulation of an immune response or may involve blocking HIV-1 cells

receptors and/or the use of genetic compositions, for example, to introduce ribozymes or antisense molecules to HIV-1 directed genetic sequences or to prepare infectious molecular clones. For convenience, all such compositions are referred hereinafter to "therapeutic compositions".

Accordingly, the present invention contemplates a method for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic HIV-1 as hereinbefore defined in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. More particularly, the present invention contemplates a method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. By "productive infection" as used in the specification and claims herein is meant the infection of a cell or cells by a pathogenic strain of HIV-1 which leads ultimately to the symptomology of AIDS or AIDS related diseases. A cell infected productively produces pathogenic virions. By definition, infection of an individual by a non-pathogenic strain of HIV-1 would not lead to productive infection. Non pathogenic HIV-1 strains generally replicate to a sufficient extent to protect cells against challenge by virulent or pathogenic strains. The methods of the present invention are applicable prophylactically (i.e. to prevent *de novo* infection) or therapeutically (i.e. to reduce or slow disease progression).

The present invention further provides a method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. The term "vaccinating" should not be taken as limiting the invention to the prevention of HIV-1 infection by solely immunological means. The term "vaccinating" includes any means of preventing productive infection of an individual by pathogenic HIV-1.

BNSDOCID: <WO___9521912A1_I_>

As an alternative to the above methods, a therapeutic composition as hereinbefore defined is administered. The non-pathogenic isolate may be administered *inter alia* as an isolated viral preparation or *via* infected blood cells. Another aspect of the invention provides a therapeutic composition for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1 said therapeutic composition comprising a non-pathogenic strain of HIV-1 or genetic sequences derived therefrom as hereinbefore described and optionally one or more pharmaceutically acceptable carriers and/or diluents. The therapeutic composition of the present invention is generally suitable for intravenous, intraperitoneal, intramuscular, intramucosal (e.g. nasal spray, respiratory spray) or other forms of parenteral administration. The therapeutic composition might also be administered *via* an implant or rectally or orally. In addition to the mutations contemplated above, the non-pathogenic HIV-1 strain may also contain one or more other mutations to further reduce the risk of reversion to virulence and/or to insert a genetic sequence capable of providing directly or indirectly an identifiable signal, having further anti-HIV-1 properties and/or immunostimulatory or cell regulatory properties.

For example, the non-pathogenic HIV-1 isolate in the therapeutic composition may comprise additional genetic material capable of directing expression of antisense nucleotide sequences to inhibit expression of one or more proteins encoded by a pathogenic strain of HIV-1. Alternatively, sense co-suppression may be employed. Preferred sense or antisense molecules would reduce expression of the *nef* gene or affect normal functioning of the LTR region.

According to this embodiment, the non-pathogenic HIV-1 strain may be considered as a targeting agent to introduce genetic constructs capable of reducing expression of one or more HIV-1 proteins or polypeptides. In this embodiment there is provided a viral isolate which:

(i) is genetically or immunologically related to a pathogenic strain of HIV-1;

(ii) is substantially non-pathogenic in human subjects;

(iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and

(iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down-regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1.

Preferred proteins or polypeptides targeted for reduced expression are those encoded by one or more of the following: *gag, pol, env, tat, rev, vpu, vpr, vif* and/or *nef* genes. The most preferred protein or polypeptide targeted for reduced expression is the product of the *nef* gene. Alternatively, the target nucleotide sequence does not encode a polypeptide or protein but is required for other functions such as integration or excision from the human genome or expression of genes on the viral genome. An example of such a nucleotide sequence is the LTR region. Accordingly, the present invention extends to disruption to the function of such regions.

The above aspect relates to use of antisense technology. The present invention extends, however, to use of ribozymes and/or co-suppression to achieve the same results. In an alternative embodiment, or in addition to, the second (or optionally a third) nucleotide sequence encodes an antiviral agent (e.g. interferon) and/or an immune enhancing agent.

The identification of deletions *inter alia* in the *nef* gene and/or LTR region in asymptomatic subjects provides a unique opportunity to study the *in vivo* effects of attenuated HIV-1 strains carrying one or more mutations in selected genetic regions. In particular, the present invention provides a means for designing therapeutic compositions directed to inhibiting expression of a *nef* gene and/or LTR region in a pathogenic HIV-1 strain (such as contemplated above) as well as developing a therapeutic regimem aimed at inhibiting the activity of the *nef* gene product for the function of the LTR region. According to this latter embodiment, the present invention provides a therapeutic composition comprising a molecule capable of inhibiting the intracellular activity of the *nef* gene product and/or LTR region, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

The molecule contemplated by the above aspect of the subject invention may be a protein, polypeptide, peptide, chemical compound, sugar moiety or derivative of the *nef* gene product. The molecule will need to be capable of entering an infected cell. Where the molecule is a protein, polypeptide or peptide, it may be encoded by the second nucleotide sequence on the targeting vector as contemplated above. Alternatively, the molecule may be a nucleic acid molecule capable of targeting the *nef* gene or LTR region.

The deletion mutants of the present invention may result in a modified *nef* gene product either having no readily discernable activity or having activity different to the naturally occurring *nef* protein. In any event, if a mutant *nef* gene product is produced, it will generally have a lower molecular weight than the naturally occurring *nef* protein and will have a different overall amino acid sequence. This provides, therefore, for a means for diagnosing individuals with benign HIV-1 infection by, for example, assaying for a modified *nef* protein or screening for a modified *nef* gene sequence. Alternatively, benign HIV-1 infection may be detected by assaying for a modified LTR region such as an altered nucleotide sequence.

According to one embodiment, there is provided a method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising contacting a biological sample from said individual with an effective amount of an antibody specific to a *nef* protein from a non-pathogenic strain of HIV-1 (as hereinbefore defined) for a time and under conditions sufficient to form an antibody-modified *nef* protein complex and then detecting said complex. The presence of said complex is indicative of a modified *nef* gene product and of the non-pathogenicity of the strain of HIV-1. The biological sample is a sample likely to contain the modified *nef* gene product such as tissue extract or cell extract of an infected cell. However, where the modified *nef* gene product is capable of permeation or transport out of the cell, suitable biological fluid would include serum, whole blood, lymph and mucosal secretion amongst other fluids. Many variations in the subject assay are possible and are contemplated herein. For example, an assay could be based on the inability for a *nef* specific antibody to bind to a modified *nef* protein. For the purposes

of the present invention the term "contacting" including "mixing".

The presence of a modified *nef* molecule in biological fluid can be detected using a wide range of immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site and two-site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays and include ELISA and RIA techniques. Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, and by way of example only, in a typical forward assay, a modified *nef* product-specific antibody is immobilised onto a solid substrate to form a first complex and the sample to be tested for modified *nef* product brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-modified *nef* product secondary complex, a second modified *nef* protein antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a tertiary complex of antibody-modified *nef* product-antibody. Any unreacted material is washed away, and the presence of the tertiary complex is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparison with a control sample containing known amounts of hapten. Variations of the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent. The antibodies used above may be monoclonal or polyclonal.

The solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other

BNSDOCID: <WO___9521912A1_I_>

surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier.

By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, produces an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecule in this type of assay re either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes). In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to one skilled in the art. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production,upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product.

Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to label a modified *nef*

product and to use same directly in the detection of, for example, circulatory antibodies specific to said modified *nef* product.

Alternatively, genetic assays may be conducted to screen for abberations in the *nef* gene and/or LTR region. Such a genetic assay may be by Southern or Northern blot analysis, PCR analysis or the like using oligonucleotides specific to a deleted region of a *nef* gene and/or LTR region.

According to this embodiment there is provided a method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining directly or indirectly the presence of a deletion mutation in the genome of said HIV-1 wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV-1. The deletion mutation may result in the genome being unable to synthesise a polypeptide or protein from a pathogenic strain of HIV-1 or may direct the synthesis of a truncated form of said polypeptide or protein. The mutation may also lead to altered expression of a polypeptide detectable by, for example, decreased synthesis of a particular protein, such as the *nef* gene product. Alternatively, the deletion mutation affects the LTR region or a regulatory region of the HIV-1 genome. In either case, affected viruses may also be detected by, for example, observing low viral copy numbers such as low viral loads.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

The above nucleotide numbers are based on the nucleotide numbering in the NL4-3 genome.

Particularly preferred oligonucleotides are based on the deleted regions of the *nef* gene and/or LTR region such as but not limited to one or more oligonucleotides based on SEQ ID NO: 2 to SEQ ID NO: 613 and/or SEQ ID NO: 652 to SEQ ID NO: 799.

The present invention further extends to kits for the diagnosis of infection by pathogenic strains of HIV-1 or for determining the pathogenicity of infecting virus. The kits would be in compartmental form each comprising one or more suitable reagents for conducting the assay.

The present invention is further described by the following non-limiting Figures and Examples.

In the Figures:

Figure 1 is a representation showing the alignment of the nucleotide sequences from donor D36 peripheral blood mononuclear cell (PBMC) [D36P] and non-pathogenic HIV-1 from recipient C18 HIV_{StV} [C18S], C18 HIV_{MBC} [C18M] and C98 HIV [C98H] and C54 PBMC [C54P] with the equivalent region of HIV-1 NL4-3. Sequences labelled PBMC are from patient PBMC, those labelled HIV are from virus isolated from patient PBMC and grown in culture. Numbering for HIV-1 NL4-3 is as per Myer *et al* (1992) where nucleotide 1 is the first nucleotide of the complete proviral DNA sequence. D36P, C18S, C18M, C98H and C54P are numbered from the start of the region sequenced. Identity with NL4-3 sequence is shown by (*). Deleted nucleotides are shown by (-). Spaces introduced to maximise alignment are shown by (,). Features in NL4-3 are marked by overlining the sequence, features in D36 and C18 are marked by underlining the sequence.

Figure 2 shows the alignment of encoded amino acid sequences of (a) *tat* exon 3 and (b) *rev* exon 3 from HIV-1 NL4-3, D36 PBMC, C18 HIV_{StV} and C98 HIV. In-phase termination codons (*) and NL4-3 encoded amino acid numbers are shown.

Figure 3 is a representation showing the alignment of C-terminal envelope glycoprotein gp41 amino acid sequences encoded by D36 PMBC, C18 HIV_{StV}, C18 HIV_{MBC} and C98 HIV. Numbering is that of the amino acid sequence of the mature envelope glycoprotein of HIV NL4-3. Termination in shown by (#).

Figure 4 is a representation showing alignment of amino acid sequences encoded by the *nef* genes of HIV-1 NL4-3, D36 PBMC, C18 HIV_{StV}, C18 HIV_{MBC} and C98 HIV. In phase termination codons are shown by (#). Identical amino acids are shown by (*). Residues underlined are those immediately before a deletion.

BNSDOCID: <WO___9521912A1_I_>

Figure 5 shows a duplication of NF*K*B and Sp1 sequences in D36 PBMC, C18 HIV_{StV}, C18 HIV_{MBC} and C98 HIV demonstrated by alignment of their low homology region sequences with the NF*K*B-Sp1 region of HIV-1 NL4-3. Nucleotide numbering according to Figure 1. Identity with NL4-3 sequence shown by (*) and NF*K*B and Sp1 sites in NL4-3 overlined. Position of *nef*/LTR region sequence deletion shown by (Δ).

Figure 6 is a graphical representation showing replication of C18 and C98 viral isolates and D36 PBMCs from asymptomatic patients in PHA-stimulated PBMCs.



Figure 7 is a graphical representation showing replication of viral isolates from asymptomatic patients in non-PHA stimulated PBMCs.



228200 is an Australian isolate of HIV-1 described by Kiernan, R. *et al* (1990). Its characteristics include being T cell trophic, with fast kinetics, high producer of HIV-1 and/or SI phenotype.

Figure 8 is a graphical representation of cell surface receptor expression for syncytia-inducing (SI)/ non-syncytia-inducing (NSI)/asymptomatic patient isolates.



228200 is defined in the legend to Figure 7. 243925 is a viral isolate of HIV-1 which is monocyte/macrophage trophic and exhibits NSI phenotype (Dr Karen Coats-Fryer, PhD thesis entitled "Viral determinants of HIV-1 syncytium formation", the University of Melbourne, Parkville, Victoria, Australia.

Figure 9 is a representation of the nucleotide sequence of C18 HIV-1_{MBC} (SEQ ID NO: 800).

Figure 10(a) - (g) are graphical representations showing clinical immunology of cohort; (a) CD3; (b)(i) CD4 (ii) CD4%; (c)(i) CD8; (ii) CD8%; (d) lymphocyte count; (e) CD4/CD8 ratio; (f) β-2-microglobulin; and (g) Kaplan-Meier estimates of time to disease progression (Cox & Oakes, 1989).

Figure 11 is a schematic representation of the deletion mutants of the present invention.

A summary of the SEQ ID Nos. used in the subject specification is shown below:

SEQ ID NO:	DESCRIPTION
1	Nucleotide sequence of HIV-1 strain NL4-3 genome
2-613	Decanucleotides of *nef* gene from HIV-1 strain NL4-3
614	Partial nucleotide sequence of D36 HIV-1 isolate
615	Partial nucleotide sequence of C18 HIV-1_{MBC} isolate
616-625	PCR primers shown in Table 1
626-633	Sequence primers shown in Table 2
634	Amino acid residues 15-27 of HIV-1 NL4-3 *nef* protein
635	HIV-1 NL4-3 *tat* exons (Figure 2)
636	HIV-1 D36 *tat* exons (Figure 2)
637	HIV-1 C18 *tat* exons (Figure 2)
638	HIV-1 NL4-3 *rev* exons (Figure 2)
639	HIV-1 D36 *rev* exons (Figure 2)
640	HIV-1 C18 *rev* exons (Figure 2)
641	HIV-1 NL4-3 C-terminal of gp41 (Figure 3)
642	HIV-1 D36 C-terminal of gp41 (Figure 3)
643	HIV-1 C18 C-terminal of gp41 (Figure 3)
644	HIV-1 NL4-3 *nef* gene (Figure 4)
645	HIV-1 D36 *nef* gene (Figure 4)
646	HIV-1 C18 *nef* gene (Figure 4)
647	HIV-1 NL4-3 NFKB/SP1 sequence (Figure 5)
648	HIV-1 D36 NFKB/SP1 sequence (Figure 5)
649	HIV-1 C18 NFKB/SP1 sequence (Figure 5)
650	Nucleotide sequence of *nef* gene from HIV-1 strain NL4-3
651	Nucleotide sequence of *env* and *nef* regions of NL4-3
652-799	Decanucleotides of LTR region from HIV-1 strain NL4-3
800	Nucleotide sequence of C18 HIV-1_{MBC}

EXAMPLE 1

Source Material

For the purposes of the following examples, a non-pathogenic HIV-1 strain was isolated from a recipient of HIV-1 infected blood. The recipient is designated "C18". Other recipients are defined as "C54" and "C98". The donor is identified herein as "D36". The place of isolation may be indicated after the abbreviation of "HIV". For example, St Vincents Hospital, Sydney (HIV_{StV}) or Macfarlane Burnet Centre of Medical Research, Melbourne (HIV_{MBC}).

Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the PHLS Centre for Applied Microbiology and Research, European Collection of Animal Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4 OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession Number V941031169.

Figure 11 is a summary of the deletion mutants of the present invention.

Viruses were isolated by the following procedures:

1. Infected peripheral blood mononuclear cells (PBMCs) were co-cultured with HIV-1 seronegative donor PBMCs. A convenient source of seronegaitve donor PBMCs is a blood bank. The supernatants and cells are harvested every 7 days and fresh medium added with CD8 depleted PBMCs. CD8 depletion promotes the ability to isolate HIV-1. The culture and procedure is continued for up to approximately 5 weeks;

2. The infected PBMCs are purified from whole blood and these cells are cultured alone for up to 5 weeks. PMBCs alone are used because the virus is more likely to be monocytotropic. Fresh medium is added weekly and supernatant fluid is harvested at this time;

3. Supernatant fluids are harvested every approximately 7 days, fresh medium and fresh HIV-1 seronegative CD8 depleted PBMCs are added at this time;

4. HIV-1 seronegative PBMCs are pretreated with with M-CSF for approximately 72 hours prior to the addition of infected PBMCs. M-CSF has been shown to enhance HIV-1 replication in monocytes (Gendelman *et al*, 1988); or

5. The supernatant fluid is harvested from the cultures of step 4 every approximately 7 days, fresh medium added together with HIV-1 seronegative stimulated CD8 depleted PBMCs. The virus is isolated from the infected PBMCs.

EXAMPLE 2

DNA Preparation and PCR Amplification

Non-pathogenic HIV-1 (e.g. strain C18) infected peripheral blood mononuclear cells (PBMC) were harvested 4 days after infection of phytohaemagglutinin (PHA) stimulated HIV-1 negative donor PBMC cultured by the method of Neate et al (1987) and washed in phosphate buffered saline (PBS). PBMC from Donor D36 and Recipients C18, C54 and C98 were prepared by Ficoll isopaque centrifugation of buffy coat cells and washed with PBS.

Approximately 10^7 cells were lysed in 1ml lysis solution (0.45% v/v NP40, 0.45% v/v Tween 20, 10mM Tris-HCl pH 8.3, 40mM KCl 2.5 mM $MgCl_2$) and digested with 60µg/ml proteinase K (Boehringer Mannheim) at 55°C for 1 hour followed by 100°C for 10 minutes. Lysates were stored at -20°C.

All polymerase chain reaction (PCR) primers (Table 1) and sequencing primers (Table 2) were synthesised using an Applied Biosystems model 391 DNA synthesiser using phosphoramidite chemistry.

Strict physical separation was maintained for sample, PCR reagent mix and PCR reaction preparations as well as amplification and analysis. Final reaction mixes (50µl) contained

2 µl neat or diluted cell lysate, 0.2µM each primer, 200mM dNTPs and 1.25 units Taq polymerase (Boehringer Mannheim) in PCR buffer, (10mM Tris-HCl pH8.3, 50mM KCl, 100µg/ml gelatine) adjusted to the optimum $MgCl_2$ concentration for the primer pair (1.5-3.0mM). Aliquoted reagent mix was overlaid with 50µl mineral oil prior to addition of DNA template lysate. After template denaturation at 94°C for 3 min amplification was achieved with 30 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, 2 mins. A final elongation reaction was conducted at 72°C for 7 minutes. For double PCR amplification 2 µl of first round product was added to the second reagent mix and amplified as before.

PCR amplified DNA was checked for quality, quantity and fragment size by agarose gel electrophoresis in Tris-Acetate-EDTA buffer (Sambrook et al, 1989) stained in ethidium bromide and viewed by UV transillumination.

EXAMPLE 3

DNA Sequence Analysis

The DNA sequence of PCR amplified HIV-1 regions was determined by the dideoxynucleotide method (Sanger et al, 1997) using Sequenase T7 polymerase (United States Biochemicals).

PCR amplified DNA was purified by PCR Magic prep resin chromatography (Promega). Approximately 2 to 7 µg purified DNA plus 10ng specific primer (Table 2) were denatured by boiling for 3 mins and snap frozen to -20°C. The initial labelling reaction was for 3 minutes at 22°C (room temperature) with ^{35}SdNTP (500Ci/mmol; Dupont) followed by dideoxynucleotide termination reactions at 37°C for 5 minutes. NP40, to 0.45% v/v, was included in denaturation and reaction mixes (Bachman et al, 1990). Sequencing reaction products were denatured in formamide and resolved on a 6% w/v polyacrylamide gel containing 8M urea, fixed in 10% v/v acetic acid, 10% v/v methanol and dried. Following autoradiography on XK1 film (Kodak) the gel sequences were read assembled, translated to protein and aligned using the PC/GENE suite of programs (IntelliGenetics, USA).

BNSDOCID: <WO__9521912A1_I_>

TABLE 1

PCR PRIMERS

PRIMER	SEQUENCE[1, 3]	POSITION[2]
Cl-1	TGGAAGGGCTAATTTGGT(616)	1-18
Cl-2	ATCTTCCCTAAAAAATTAGCCTGTC(617)	2099-2075
LTR-3′	AGGCTCAGATCTGGTCTAAC(618)	9559-9540
SK68	AGCAGCAGGAAGCACTATGG(619)	7786-7805
Cl-6	TGCTAGAGATTTTCCACAC(620)	9709-9691
KS-2	AGTGAATAGAGTTAGGCAGG(621)	8326-8345
RT5′-v3	GTAAGACAGTATGATCAGATA(622)	2418-2438
RT3′-v2	TTGTAGGGAATTCCAAATTCC(623)	4660-4640
RT5′-v2	CAGGATCCTACACCTGTCAACATAAT(624)	2487-2506
RT3′-v1	GGGAATTCCTTATTCCTGCTTG(625)	4655-4634

1. Sequence is presented from 5′ to 3′ of the primer.
2. Position is according to the numbering of HIV NL4-3 in Myers *et al* (1992).
3. SEQ ID NOs are given in parentheses.

TABLE 2

SEQUENCING PRIMERS

PRIMER	SEQUENCE[1, 3]	POSITION[2]
KS3	CCAGAAGTTCCACAATCC(626)	8570-8553
KS4	TTCTTCTAGGTATGTGGAG(627)	8753-8735
KS5	AGTGAATTAGCCCTTCCAG(628)	9093-9075
KS6	TGCTAGAGATTTTCCACAC(629)	9709-9691
SP2	TGCTCTGGAAAACTCAT(630)	8006-8022
SP3	CTTTCTATAGTGAATAGAG(631)	8318-8336
SP4	TATTGGAGTCAGGAACT(632)	8618-8634
SPR	GGTCTAACCAGAGAGAC(633)	9547-9531

1. Sequence is presented from 5′ to 3′ of the primer.
2. Position is according to the numbering of HIV NL4-3 in Myers *et al* (1992).
3. SEQ ID NOs are given in parentheses.

EXAMPLE 4

Cells and Cell Culture

Peripheral blood was obtained from HIV-1 sero-negative volunteers and mononuclear cells prepared by centrifugation on a Ficoll/Hypaque density gradient (Peper et al, 1968). PBMC were activated with phytohemagglutinin (PHA; 10μg/10^6 cells) for 48 h at 37°C washed and then cultured in RPMI 1640 medium containing 10% v/v heat inactivated foetal calf serum, 15mM HEPES, 0.1% v/v sodium bicarbonate, 25μg/ml polybrene (Sigma), 10% v/v interleukin 2 (Boehringer Mannheim) and 1:1000 anti-interferon (Miles) (IL-2 medium). Non-PHA stimulated cells were prepared in a similar manner except they were cultured in medium lacking PHA and IL-2.

BNSDOCID: <WO___9521912A1_I_>

EXAMPLE 5

Antipeptide-antisera

Antibodies specific for HIV-1 Nef were raised against a peptide corresponding to the predicted amino acid residues 15-27 (AVRERMRRAEPAA SEQ ID NO: 634) of Nef encoded by the HIV-1 clone pNL4.3 (Kemp et al, 1988). The peptide was conjugated to keyhole limpet hemocyanin (KLH; Calbiochem, Behring Diagnostics, CA) *via* glutaraldehyde and this complex used to immunise sheep (0.5mg peptide conjugate/sheep). Antibodies to the peptide were purified by affinity chromatography. Reactivity of the antibodies with recombinant HIV-1 Nef 25 and 27 was demonstrated by immunoblotting.

EXAMPLE 6

Reactivity of anti-Nef $_{(15-27)}$ with HIV C18-infected Cells in Immunoblotting

Seven days post-infection HIV-1 C18-infected PBMCs and mock - infected cells were washed in PBS then lysed (0.5% w/v NP-40, 0.5% w/v sodium deoxycholate, 50mM NaCl, 25mM Tris-HCl, 10mM EDTA, 0.01% w/v sodium azide and 10mM phenylmethylsulphonylfluoride). After nuclei were spun out lysates were electrophoresed in a 13% w/v SDS-polyacrylamide gel (SDS-PAGE) and subsequently transferred to Hybond-C nitrocellulose (Amersham, Buckinghamshire, England) for 1 h at 100 V using a Bio-Rad protein transfer cell (Bio-Rad, Richmond, Ca). Membranes were pre-incubated with 1% w/v BSA/PBS for 2 h at room temperature and then reacted with affinity purified sheep anti-Nef$_{(15-27)}$, diluted 1:100, overnight at room temperature. After three washes in 1% w/v BSA/PBS, the blots were incubated with donkey anti-sheep Ig conjugated to biotin (Amersham, diluted 1:500) for 1 h at room temperature. After extensive washing as described above the membranes were incubated with streptavidin-conjugated horse radish peroxidase (Amersham; diluted 1:500 for 1 h at room temperature. All dilutions were made with 1% w/v BSA in PBS. After further washing the membrane was developed with phenylenediamine substrate (Dako, Dapopatts, Denmark). The antibody preparation used in the immunoblotting experiments was free of detectable antibodies to the immunogenic carrier protein and coupling reagent.

EXAMPLE 7

Analysis by Polymerase Chain Reaction Amplification

A 5′ fragment defined by primers Cl-1 and Cl-2 containing the 5′ LTR and part of the *gag* gene was amplified. DNA from HIV-1 C18 infected PBMC gave an amplified fragment (amplimer) of about 1.9 kb compared with 2.1kb for pHXB2 control template, implying a deletion of about 200bp from HIV C18. Further amplification of this fragment with primers defining the U3 region of the LTR (Cl-1 and LTR-3′) gave amplimers of about 300 bp for HIV-1 C18 infected PBMC DNA compared with 340bp for C18 and D36 PBMC DNA and 484 bp for pHXB2 control. This implies the loss of approximately 140 to 180bp from the U3 region of these proviral DNAs.

To analyse the *nef*-gene-3′ LTR region, the nested primer pairs SK68-Cl-6 and KS-2-LTR-3′ were used in a double PCR. Amplimers of approximately 830bp were obtained for HIV-1 C18 infected PBMC DNA as well as for PBMC DNA from Donor D36 and Recipients C18, C54 and C98 compared with approximately 1230bp for pHXB2 DNA. These results suggest that about 400bp of DNA have been deleted from the Donor and Recipient proviral DNAs.

In comparison, amplification of the polymerase gene region by double PCR with the nested primer pairs RT5′-v3-RT3′-v2 and RT5′-v2-RT3′-v1 gave a fragment (approximately 2.1 kb) the same size as the molecular clone pHXB2 fragment for HIV-1 C18 infected PBMC DNA, suggesting that deletions from this region were unlikely.

EXAMPLE 8

Nucleotide Sequence of the nef-3′ LTR Region

PCR amplification experiments indicated an approximately 200bp nucleotide deletion from both the *nef* gene and LTR regions of Donor D36 PBMC and Recipient C18 HIV-1 proviral DNA. To further analyse these regions, the DNA sequence was determined for the PCR amplified *nef-3′*-LTR region of D36 PBMC, C18 isolates HIV_{MBC} and HIV_{StV} as well as isolate C98 HIV infected PBMC proviral DNA. The 3′ region was amplified with outer primers (SK68-Cl6) and inner primers (SK68-LTR 3′ or KS2-Cl6) and sequenced directly using a number of internal sequencing primers based on the HIV-1

BNSDOCID: <WO___9521912A1_I_>

NL4-3 nucleotide sequence (Table 2).

Alignment of the nucleotide sequences of the amplified 3' region of donor D36 PBMC and recipient C18 isolates HIV_{MBC} and HIV_{StV} and C98 HIV (Fig 1) showed a number of nucleotide sequences changes, including deletions, relative to the nucleotide sequence of wild-type infectious HIV-1 (HIV-1 NL4-3). In the region of alignment, D36 PBMC lacked 291 nucleotides, C18 HIV_{StV} differed in size by 388 nucleotides (comprising deletions of 397 nucleotides and an insertion of 9 nucleotides), C18 HIV_{MBC} differed by 456 nucleotides and C98 HIV lacked 158 nucleotides compared with HIV-1 NL4-3. The overall identity with HIV-1 NL4-3 nucleotide sequence of D36 PBMC, C18 HIV_{StV}, HIV_{MBC} and C98 HIV nucleotide sequences, including deletions, was 73% (1157/1596), 67% (1459/1592), 62% (982/1592) and 79% (1105/1399), respectively.

The D36 PBMC sequence differed from HIV-1 NL4-3 in a number of features. A change in the wild type *tat* termination codon from TAG to TCG (Ser) extended the third *tat* exon (which starts at splice acceptor 10) by a further 15 amino acids to terminate at a conserved TAG (Fig 1). The resulting C-terminal peptide is rich in charged amino acids (8/15) (Fig 2a). The wild type *rev* termination codon has also changed (TAG to GAG, Glu) and the third *rev* exon is extended for 14 codons to terminate at a conserved TAG (Fig 2b). The encoded extra amino acids are mainly polar (11/14) and charged in nature (Fig 2b). The sequence also encodes the C-terminal 237 amino acids of Env gp41 (Fig 3) terminating at the normal termination codon. The D36 PBMC Env amino acid sequence has 85% identity with the HIV NL4-3 sequence, increasing to 89% if similarities are included.

There are significant differences from HIV-1 NL4-3 downstream of the *env* (gp41) gene. A change in the fifth *nef* codon, from TGG (Trp) to TGA (Fig 1), introduces an early termination in the D36 PBMC *nef* gene. The encoded Nef protein is identical to the N-terminal 4 amino acids of NL4-3 Nef (Fig 4). Following the early termination there are deletions of 33, 47, 93 and 91 nucleotides and a region of low sequence homology, compared with HIV NL4-3, prior to the wild type *nef* termination codon site (HIV NL4-3 nts 9405-9407). As well as removing a significant part of the *nef* gene, these deletions

also bring into phase a further 6 termination codons. While the polypurine tract (plus strand primer binding site) and the first 38 nucleotides of the LTR U3 region are perfectly conserved, downstream U3 region sequences are disrupted by the 93 and 91 nucleotide deletions and the low homology region. The resulting U3 region lacks recognition sequences for the transcription factors *c-myb*, USF and TCF1α as well as one of the suggested NF-AT sites (Gaynor et al, 1992). Downstream from the 91 nucleotide deletion, a 59 nucleotide region of low homology contains two extra NFKB enhancer sites 19 nucleotides upstream of the usual site of a pair of NFKB sites, the upstream one of which is altered in its 5'-half in D36. Sequences further downstream are highly conserved with respect to HIV-1 NL4-3, including the position and number of Sp1 basal promoter sites, TATA box, TAR and polyadenylation signal sequences.

Similar to D36 PBMC, the C18 HIV_{StV} and HIV_{MBC} sequences show the *tat* third exon to be extended by 15 codons. All but two codons (altered by point mutations) are identical to those of D36 PBMC (Fig 2a). The *rev* third exon of both C18 isolates is also extended (Fig 2b) but by only three codons, identical to the first three codons of the D36 PBMC *rev* extension. The same 237 amino acid coding region of Env gp41 is found in both the C18 HIV DNA sequences (Fig 3) and shows 85% identify, increasing to 88% if similarities are included, with the same region of the NL4-3 Env gp41.

It is in the *nef* gene and LTR regions that the major differences from wild-type HIV-1 arise, just as in D36 PBMC. The *nef* gene of C18 HIV_{StV} encodes 24 amino acids with 9 of the 10 N-terminal being identical to the NL4-3 Nef protein (Fig 4). Thereafter, deletions of 177 and 11 nucleotides cause a frameshift and termination at the 25th codon (Fig 1). Downstream deletions of 120, 82 and 7 nucleotides cause further loss of wild type *nef* gene sequence and bring into phase a further three termination codons.

The *nef* gene of C18 HIV_{MBC} encodes only 7 amino acids with only the initiator methionine identical to the NL4-3 Nef protein. This loss of identity and early termination is brought about by a 250 nucleotide deletion after the fifth nucleotide of the *nef* gene. Downstream deletions of 120 and 86 nucleotides cause further loss of wild-type *nef* gene sequences. In both C18 isolates there is perfect conservation of the

polypurine tract and 29/31 nucleotides at the 5′ end of the U3 region immediately before the 120 nucleotide deletion (Fig 1). This deletion together with the downstream 82 and 7 nucleotide deletions in HIV_{StV} and 86 nucleotide deletion in HIV_{MBC} and the low homology region cause the loss of the 5′ half of the NRT-1 site (Yamamoto et al 1992) and the downstream NFAT site. A third NFKB site is present 31 (HIV_{stV}) and 33 (HIV_{MBC}) nucleotides upstream of the expected pair of NFKB sites which are themselves separated by 13 nucleotides instead of the 4 nucleotides in HIV-1 NL4-3. The 5′-most Sp1 site sequence is slightly altered but sequences downstream including the other 2 Sp1 sites, the TATA box, TAR and polyadenylation signal sequences are identical to HIV-1 NL4-3 sequence.

The three sequences, D36 PBMC, C18 HIV_{StV} and C18 HIV_{MBC} show a number of similarities consistent with the transmission of virus from person D36 to person C18 as well as a number of differences indicating post-transmission divergence of sequence. All three have *tat* open reading frames (ORFs) extended by 15 codons. All three have extended *rev* ORFs. The new *rev* termination codon in both C18 HIV-1 isolates, three codons downstream of the NL4-3 *rev* termination codon, has a point mutation in D36 PBMC to make a Glu codon so that it continues for a further 11 codons (Fig 2b) to terminate at a conserved TGA. The partial Env gp41 amino acid sequences are more closely related to each other (86% identity or 90% including similarities) than to HIV NL4-3 (85% and 89%, respectively).

The nucleotide sequence of the *nef* and LTR region of the HIV-1 isolate from recipient C98 (C98 HIV) is 90.3% identical (1264/1399) to the HIV NL4-3 sequence, ignoring deletions. Similar to the D36 PBMC and C18 HIV_{StV} and HIV_{MBC} isolates the C98 HIV sequence shows the third exon of *tat* to be extended by 15 codons with all but one being identical to the D36 PBMC *tat* extension. Also, the *rev* gene is extended by 3 codons, 2 of which are identical to the first 2 codons of the D36 PBMC *rev* extension. The sequence also encodes the C-terminal 223 amino acids of Env gp41 terminating at the normal termination codon. The C98 HIV Env amino acid sequence has 89% identity with HIV NL4-3 Env sequence, increasing to 92% of similarities are included.

As with the D36 PBMC and the C98 HIV isolate sequences it is the *nef* gene and LTR regions that major differences from the HIV NL4-3 sequence arise. The *nef* gene open reading frame of C98 HIV is much longer than in D36 PBMC, C18 HIV_{StV} and HIV_{MBC}, encoding 85 amino acids compared with 206 amino acids for NL4-3. Sixty eight of those 85 amino acids are identical to the N-terminal sequence of NL4-3 Nef. The single, small deletion (16 nucleotides) in the C98 HIV *nef*-alone regions (Table 3) occurs after *nef* codon 82 causing a frameshift and termination after a further 3 codons at the start of the highly conserved polypurine tract sequence immediately before the 3′-LTR. The *nef*/LTR region has two deletions totalling 142 nucleotides. The 5′-most deletion of 42 nucleotides includes the splice acceptor 12 sequence. The NRT-1, dyad symmetry and *myb* response element sequences are all intact. However, the downstream 100 nucleotide deletion includes sequences from the 3′ end of the 5′-NF-AT and all of the 3′ NF-AT sequences as well as the USF transcription factor recognition sequence. The downstream low homology region of 77 nucleotides lacks the TCF-1α sequence but has two additional NFKB sites 13 nucleotides apart and 26 nucleotides upstream of the 3′-half-remmant of the normal 5′-NFKB site. Sequence downstream, including the 3′-NFKB site, the 3 Sp1 sites, TATA box TAR and polyadenylation signal sequences are all highly conserved.

The main feature of the sequences is the series of deletions, with respect to HIV NL4-3, in the *nef* gene-3′-LTR region. These can be grouped into two regions namely the *nef*-alone region, that part of the *nef* gene upstream of the LTR, and the *nef*/LTR region, where the *nef* gene and LTR U3 regions overlap. The deletions in these regions of each of the sequences start and end at the same or similar positions (Table 3). The deletions are larger in C18 HIV_{StV} and C18 HIV_{MBC} sequences where totals of 397 and 456 nucleotides have been deleted (relative to NL4-3) compared to 291 nucleotides, from D36 and 158 nucleotides from C98 HIV. In the *nef*-alone region the two deletions in C18 HIV_{StV} and the single deletion in C18 HIV_{MBC} occupy the same region as the three deletions in D36 PBMC. Similarly, the *nef*/LTR region in the three deletions in the C18 HIV_{StV}, the two deletions in the C18 HIV_{MBC} and the D36 PBMC sequences occupy the same region. These findings indicate that mutant virus was transmitted from D36 to C18 after which further deletions and rearrangements occurred. Similarly, the

BNSDOCID: <WO___9521912A1_I_>

sequence of C98 HIV in the *nef*/LTR region indicates two deletions occupying the same region as the *nef*/LTR deletions in D36 and the C18 sequences. However, the size (only 16 nucleotides) and the position of the deletion in the *nef*-alone region of C98 HIV are distinct from those of the D36 PBMC and C18 sequences.

The timing of transmission of virus by transfusion was that recipient C18 was transfused approximately 19 months after C98. Consistent with the relative timing of transmission and the sequence similarities and differences is the suggestion that at the time of transmission to C98, the D36 sequence had deletions in the *nef*/LTR region but not in *nef*-alone region. After transmission to C98, the C98 virus developed further deletions and rearrangements, including the deletion in the *nef*-alone region. The D36 virus evolved so that at the time of transmission to C18, further deletions and rearrangements had occurred including deletion of sequence from the *nef*-alone region distinct from the C98 HIV *nef*-alone region deletion. After transmission to C18, further deletions and rearrangements occurred in the C18 virus giving rise to at least two sequences (HIV_{StV} and HIV_{MBC}).

The *nef*-alone deletion region may be a mutation or recombination "hotspot" as it includes sequences that were found to be variably duplicated in 28 out of 54 Nef protein sequences derived from 8 of 12 patients analysed in a study (Shugars *et al* 1993). The sequence between the *nef*-alone and the *nef*/LTR region deletions is highly conserved and is important in provirus integration into the infected cell genome and interacts with a number of cellular proteins. It is interesting that the sequence equivalent to NL4-3 nucleotides 9209 to 9225 is retained in D36 and C98 HIV but lost in the C18 HIV sequences. This includes part of a sequence of dyad symmetry (9210 to 9231) and is a significant part of the binding site for NRT-1 (Yamamoto et al 1991) which has been shown to have a negative regulatory effect on HIV-1 expression. The presence of this sequence in D36 and C98 HIV and its absence from the C18 isolates may correlate with the inability to isolate virus from D36 PBMC and the poor replication of C98 HIV but the ability to isolate HIV-1 from C18 PBMC. The deletion of sequence equivalent to nucleotides 9281 to 9395 of NL4-3 causes the loss of some transcription factor binding sites including NFAT and USF from the D36, C18 HIV and C98 HIV sequences.

A further similarity between the D36, C18 HIV_{StV}, C18 HIV_{MBC} and C98 HIV sequences is a region of low homology to HIV-1 NL4-3 extending downstream of the *nef*/LTR deleted region to the NFKB enhancer/Sp1 promoter site region. This low homology region in fact consists of incomplete duplications of part of the NFKB/Sp1 region (Fig 5) resulting in D36 and C98 HIV having 2 extra NFKB sites upstream of an altered 5′ NFKB site while the C18 sequences have one extra NFKB site and altered spacing between the 5′ and 3′ wild type NFKB sites due to an insertion of 9 nucleotides.

For the C18 and C98 HIV-1 isolates virus replication was assessed in PHA-stimulated and non-stimulated PBMCs (Figs 6 and 7). In PHA-stimulated PBMCs we also studied cell surface CD4 and IL-2R expression (Fig 8). In comparison with HIV-1 wild type SI and NSI isolates clearly both C18 HIV_{MBC} and C98 viruses are replication competent, though C98 HIV replicates more poorly than C18 HIV_{MBC} and are of the NSI phenotype when syncytium formation and CD4 and IL-2R surface expression are taken into account. Additionally, and more surprisingly, these two viruses replicated almost as efficiently in non-PHA stimulated PBMCs when compared to a typical local wild type SI isolate (HIV-1 228200, Fig 7).

When protein expression was assessed for C18 HIV_{MBC} and C98 HIV_{MBC} although structural proteins were identified, no typical Nef protein was seen in infected cells. However, analysis of cell lysates prepared from PBMC infected with C18 HIV_{MBC} or PBMC infected with C98 HIV_{MBC} (which were subsequently stimulated by UV irradiation, see Valerie *et al,* 1988) by Western immunoblotting using two antibodies specific for the N-terminal region of Nef showed the presence of smaller proteins of 19 kDa and 21 kDa, respectively. These proteins were not observed in mock-injected control PBMC lysates and were not observed when the infected-cell lysates were probed were probed with antibodies reactive with the C-terminus of Nef.

Thus, although the C18 and C98 HIV isolates are replication competent *in vitro* they clearly replicate differently using different conditions for cell activation and from the known functions of HIV-1 Nef protein and the LTR show that the major deletion in the *nef* gene and/or the LTR is at least in part responsible for the outcome of infection,

BNSDOCID: <WO___9521912A1_I_>

implicating the importance of Nef and/or the LTR in the clinical outcome of infection *in vivo*.

EXAMPLE 9

Determination of Degree of Relatedness Between Viruses

To determine the degree of relatedness between viruses such as between mutants or between mutants and a wild-type virus and to ascertain putative infected patients, the method of Delwart *et al* was employed.

EXAMPLE 10

Immune responsiveness of subjects infected by non-pathogenic HIV-1 isolate

In this example, the donor and recipients of the cohort were tissue typed and assessed for basic cellular immune responses. Proliferative responses and IL-2 production to the mitogens ConA and PHA, to allogeneic mononuclear cells (irradiated pooled mononuclear cells from 20 random donors) and to recall antigens (e.g. influenza and tetanus toxoid) were within normal ranges. While at the immunogenetic level, HLA typing failed to identify a consistently common allele or haplotype within the group.

The conservation of CD4+ counts observed in the cohort, the relative integrity of their immune system and the varied HLA types of the donor and recipients further supports the fact that the symptomless condition of the cohort members is due to a non-pathogenic strain of HIV-1 or a strain of low virulence.

Accordingly, this provides a screening procedure for subjects putatively infected by a non-pathogenic HIV-1 isolate where such subjects are seropositive for HIV-1 (e.g. have antibodies to an HIV-1 glycoprotein) yet have normal proliferative responses and cytokine production to mitogens, allogeneic mononuclear cells and to recall antigens.

EXAMPLE 11

Clinical Immunology of Cohort

To establish that the donor and the recipients belonging to the cohort exhibit normal immunological profiles, members of the cohort were assayed for CD3, CD4, CD8, lymphocyte count, CD4/CD8 ratio and β-2-microglobulin over time since seroconversion.

Parameters considered normal in non-infected individuals range as follows:

Parameter		
CD3	55-82%	620-2200 ($x10^6$/L)
CD4	29-58%	420-1410 ($x10^6$/L)
CD8	12-43%	200-980 ($x10^6$/L)
Lymphocyte count	1000-3500 ($x10^6$/L)	
CD4/CD8	0.7-3.7	
β-2-microglobulin	0.00-2.20 mg/L	

The results are shown in Figures 10(a)-(g) and clearly show that the immunological profiles of cohort members are substantially normal further highlighting the non-pathogenicity of the HIV-1 isolates of the present invention. Figure 10(g) shows a graph of the Kaplan-Meier (Ox and Oates, 1989) estimates of time to disease progression (AIDS or CD4 > 250). The results demonstrate that the difference is large in spite of the conservative bias, with a median time to progression of 6.2 years in the main database. An exact logrank test (Cytel Software Corporation, 1989, StatXact: Statistical Software for Exact Nonparametric Inference. Cambridge, Massachusetts.) was performed, demonstrating that the difference between the groups was highly statistically significant (logrank statistic 11.8, $p<0.0001$).

BNSDOCID: <WO___9521912A1_I_>

Table 3

Deletions and their sizes in the *nef*-alone and the *nef*/LTR regions of the Long-Term Asymptomatic HIV-1 Sequences

Sequence	*nef*-alone Region	Region Deletion (nt)	*nef*/LTR Region	Region Deletion (nt)	Total Deletion (nt)
D36 PBMC	8830-8862 (33) 8882-8928 (47) 9009-9035 (27)	107	9112-9204 (93) 9281-9371 (91)	184	291
C18 HIV_{StV}	8830-9006 (177) 9019-9029 (11)	188	9105-9224 (120) 9281-9362 (82)	202	390
C18 HIV_{MBC}	8792-9041 (250)	250	9105-9224 (120) 9281-9366 (86)	206	456
C98 HIV	9033-9048 (16)	16	9148-9189 (42) 9271-9370 (100)	142	158
C54 PBMC	incomplete	?	9281-9375 (95)	95	95 +

Sequence numbering relates to the equivalent position in HIV-1 NL4-3. Numbers in brackets are the deletion sizes in nucleotides (nt).
The *nef* ORF starts at nt 8787and the 3'-LTR starts at nt 9074 in HIV-1 NL4-3.

EXAMPLE 12

Sequencing of isolate HIV-1 $C18_{MBC}$

The genome of variant HIV-1 designated C18 HIV-1_{MBC} was amplified by the polymerase chain reaction (PCR) as 7 overlapping fragments using the sets of inner and outer oligonucleotide primers, designed using the programme PCRPLAN (IntelliGenetics), listed in Table 5 and either UlTma (Applied Biosystems) or a mixture of KlenTaq and Pfu (KlenTaq LA, Ab Peptides Inc) polymerases (for faithful amplification of long fragments). The resulting fragments were cloned into the SmaI site of the plasmid vector pGEM7Zf+. Insert-containing clones representing each region of the full length variant HIV-1 were sequenced by a nested deletion strategy (Gou & Wu, 1982) and cycle sequencing with Taq polymerase and dye labelled primers complimentary to the T7 or SP6 sites within the cloning vector. Nucleotide sequences were entered and collated by ASSEMGEL and SEQIN (IntelliGenetics) and SEQED (Applied Biosystems) and translated to the encoded amino acid sequences using TRANSL (IntelliGenetics) programmes. Sequence alignments used NALIGN, CLUSTAL (IntelliGenetics) and SEQED programmes.

The full length sequence (Fig 9; SEQ ID NO:800) of isolate HIV-1 $C18_{MBC}$ is 9207 nucleotides long which is 506 nucleotides shorter than the HIV NL4-3 sequence. This size difference is comprised of 126 nucleotides of insertions and 632 nucleotides of deletions, see Table 6. The most extensive differences between the HIV-1 $C18_{MBC}$ sequence and HIV-1 NL4-3 are in the U3 region of the LTR and in the *nef* gene, as hereinafter described.

The 5' LTR has deletions of 120 and 87 nucleotides and a region of low sequence homology, which is the result of an imperfect duplication of the downstream NFκB and Sp1 response sequences. These result in the loss of sequence from a number sites important in the regulation of transcription of HIV-1 genes, including the negative response element (NRE) and the response elements for a number of transcription factors including NF-AT, NRT-1, USF and TCF-1α. Furthermore, the low homology region contains an extra NFκB and Sp1 sites as well as an insertion of 9 nucleotides between

BNSDOCID: <WO___9521912A1_I_>

the usual NFκB sites. Downstream of the NFκB sites the sequence of the LTR has a high level of homology (96.2%) with the same region of HIV NL4-3.

The *gag* gene contains 3 insertions, which represent direct repetitions of adjacent sequences. The first is a perfect repeat of 15 nucleotides after the equivalent of nucleotide 1134 of HIV-1 NL4-3 and adds 5 amino acids to the C-terminus region of $p17^{gag}$. The remaining 2 insertions are imperfect and perfect repeats of 30 and 6 nucleotides, respectively, after the equivalent of HIV NL4-3 nucleotides 2163 and 2232, respectively. These encode an extra 12 amino acids in the C-terminus region of $p15^{gag}$ just downstream of the *gag* to *pol* frameshift sequences. The variation in sequence length of the *gag* gene at these two positions is unusual. The homology of the encoded amino acid sequence of HIV-1 $C18_{MBC}$ and HIV NL4-3 for the *gag* p17, p24, and p15 proteins is 87.1%, 93.5% and 94.3%, respectively.

In the *pol* ORF, the encoded proteins have high homology with the NL4-3 sequences being 95.5% overall comprising p10 protease 92.9%, p66 reverse transcriptase 95.4% and p34 integrase 95.8%. The amino acid sequence of the p61 RT lacks the mutations associated with resistance to the nucleoside (AZT, ddI, ddC)and non-nucleoside (Nevirapine) analogue drugs used in the treatment of HIV-1-infected persons.

The *vif* gene encodes a 192 amino acid protein with 88.0% homology with that of HIV-1 NL4-3. The *vpr* gene encodes a 96 amino acid protein with 89.6% homology with that of HIV-1 NL4-3.

There are 2 insertions and 1 deletion of sequences in the *vpu* gene. The insertions of 3 and 9 nucleotides are after the equivalent of nucleotide 6071 and 6234, respectively, of HIV-1 NL4-3. These add 1 amino acid after amino acid 3, and 3 amino acids after amino acid 59 of the encoded *Vpu* protein. The deletion of 12 nucleotides after the equivalent of HIV-1 NL4-3 nucleotide 6261 deletes 4 amino acids from the C-terminal region of *Vpu* as well as from the signal peptide of the *env* polyprotein, which is encoded by an overlapping reading frame. Amino acid sequence homology of HIV-1 $C18_{MBC}$ Vpu with NL4-3 is 85.2%.

The sequence encoding the *env* gp120 has 9 insertions totalling 45 nucleotides (encoding 15 amino acids) and the deletion of a total of 18 nucleotides (encoding 6 amino acids). These are listed in Table 6. All of these events (insertions and deletions) are at positions in the *env* gene. This is within the *env* V3 coding region, immediately upstream of the sequence encoding the so called V3 tip (or loop) amino acid sequence, Gly Pro Gly Arg. The V3 region sequence is that of a typical clade B subtype (North America, Europe and Australia) being identical to the clade B consensus sequence (based on 186 *env* sequences) at 29/35 positions. The type of amino acid at positions 11 and 28 of the V3 loop region (where position 1 is the Cys at amino acid 266 of the *env* gp120) is predictive of the viral non-syncytium / syncytium forming phenotype (Fouchier et al, 1992). The HIV-1 $C18_{MBC}$ *env* gene encoded amino acid sequence has Ser at position 11 and Ile at position 28 of the V3 loop region. The lack of a positively charged amino acid at both positions is strongly indicative of a non-syncytium viral phenotype. The overall amino acid sequence homology with HIV-1 NL4-3 (ignoring deletions and insertions) is 86.1%, comprising 85.5% for the gp120 region and 87.6% for the gp41 region.

Both the *tat* and *rev* second exon open reading frames (ORF) are longer than in HIV-1 NL4-3. A change of the *tat* termination codon from TAG to TCG extends the *tat* ORF to a downstream in phase termination codon extending the encoded *tat* amino acid sequence by 15 residues, compared with the 86 amino acid long NL4-3 *tat* protein, to a total length of 101 amino acids. However, this is the usual length of the HIV-1 *tat* protein.

Similarly, the normal *rev* termination codon is changed from TAG to GAG. This extends the *rev* ORF to an in-phase termination codon 3 codons downstream so that the encoded Rev protein is 119 amino acids long instead of the usual 116.

As mentioned above the most extensive differences between the sequences of the isolate HIV-1 $C18_{MBC}$ and HIV-1 NL4-3 are in the *nef* gene and the LTR region. While the *nef* gene overlaps the 3' LTR, these differences are found in both the *nef* alone and the *nef* / LTR overlap regions. The HIV $C18_{MBC}$-encoded *nef* protein is only 24 amino

acids long compared with the normal length of 206 amino acids. This severe shortening of the *nef* protein is due to the deletion of 188 nucleotides (the 177 and 11 nucleotide deletions) from the *nef*-alone region which also brings into phase a termination codon, TAG, at the resulting 25th codon. Downstream there is further loss of potential *nef* gene sequences by the 120 and 87 nucleotide deletions situated in the *nef* / LTR overlap region. The resulting 24 amino acid *nef* protein is identical to the N-terminus of the HIV-1 NL4-3 *nef* at 9 of the first 10 positions. Thereafter, homology is lost completely.

Some sequences used in the generation of mature mRNAs are altered or lost in $C18_{MBC}$. The dinucleotide immediately after the splice donor site 2 (SD2) at nts 4818-4819 (NL4-3 equivalent nts 4963-4964)is changed from the conserved GT to GC. It is expected that this change would lead to loss of function of this site as a splice donor. Splice donor 2 is used in the processing of HIV-1 transcripts to some of the mRNAs that encode Tat, Rev and *nef* proteins. Similarly the splice acceptor site 7 (SA7) sequence at nts 6477-6478 (NL4-3 equivalent nts 6602-6603) is changed from the conserved AG dinucleotide to TC. This change is expected to lead to loss of function of this site as a splice acceptor. While this SA site is used in HIV-1 mRNA processing it is not a major site and is not used in the production of the regulatory proteins (Tat, Rev or *nef*) mRNAs. The splice donor 12 site is absent from the $C18_{MBC}$ sequence (NL43 equivalent nts 9161-9162) as it is within the first deletion region in the *nef* / LTR overlap region which occurs at nt 8797 and results in the loss of NL43 nucleotides 9105 to 9224. It is significant that the SA12 site is absent from the sequence of all of the cohort virus isolates so far obtained as well as from the sequence of D36 PBMC, however, the C54 PBMC sequence does contain the SA12 site. SA12 is not used in the processing of mRNAs that encode the viral regulatory proteins. Normally SA12 is used in splicing in conjunction with SD1, 2, 3 and 4 and the resulting spliced RNA is probably not a mRNA but may have a regulatory role involving binding to cellular proteins (Smith et al, 1992).

An interesting feature of the sequence of the HIV-1 $C18_{MBC}$ isolate is the deletion and rearrangement of sequence from the 5'-LTR U3 region and the deletion of sequence from the *nef* gene (both *nef* alone and *nef* / 3' LTR regions). These being the only

features of the sequence distinct from disease-causing HIV-1. The lack of AIDS or AIDS-like symptoms in the patient C18 is attributed to the effects of the loss of LTR sequence and / or the loss of *nef* coding sequences and their role in the pathogenesis of AIDS.

TABLE 4

Primers used to Amplify Overlapping regions of HIV-1 $C18_{MBC}$

Primer	5'-Coordinate	Direction (+/-)	Primer Length	Sequence (nt)
CL 1A	1	+	30	TGGAAGGGCTAATTTACTCCCAAAAAAGAC
CL 14	896	-	25	AATCGTTCTAGCTCCCTGCTTGCCC
CL 1B	1	+	30	AATCCCGGGTGGAAGGGCTAATTTACTCCC
CL 13	796	-	31	CCTCTAGACCGCTTAATACTGACGCTCTCGC
CL 11	682	+	23	TCTCTCGACGCAGGACTCGGCTT
CL 18	3440	-	30	CTGTTTTCTGCCAGTTCTAGCTCTGCTTCT
CL 12A	732	+	26	TTTCCCGGGCGGCGACTGGTGAGTAC
CL 17	3330	-	32	CCCTCTAGACTTGCCCAATTCAATTTTCCCAC
CL 26	3193	+	39	CCACACCAGACAAAAAGCATCAGAAAGAACCCCCATTCC
CL 6B	9671	-	39	TGCTAGAGATTTTCCACACGGACTAAAATGGTCTGAGGG
CL 27	3251	+	39	CCATCCTGATAAATGGACAGTACAACCCATAGTACTGCC
CL 28	639	-	37	TGGCCCAAACATTATGTACCTCTGCATCATATGC
CL 19	5448	+	30	AGCAGGACATAACAAGGTAGGATCTCTACA
CL 24	8422	-	28	GGATCTGTCTCTGTCTCTCTCTCCACCT

Underlined sequences depict added restriction enzyme site

+ and - orientations refer to sense and antisense strands of the double stranded DNA sequence

BNSDOCID: <WO___9521912A1_I_>

TABLE 5

Sequence Deletions and Insertions in HIV-1 $C18_{MBC}$ Compared with HIV-1 NL43

Gene or Region	Position (nt) $C18_{MBC}$	Position (nt) NL43	Deletions (nt)	Insertions (nt)
5'-LTR U3	29	29	120	-
5'-LTR U3	85	205	87	-
5'-LTR U3	154	360	-	9
gag p17	939	1134	-	15
gag p15	1982	2163	-	30
gag p15	2081	2232	-	6
vpu	5927	6062	-	3
vpu/env	6092	6234	-	9
vpu/env	6128	6261	12	-
env	6483	6628	-	6
env	6514	6653	2	-
env	6524	6665	1	-
env	6630	6772	-	9
env	6646	6778	-	3
env	7011	7141	6	-
env	7140	7276	3	-
env	7195	7334	-	6
env	7266	7399	3	-
env	7278	7414	-	6
env	7290	7420	-	2
env	7300	7429	-	1
env	7314	7441	3	-
env	7463	7593	-	3
env	7471	7598	-	9
nef	8711	8829	177	-
nef	8723	9018	11	-
nef / LTR	8798	9104	120	-
nef / LTR	8854	9280	87	-
LTR U3	8923	9435	-	9
			632	126

EXAMPLE 13

Macrophage Isolates of HIV-1 C18 and HIV-1 C98

HIV-1 has been isolated from the macrophages of patients C18 and C98.

Patient monocytes were prepared as follows. Whole blood was spun at 2000rpm for 10 minutes. Plasma was removed into a separate tube and the remaining cells were diluted 1:2 in PBS^- (magnesium and calcium free phosphate buffered saline). This was underlaid with 10 ml of Ficoll Isopaque and spun at 2000rpm for 20 minutes. Cells were collected from the interphase and washed three times with PBS^-. These cells were then seeded into a 6 well Costar tray at a concentration of 1.0×10^7/ml and allowed to adhere for 1 hour. Any non-adherent cells were removed by aspiration.

Donor HIV-1 negative macrophages for use in co-cultivation were prepared as follows. Peripheral blood mononuclear cells were purified from whole blood using Ficoll/Isopaque density gradient. These cells were seeded at a concentration of 2.0×10^6/ml in teflon. PBMC were cultured in the presence of 3μg/ml of PHA and 1000U/ml of M-CSF 3 days prior to co-culture.

On day of co-culture, donor PBMC were CD8 depleted. Dyna beads coated with anti-CD8 were used for this purpose. Dyna beads were washed once in PBS^- and then applied to a magnet for 3 minutes. Supernatant was removed and the beads were then resuspended in 250μl of RF-10. Aliquots of 2.0×10^8 patient cells were then added to 250μl (3 beads : 1 CD8 T-cell) of Dyna beads and allowed to incubate for 30 minutes on ice with occasional mixing. After 30 minutes the cell suspension was placed onto a magnet for 3 minutes. The supernatant was then removed placed into a second tube containing 142 μl (1 bead : 1 CD8 T-cell) of Dyna beads. This suspension was placed on ice for an additional 30 minutes with occasional mixing. After 30 minutes cell suspension was placed onto a magnet for 3 minutes. Supernatant was removed and washed once in RF-10.

BNSDOCID: <WO___9521912A1_I_>

For co-culture, CD8 depleted PBMC were then added to patient monocytes. Half media changes were done every 7 days for a period of 21 days. Aliquots of 2.5 ml of medium was removed from these cultures and replaced with CD8 depleted donor PBMC in Iscoves containing 10% HuS (Human serum), 5% v/v FCS and 5% w/v IL-2 and 1000U/ml of M-CSF. Harvested supernatants were spun at 1400 rpm for 10 minutes and stored as 1ml aliquots. Cell pellets were lysed in 200μl of lysis buffer for PCR analysis. Infection was quantitated using a p24 EIA Kit.

Cells were harvested from the co-cultures and used to prepare DNA as described above. The *nef* / 3'-LTR region of both virus isolates was amplified by PCR using the above described primer sets and conditions (Example 12). The resulting amplimers were cloned into the plasmid vector pT7T3U19 and the nucleotide sequence determined by the Taq cycle sequencing method with dye-labelled primers.

The C18 macrophage sequence has 3 deletions starting and finishing at positions within 3 nucleotides of the same deletions in $C18_{MBC}$. The encoded *nef* protein is 3 amino acids long compared with 7 amino acids for $C18_{MBC}$. The low homology region of the LTR U 3 region of C18 macrophage is very similar in sequence to $C18_{MBC}$ and similarly it has one extra upstream NFκB site.

On the other hand, the sequence of C98 macrophage has a number of differences from the C98 isolate. While it has exactly the same first deletion of 16 nucleotides just upstream of the polypurine tract (PPT), in the *nef*-alone region, and exactly the same second deletion (position and size) it has an extra deletion of 18 nucleotides at NL4-3 equivalent nucleotides 9206 to 9223. The final deletion is in approximately the same position as in the C98 isolate but is 5 nucleotides longer. The encoded *nef* protein is 34 amino acids long compared with 86 amino acids for the C98 isolate. The low homology region is very similar to the C98 isolate, having the same 2 extra upstream NFκB sites and completely lacking the normal 5'-NFκB site.

EXAMPLE 14

Construction and Use of an Infectious Molecular Clone

Molecular biological techniques can be used to construct a molecular clone of, for example, HIV-1 $C18_{MBC}$. Two schemes may be used. In the first scheme genomic DNA, extracted from either the CD4 positive PBMC of the patient C18 or donor PBMC that have been infected with the isolate HIV-1 $C18_{MBC}$, is used as the template for polymerase chain reaction amplification, using thermostable polymerase of high transcriptional fidelity (eg UlTma polymerase or KlenTaq/Pfu polymerase mixture), of long (6 to 7 kb) overlapping fragments representing the 5'- and 3'-parts of the HIV-1 $C18_{MBC}$ proviral genome of total length 9207nts. The amplified fragments may then be ligated together after digestion with a restriction enzyme that cleaves at a unique site common to the overlapping region of the amplified fragments, for example the unique Bgl I or Nco I sites. Ligation of this full length proviral DNA into a plasmid vector will allow its propagation in *E coli* and the subsequent preparation of large (mg) quantities of this molecularly cloned proviral DNA.

In the second scheme donor PBMC that have been infected with the isolate HIV-1 $C18_{MBC}$ are used as a source of non-integrated proviral DNA which can be extracted from the infected cells by the Hirt extraction method (Hirt, 1967). Circular proviral DNA molecules may be linearised by digestion with a restriction enzyme that cleaves at a unique position in the genome (eg the Bgl I or Nco I sites). The resilting linearised molecules can be ligated into a plasmid or, more usually, a bacteriophage lambda (λ) based vector (eg Charon 4a, λWES) after modification of the end to provide blunt or cohesive ends compatible with the vector. Transformation or transduction of *E coli* with the recombinant plasmid or bacteriophage material, respectively allows the propagation of the proviral DNA. Clones of *E coli* containing proviral DNA may be selected and DNA prepared. Molecular clones of retroviral genomes prepared in this way are often permuted. Rearrangement to the functional arrangement of sequences is achieved by restriction enzyme cleavage and religation of fragments to reconstruct the correctly permuted proviral genome.

BNSDOCID: <WO___9521912A1_I_>

The molecularly cloned DNA products of both schemes can be used to prepare variant proviral genomes that may be used as the basis of a biologically attenuated HIV-1 vaccine strain. Similarly, they may be modified to contain extra DNA sequences in the *nef*-alone deletion region that may deliver sequences that may be of therapeutic advantage (eg antisense or ribozyme sequences).

Infectious virus particles of HIV-1 $C18_{MBC}$, or modified virus, can be produced by transfection of human cells (eg HeLa cells) which will produce, and release to the culture medium, virus particles of HIV-1 $C18_{MBC}$, or modified virus. These virus particles can be used to infect a variety of CD4 positive cells for further propagation or experimentation.

EXAMPLE 15

In vivo Primate Model

Following construction of infectious molecular clones of the mutant HIV-1 strains, studies are then undertaken in primates to establish attenuation, immunogenicity and vaccine prophylactic efficacy. All studies compare mutant clones of HIV-1 with isogenic wild-type (WT) virus. Initial studies are performed using the macaque (*M. nemistrina*) model of HIV-1 infection. Macaque-infectious WT HIV-1 and mutant clones are compared with respect to duration of viremia, anatomic sites of replication, and cellular and humoral immune responses. Where the mutant HIV-1 clones induce an immune response in the macques infected, challenge studies with WT virus are also performed. Studies are performed in a limited number of chimpanzees, generally in parallel with the macaque studies. Relevant mutations are engineered into WT HIV-1 clones previously shown to produce chronic infection in chimps, and the course of chimp infection with mutant clones compared with historical controls. If infection is established, WT challenge studies is also performed.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

BACHMANN B, LÜKE W AND HUNSMANN G (1990). *Nucl Acids Res 18*: 1309.

BARRE-SINOUSSI F, CHERMANN JC, REY F, *et al* (1983) *Science 220:* 868-871.

BUSCH MP, EL AMAD Z, SHEPPARD HW, ASCHER MS, LANG W (1991) *N Engl J Med 325:* 733-735.

CHENG-MAYER C, SHIODA T, LEVY JA (1991) *J Virol 65:* 6931-6941.

CLERICI M, STOCKS NI, ZAJAC RA, *et al* (1989) *J Clin Invest 84:* 1892-1899.

COX and OAKES (1989) *Survival Analysis, Chapman & Hall.*

DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL P AND DESROSIERS RC (1992). *Science 258:* 1938-1941.

DELWART EL, *et al* (1993) *Science 262:* 1257-1261.

FOUCHER RAM, *et al* (1992) *J. Virol. 66:* 3183-3187.

GAYNOR R (1992). *AIDS 6m* 347-363.

GOU L-H and WU R. (1982) *Nucleic Acids Research 10*: 2065-2084.

GREENWAY *et al* (1994) *Virology 198:* 245-256.

GROENINK M, FOUCHIER RAM, BROERSEN S, *et al* (1993) *Science 260:* 1513-1515.

HAMMES SR, DIXON EP, MALIM MH, CULLEN BR and GREENE WC, (1989) *Proc Natl Acad Sci USA 86:* 9549-9553.

HIRT B. (1967) *J Mol Biol 26*: 365-369.

HWANG SS, BOYLE TJ, LYERLY HK, CULLEN BR (1991) *Science 253:* 71-74.

KASLOW RA, DUQUESNOY R, VAN RADEN M, KINGSLEY L, MARRARI M. (1990) *Lancet 335:* 927-930.

KEMP BE, RYLATT DB, BUNDESEN PG, DOHERTY RR, MCPHEE DA, STAPLETON D, COTTIS LE, WILSON K, JOHN MA, KHAN JM, DINH DP, MILES S & HILLYARD CJ (1988). *Science 241:* 1352-1354.

KESTLER HW, RINGLER DJ, MORI K, PANICALI DL, SEHGAL PK, DANIEL MD & DESROSIERS RC (1991). *Cell 65:* 651-662.

KIERNAN R, *et al* (1990) *AIDS Res. Hum. Retroviruses 6:* 743-752.

KIM S, IKEUCHI K, BYRN R, GROOPMAN J and BALTIMORE D (1989) *Proc Natl Acad Sci USA 86:* 9544-9548.

LANG W, PERKINS H, ANDERSON RE, ROYCE R, JEWELL N. WILKELSTEIN W. (1989) *J Acquir Immune Defic Syndr 2:* 63-69.

LEARMONT J, TINDALL B, EVANS L, CUNNINGHAM A, CUNNINGHAM P, WELLS J, PENNY R, KALDOR J AND COOPER DA. (1992). *Lancet 340:* 863-867.

LEGUERN M, SHIODA T, LEVY JA, CHENG-MAYER C. (1993) *Virology 195;* 441-447.

LEVY JA, (1993) *AIDS 7;* 1401-1410.

BNSDOCID: <WO___9521912A1_I_>

LIFSON AR, BUCHBINDER SP, SHEPPARD HW, *et al* (1991) *J infect Dis 163:* 959-965.

LUCIW PA, CHENG-MAYER C and LEVY JA (1987) *Proc Natl Acad Sci USA 84:* 1434-1438.

MANIATIS T *et al* (1982). Molecular cloning. A Laboratory Manual, 1st edition Pub. Cold Spring Harbor Laboratory Press.

MOSIER DE, GULIZIA RJ, MACISAAC PD, TORBETT BE, LEVY JA (1993) *Science 260:* 689-692.

MYERS A, KORBAR B, BERZOFSKY JA, SMITH RF & PAVLAKIS SA eds (1992; 1993). Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Pub Theoretical Biology and Biophysics Group. Los Alamos National Laboratory, Los Alamos, NM USA.

NEATE EV, HEALY DS, PRINGLE RC, GUST ID, AND JOWLETT JMB (1987). *Aust NZ J Med 17:* 461-466.

NIEDERMAN TMJ, THIELAN BJ, and RATNER L. (1989) *Proc Natl Acad Sci USA 86:* 1128-1132.

PEPER RJ, TINA WZ, & MICHELSON MM (1968). *J Lab Clin Med 72:* 842-846.

SANGER F, NICKLEN S AND COULSON AR (1977). *Proc Natl Acad Sci USA 4:* 5463-67.

SHEPPARD HW, LANG W, ASCHER MS, VITTINGHOF E and WINKELSTEIN W. (1993) *AIDS 7:* 1159-1166.

SHIODA T, LEVY JA, CHENG-MAYER C (1992) *Proc Natl Acad Sci USA 89:* 9434-9438.

SHUGARS DC, SMITH MS, GLUECK DH, NANTERMET PV, SEILLIER-MOISEIWITSCH F AND SWANSTROM R (1993). *J Virol 67:* 4639-4650.

SMITH J, AZAD AA, and DEACON NJ (1992) *J Gen Virol 73:* 1825-1828.

SULLIVAN N, THALI M, FURMAN C, HO DD, SODROSKI J (1993) *J Virol 67:* 3674-3679.

TEEUWSEN VJP, SIEBELINK KHJ, DE WOLF F, GOUDSMIT J, UYTDEHAAG FGCM, OSTERHAUS ADME (1990) *AIDS 4:* 77-81.

TERSMETTE M, DE GOEDE REY, BERT JM, *et al* (1988) *J Virol 62:* 2026-2032.

TERWILLIGER E, SODROSKI JG, ROSEN CA, and HASELTINE WA, (1986) *J Virol 60:* 754-760.

YAMANOTO K MORI S, OKAMOTO T, SHINOTOHNO K AND KYOGOKU Y (1991). *Nucl Acids Res 22:* 6107-6112.

YANISCH-PERRON C, VIEIRA J, and MESSING J *Gene 13:* 103-119.

BNSDOCID: <WO___9521912A1_I_>

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i)(a) APPLICANT: (Other than US)
THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH LIMITED and AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION)

(b) INVENTORS/APPLICANTS (US only):
DEACON, N; LEARMONT, J; McPHEE, D; CROWE, S and COOPER, D.

(ii) TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1

(iii) NUMBER OF SEQUENCES: 800

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: DAVIES COLLISON CAVE
(B) STREET: 1 LITTLE COLLINS STREET
(C) CITY: MELBOURNE
(D) STATE: VICTORIA
(E) COUNTRY: AUSTRALIA
(F) ZIP: 3000

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT INTERNATIONAL
(B) FILING DATE: 14-FEB-1995

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: PM3864 (AU)
(B) FILING DATE: 14-FEB-1994
(A) APPLICATION NUMBER: PM4002 (AU)
(B) FILING DATE: 21-FEB-1994
(A) APPLICATION NUMBER: PN0284 (AU)
(B) FILING DATE: 23-DEC-1994

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: HUGHES, Dr E JOHN L
(C) REFERENCE/DOCKET NUMBER: EJH/EK

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: +61 3 254 2777
(B) TELEFAX: +61 3 254 2770

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9709 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGGAAGGGCT AATTTGGTCC CAAAAAAGAC AAGAGATCCT TGATCTGTGG ATCTACCACA 60
CACAAGGCTA CTTCCCTGAT TGGCAGAACT ACACACCAGG GCCAGGGATC AGATATCCAC 120
TGACCTTTGG ATGGTGCTTC AAGTTAGTAC CAGTTGAACC AGAGCAAGTA GAAGAGGCCA 180
AATAAGGAGA GAAGAACAGC TTGTTACACC CTATGAGCCA GCATGGGATG GAGGACCCGG 240
AGGGAGAAGT ATTAGTGTGG AAGTTTGACA GCCTCCTAGC ATTTCGTCAC ATGGCCCGAG 300
AGCTGCATCC GGAGTACTAC AAAGACTGCT GACATCGAGC TTTCTACAAG GGACTTTCCG 360
CTGGGGACTT TCCAGGGAGG TGTGGCCTGG GCGGGACTGG GGAGTGGCGA GCCCTCAGAT 420
GCTACATATA AGCAGCTGCT TTTTGCCTGT ACTGGGTCTC TCTGGTTAGA CCAGATCTGA 480
GCCTGGGAGC TCTCTGGCTA ACTAGGGAAC CCACTGCTTA AGCCTCAATA AAGCTTGCCT 540
TGAGTGCTCA AAGTAGTGTG TGCCCGTCTG TTGTGTGACT CTGGTAACTA GAGATCCCTC 600
AGACCCTTTT AGTCAGTGTG GAAAATCTCT AGCAGTGGCG CCCGAACAGG GACTTGAAAG 660
CGAAAGTAAA GCCAGAGGAG ATCTCTCGAC GCAGGACTCG GCTTGCTGAA GCGCGCACGG 720
CAAGAGGCGA GGGGCGGCGA CTGGTGAGTA CGCCAAAAAT TTTGACTAGC GGAGGCTAGA 780
AGGAGAGAGA TGGGTGCGAG AGCGTCGGTA TTAAGCGGGG GAGAATTAGA TAAATGGGAA 840
AAAATTCGGT TAAGGCCAGG GGGAAAGAAA CAATATAAAC TAAAACATAT AGTATGGGCA 900
AGCAGGGAGC TAGAACGATT CGCAGTTAAT CCTGGCCTTT TAGAGACATC AGAAGGCTGT 960
AGACAAATAC TGGGACAGCT ACAACCATCC CTTCAGACAG GATCAGAAGA ACTTAGATCA 1020
TTATATAATA CAATAGCAGT CCTCTATTGT GTGCATCAAA GGATAGATGT AAAAGACACC 1080
AAGGAAGCCT TAGATAAGAT AGAGGAAGAG CAAAACAAAA GTAAGAAAAA GGCACAGCAA 1140
GCAGCAGCTG ACACAGGAAA CAACAGCCAG GTCAGCCAAA ATTACCCTAT AGTGCAGAAC 1200
CTCCAGGGGC AAATGGTACA TCAGGCCATA TCACCTAGAA CTTTAAATGC ATGGGTAAAA 1260
GTAGTAGAAG AGAAGGCTTT CAGCCCAGAA GTAATACCCA TGTTTTCAGC ATTATCAGAA 1320
GGAGCCACCC CACAAGATTT AAATACCATG CTAAACACAG TGGGGGGACA TCAAGCAGCC 1380
ATGCAAATGT TAAAAGAGAC CATCAATGAG GAAGCTGCAG AATGGGATAG ATTGCATCCA 1440
GTGCATGCAG GGCCTATTGC ACCAGGCCAG ATGAGAGAAC CAAGGGGAAG TGACATAGCA 1500
GGAACTACTA GTACCCTTCA GGAACAAATA GGATGGATGA CACATAATCC ACCTATCCCA 1560
GTAGGAGAAA TCTATAAAAG ATGGATAATC CTGGGATTAA ATAAAATAGT AAGAATGTAT 1620
AGCCCTACCA GCATTCTGGA CATAAGACAA GGACCAAAGG AACCCTTTAG AGACTATGTA 1680
GACCGATTCT ATAAAACTCT AAGAGCCGAG CAAGCTTCAC AAGAGGTAAA AAATTGGATG 1740
ACAGAAACCT TGTTGGTCCA AAATGCGAAC CCAGATTGTA AGACTATTTT AAAAGCATTG 1800
GGACCAGGAG CGACACTAGA AGAAATGATG ACAGCATGTC AGGGAGTGGG GGGACCCGGC 1860
CATAAAGCAA GAGTTTTGGC TGAAGCAATG AGCCAAGTAA CAAATCCAGC TACCATAATG 1920
ATACAGAAAG GCAATTTTAG GAACCAAAGA AAGACTGTTA AGTGTTTCAA TTGTGGCAAA 1980
GAAGGGCACA TAGCCAAAAA TTGCAGGGCC CCTAGGAAAA AGGGCTGTTG GAAATGTGGA 2040
AAGGAAGGAC ACCAAATGAA AGATTGTACT GAGAGACAGG CTAATTTTTT AGGGAAGATC 2100
TGGCCTTCCC ACAAGGGAAG GCCAGGGAAT TTTCTTCAGA GCAGACCAGA GCCAACAGCC 2160
CCACCAGAAG AGAGCTTCAG GTTTGGGGAA GAGACAACAA CTCCCTCTCA GAAGCAGGAG 2220
CCGATAGACA AGGAACTGTA TCCTTTAGCT TCCCTCAGAT CACTCTTTGG CAGCGACCCC 2280

TCGTCACAAT AAAGATAGGG GGGCAATTAA AGGAAGCTCT ATTAGATACA GGAGCAGATG 2340
ATACAGTATT AGAAGAAATG AATTTGCCAG GAAGATGGAA ACCAAAAAATG ATAGGGGGAA 2400
TTGGAGGTTT TATCAAAGTA GGACAGTATG ATCAGATACT CATAGAAATC TGCGGACATA 2460
AAGCTATAGG TACAGTATTA GTAGGACCTA CACCTGTCAA CATAATTGGA AGAAATCTGT 2520
TGACTCAGAT TGGCTGCACT TTAAATTTTC CCATTAGTCC TATTGAGACT GTACCAGTAA 2580
AATTAAAGCC AGGAATGGAT GGCCCAAAAG TTAAACAATG GCCATTGACA GAAGAAAAAA 2640
TAAAAGCATT AGTAGAAATT TGTACAGAAA TGGAAAAGGA AGGAAAAATT TCAAAAATTG 2700
GGCCTGAAAA TCCATACAAT ACTCCAGTAT TTGCCATAAA GAAAAAAGAC AGTACTAAAT 2760
GGAGAAAATT AGTAGATTTC AGAGAACTTA ATAAGAGAAC TCAAGATTTC TGGGAAGTTC 2820
AATTAGGAAT ACCACATCCT GCAGGGTTAA AACAGAAAAA ATCAGTAACA GTACTGGATG 2880
TGGGCGATGC ATATTTTTCA GTTCCCTTAG ATAAAGACTT CAGGAAGTAT ACTGCATTTA 2940
CCATACCTAG TATAAACAAT GAGACACCAG GGATTAGATA TCAGTACAAT GTGCTTCCAC 3000
AGGGATGGAA AGGATCACCA GCAATATTCC AGTGTAGCAT GACAAAAATC TTAGAGCCTT 3060
TTAGAAAACA AAATCCAGAC ATAGTCATCT ATCAATACAT GGATGATTTG TATGTAGGAT 3120
CTGACTTAGA AATAGGGCAG CATAGAACAA AAATAGAGGA ACTGAGACAA CATCTGTTGA 3180
GGTGGGGATT TACCACACCA GACAAAAAAC ATCAGAAAGA ACCTCCATTC CTTTGGATGG 3240
GTTATGAACT CCATCCTGAT AAATGGACAG TACAGCCTAT AGTGCTGCCA GAAAAGGACA 3300
GCTGGACTGT CAATGACATA CAGAAATTAG TGGGAAAATT GAATTGGGCA AGTCAGATTT 3360
ATGCAGGGAT TAAAGTAAGG CAATTATGTA AACTTCTTAG GGGAACCAAA GCACTAACAG 3420
AAGTAGTACC ACTAACAGAA GAAGCAGAGC TAGAACTGGC AGAAAACAGG GAGATTCTAA 3480
AAGAACCGGT ACATGGAGTG TATTATGACC CATCAAAAGA CTTAATAGCA GAAATACAGA 3540
AGCAGGGGCA AGGCCAATGG ACATATCAAA TTTATCAAGA GCCATTTAAA AATCTGAAAA 3600
CAGGAAAATA TGCAAGAATG AAGGGTGCCC ACACTAATGA TGTGAAACAA TTAACAGAGG 3660
CAGTACAAAA AATAGCCACA GAAAGCATAG TAATATGGGG AAAGACTCCT AAATTTAAAT 3720
TACCCATACA AAAGGAAACA TGGGAAGCAT GGTGGACAGA GTATTGGCAA GCCACCTGGA 3780
TTCCTGAGTG GGAGTTTGTC AATACCCCTC CCTTAGTGAA GTTATGGTAC CAGTTAGAGA 3840
AAGAACCCAT AATAGGAGCA GAAACTTTCT ATGTAGATGG GGCAGCCAAT AGGGAAACTA 3900
AATTAGGAAA AGCAGGATAT GTAACTGACA GAGGAAGACA AAAAGTTGTC CCCCTAACGG 3960
ACACAACAAA TCAGAAGACT GAGTTACAAG CAATTCATCT AGCTTTGCAG GATTCGGGAT 4020
TAGAAGTAAA CATAGTGACA GACTCACAAT ATGCATTGGG AATCATTCAA GCACAACCAG 4080
ATAAGAGTGA ATCAGAGTTA GTCAGTCAAA TAATAGAGCA GTTAATAAAA AAGGAAAAAG 4140
TCTACCTGGC ATGGGTACCA GCACACAAAG GAATTGGAGG AAATGAACAA GTAGATGGGT 4200
TGGTCAGTGC TGGAATCAGG AAAGTACTAT TTTTAGATGG AATAGATAAG GCCCAAGAAG 4260
AACATGAGAA ATATCACAGT AATTGGAGAG CAATGGCTAG TGATTTTAAC CTACCACCTG 4320
TAGTAGCAAA AGAAATAGTA GCCAGCTGTG ATAAATGTCA GCTAAAAGGG GAAGCCATGC 4380
ATGGACAAGT AGACTGTAGC CCAGGAATAT GGCAGCTAGA TTGTACACAT TTAGAAGGAA 4440
AAGTTATCTT GGTAGCAGTT CATGTAGCCA GTGGATATAT AGAAGCAGAA GTAATTCCAG 4500
CAGAGACAGG GCAAGAAACA GCATACTTCC TCTTAAAATT AGCAGGAAGA TGGCCAGTAA 4560
AAACAGTACA TACAGACAAT GGCAGCAATT TCACCAGTAC TACAGTTAAG GCCGCCTGTT 4620
GGTGGGCGGG GATCAAGCAG GAATTTGGCA TTCCCTACAA TCCCCAAAGT CAAGGAGTAA 4680
TAGAATCTAT GAATAAAGAA TTAAAGAAAA TTATAGGACA GGTAAGAGAT CAGGCTGAAC 4740
ATCTTAAGAC AGCAGTACAA ATGGCAGTAT TCATCCACAA TTTTAAAAGA AAAGGGGGGA 4800
TTGGGGGGTA CAGTGCAGGG GAAAGAATAG TAGACATAAT AGCAACAGAC ATACAAACTA 4860
AAGAATTACA AAAACAAATT ACAAAAATTC AAAATTTTCG GGTTTATTAC AGGGACAGCA 4920
GAGATCCAGT TTGGAAAGGA CCAGCAAAGC TCCTCTGGAA AGGTGAAGGG GCAGTAGTAA 4980
TACAAGATAA TAGTGACATA AAAGTAGTGC CAAGAAGAAA AGCAAAGATC ATCAGGGATT 5040
ATGGAAAACA GATGGCAGGT GATGATTGTG TGGCAAGTAG ACAGGATGAG GATTAACACA 5100

TGGAAAAGAT TAGTAAAACA CCATATGTAT ATTTCAAGGA AAGCTAAGGA CTGGTTTTAT 5160
AGACATCACT ATGAAAGTAC TAATCCAAAA ATAAGTTCAG AAGTACACAT CCCACTAGGG 5220
GATGCTAAAT TAGTAATAAC AACATATTGG GGTCTGCATA CAGGAGAAAG AGACTGGCAT 5280
TTGGGTCAGG GAGTCTCCAT AGAATGGAGG AAAAAGAGAT ATAGCACACA AGTAGACCCT 5340
GACCTAGCAG ACCAACTAAT TCATCTGCAC TATTTTGATT GTTTTTCAGA ATCTGCTATA 5400
AGAAATACCA TATTAGGACG TATAGTTAGT CCTAGGTGTG AATATCAAGC AGGACATAAC 5460
AAGGTAGGAT CTCTACAGTA CTTGGCACTA GCAGCATTAA TAAAACCAAA ACAGATAAAG 5520
CCACCTTTGC CTAGTGTTAG GAAACTGACA GAGGACAGAT GGAACAAGCC CCAGAAGACC 5580
AAGGGCCACA GAGGGAGCCA TACAATGAAT GGACACTAGA GCTTTTAGAG GAACTTAAGA 5640
GTGAAGCTGT TAGACATTTT CCTAGGATAT GGCTCCATAA CTTAGGACAA CATATCTATG 5700
AAACTTACGG GGATACTTGG GCAGGAGTGG AAGCCATAAT AAGAATTCTG CAACAACTGC 5760
TGTTTATCCA TTTCAGAATT GGGTGTCGAC ATAGCAGAAT AGGCGTTACT CGACAGAGGA 5820
GAGCAAGAAA TGGAGCCAGT AGATCCTAGA CTAGAGCCCT GGAAGCATCC AGGAAGTCAG 5880
CCTAAAACTG CTTGTACCAA TTGCTATTGT AAAAAGTGTT GCTTTCATTG CCAAGTTTGT 5940
TTCATGACAA AAGCCTTAGG CATCTCCTAT GGCAGGAAGA AGCGGAGACA GCGACGAAGA 6000
GCTCATCAGA ACAGTCAGAC TCATCAAGCT TCTCTATCAA AGCAGTAAGT AGTACATGTA 6060
ATGCAACCTA TAATAGTAGC AATAGTAGCA TTAGTAGTAG CAATAATAAT AGCAATAGTT 6120
GTGTGGTCCA TAGTAATCAT AGAATATAGG AAAATATTAA GACAAAGAAA AATAGACAGG 6180
TTAATTGATA GACTAATAGA AAGAGCAGAA GACAGTGGCA ATGAGAGTGA AGGAGAAGTA 6240
TCAGCACTTG TGGAGATGGG GGTGGAAATG GGGCACCATG CTCCTTGGGA TATTGATGAT 6300
CTGTAGTGCT ACAGAAAAAT TGTGGGTCAC AGTCTATTAT GGGGTACCTG TGTGGAAGGA 6360
AGCAACCACC ACTCTATTTT GTGCATCAGA TGCTAAAGCA TATGATACAG AGGTACATAA 6420
TGTTTGGGCC ACACATGCCT GTGTACCCAC AGACCCCAAC CCACAAGAAG TAGTATTGGT 6480
AAATGTGACA GAAAATTTTA ACATGTGGAA AAATGACATG GTAGAACAGA TGCATGAGGA 6540
TATAATCAGT TTATGGGATC AAAGCCTAAA GCCATGTGTA AAATTAACCC CACTCTGTGT 6600
TAGTTTAAAG TGCACTGATT TGAAGAATGA TACTAATACC AATAGTAGTA GCGGGAGAAT 6660
GATAATGGAG AAAGGAGAGA TAAAAAACTG CTCTTTCAAT ATCAGCACAA GCATAAGAGA 6720
TAAGGTGCAG AAAGAATATG CATTCTTTTA TAAACTTGAT ATAGTACCAA TAGATAATAC 6780
CAGCTATAGG TTGATAAGTT GTAACACCTC AGTCATTACA CAGGCCTGTC CAAAGGTATC 6840
CTTTGAGCCA ATTCCCATAC ATTATTGTGC CCCGGCTGGT TTTGCGATTC TAAAATGTAA 6900
TAATAAGACG TTCAATGGAA CAGGACCATG TACAAATGTC AGCACAGTAC AATGTACACA 6960
TGGAATCAGG CCAGTAGTAT CAACTCAACT GCTGTTAAAT GGCAGTCTAG CAGAAGAAGA 7020
TGTAGTAATT AGATCTGCCA ATTTCACAGA CAATGCTAAA ACCATAATAG TACAGCTGAA 7080
CACATCTGTA GAAATTAATT GTACAAGACC CAACAACAAT ACAAGAAAAA GTATCCGTAT 7140
CCAGAGGGGA CCAGGGAGAG CATTTGTTAC AATAGGAAAA ATAGGAAATA TGAGACAAGC 7200
ACATTGTAAC ATTAGTAGAG CAAAATGGAA TGCCACTTTA AAACAGATAG CTAGCAAATT 7260
AAGAGAACAA TTTGGAAATA ATAAAACAAT AATCTTTAAG CAATCCTCAG GAGGGGACCC 7320
AGAAATTGTA ACGCACAGTT TTAATTGTGG AGGGGAATTT TTCTACTGTA ATTCAACACA 7380
ACTGTTTAAT AGTACTTGGT TTAATAGTAC TTGGAGTACT GAAGGGTCAA ATAACACTGA 7440
AGGAAGTGAC ACAATCACAC TCCCATGCAG AATAAAACAA TTTATAAACA TGTGGCAGGA 7500
AGTAGGAAAA GCAATGTATG CCCCTCCCAT CAGTGGACAA ATTAGATGTT CATCAAATAT 7560
TACTGGGCTG CTATTAACAA GAGATGGTGG TAATAACAAC AATGGGTCCG AGATCTTCAG 7620
ACCTGGAGGA GGCGATATGA GGGACAATTG GAGAAGTGAA TTATATAAAT ATAAAGTAGT 7680
AAAAATTGAA CCATTAGGAG TAGCACCCAC CAAGGCAAAG AGAAGAGTGG TGCAGAGAGA 7740
AAAAAGAGCA GTGGGAATAG GAGCTTTGTT CCTTGGGTTC TTGGGAGCAG CAGGAAGCAC 7800
TATGGGCTGC ACGTCAATGA CGCTGACGGT ACAGGCCAGA CAATTATTGT CTGATATAGT 7860
GCAGCAGCAG AACAATTTGC TGAGGGCTAT TGAGGCGCAA CAGCATCTGT TGCAACTCAC 7920

AGTCTGGGGC ATCAAACAGC TCCAGGCAAG AATCCTGGCT GTGGAAAGAT ACCTAAAGGA 7980

TCAACAGCTC CTGGGGATTT GGGGTTGCTC TGGAAAACTC ATTTGCACCA CTGCTGTGCC 8040

TTGGAATGCT AGTTGGAGTA ATAAATCTCT GGAACAGATT TGGAATAACA TGACCTGGAT 8100

GGAGTGGGAC AGAGAAATTA ACAATTACAC AAGCTTAATA CACTCCTTAA TTGAAGAATC 8160

GCAAAACCAG CAAGAAAAGA ATGAACAAGA ATTATTGGAA TTAGATAAAT GGGCAAGTTT 8220

GTGGAATTGG TTTAACATAA CAAATTGGCT GTGGTATATA AAATTATTCA TAATGATAGT 8280

AGGAGGCTTG GTAGGTTTAA GAATAGTTTT TGCTGTACTT TCTATAGTGA ATAGAGTTAG 8340

GCAGGGATAT TCACCATTAT CGTTTCAGAC CCACCTCCCA ATCCCGAGGG GACCCGACAG 8400

GCCCGAAGGA ATAGAAGAAG AAGGTGGAGA GAGAGACAGA GACAGATCCA TTCGATTAGT 8460

GAACGGATCC TTAGCACTTA TCTGGGACGA TCTGCGGAGC CTGTGCCTCT TCAGCTACCA 8520

CCGCTTGAGA GACTTACTCT TGATTGTAAC GAGGATTGTG GAACTTCTGG GACGCAGGGG 8580

GTGGGAAGCC CTCAAATATT GGTGGAATCT CCTACAGTAT TGGAGTCAGG AACTAAAGAA 8640

TAGTGCTGTT AACTTGCTCA ATGCCACAGC CATAGCAGTA GCTGAGGGGA CAGATAGGGT 8700

TATAGAAGTA TTACAAGCAG CTTATAGAGC TATTCGCCAC ATACCTAGAA GAATAAGACA 8760

GGGCTTGGAA AGGATTTTGC TATAAGATGG GTGGCAAGTG GTCAAAAAGT AGTGTGATTG 8820

GATGGCCTGC TGTAAGGGAA AGAATGAGAC GAGCTGAGCC AGCAGCAGAT GGGGTGGGAG 8880

CAGTATCTCG AGACCTAGAA AAACATGGAG CAATCACAAG TAGCAATACA GCAGCTAACA 8940

ATGCTGCTTG TGCCTGGCTA GAAGCACAAG AGGAGGAAGA GGTGGGTTTT CCAGTCACAC 9000

CTCAGGTACC TTTAAGACCA ATGACTTACA AGGCAGCTGT AGATCTTAGC CACTTTTTAA 9060

AAGAAAAGGG GGGACTGGAA GGGCTAATTC ACTCCCAAAG AAGACAAGAT ATCCTTGATC 9120

TGTGGATCTA CCACACACAA GGCTACTTCC CTGATTGGCA GAACTACACA CCAGGGCCAG 9180

GGGTCAGATA TCCACTGACC TTTGGATGGT GCTACAAGCT AGTACCAGTT GAGCCAGATA 9240

AGGTAGAAGA GGCCAATAAA GGAGAGAACA CCAGCTTGTT ACACCCTGTG AGCCTGCATG 9300

GAATGGATGA CCCTGAGAGA GAAGTGTTAG AGTGGAGGTT TGACAGCCGC CTAGCATTTC 9360

ATCACGTGGC CCGAGAGCTG CATCCGGAGT ACTTCAAGAA CTGCTGACAT CGAGCTTGCT 9420

ACAAGGGACT TTCCGCTGGG GACTTTCCAG GGAGGCGTGG CCTGGGCGGG ACTGGGGAGT 9480

GGCGAGCCCT CAGATGCTGC ATATAAGCAG CTGCTTTTTG CCTGTACTGG GTCTCTCTGG 9540

TTAGACCAGA TCTGAGCCTG GGAGCTCTCT GGCTAACTAG GGAACCCACT GCTTAAGCCT 9600

CAATAAAGCT TGCCTTGAGT GCTTCAAGTA GTGTGTGCCC GTCTGTTGTG TGACTCTGGT 9660

AACTAGAGAT CCCTCAGACC CTTTTAGTCA GTGTGGAAAA TCTCTAGCA 9709

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGGGTGGCA

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGGTGGCAA

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGGTGGCAAG

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGTGGCAAGT

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTGGCAAGTG

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGGCAAGTGG

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGCAAGTGGT

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCAAGTGGTC

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CAAGTGGTCA

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAGTGGTCAA

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AGTGGTCAAA

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGGTCAAAA

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGTCAAAAA

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGTCAAAAAG

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTCAAAAAGT

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TCAAAAAGTA

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CAAAAAGTAG

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAAAAGTAGT

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AAAAGTAGTG

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAAGTAGTGT

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AAGTAGTGTG

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGTAGTGTGA

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GTAGTGTGAT

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TAGTGTGATT

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AGTGTGATTG

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GTGTGATTGG

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TGTGATTGGA

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GTGATTGGAT

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

TGATTGGATG

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GATTGGATGG

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

ATTGGATGGC

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

TTGGATGGCC

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TGGATGGCCT

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GGATGGCCTG

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GATGGCCTGC

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATGGCCTGCT

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TGGCCTGCTG

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GGCCTGCTGT

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GCCTGCTGTA

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CCTGCTGTAA

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CTGCTGTAAG

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TGCTGTAAGG

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCTGTAAGGG

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

CTGTAAGGGA

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TGTAAGGGAA

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GTAAGGGAAA

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

TAAGGGAAAG

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

AAGGGAAAGA

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

AGGGAAAGAA

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GGGAAAGAAT

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GGAAAGAATG

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GAAAGAATGA

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

AAAGAATGAG

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

AAGAATGAGA

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

AGAATGAGAC

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GAATGAGACG

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

AATGAGACGA

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ATGAGACGAG

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

TGAGACGAGC

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

GAGACGAGCT

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

AGACGAGCTG

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

GACGAGCTGA

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

ACGAGCTGAG

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

CGAGCTGAGC

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GAGCTGAGCC

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

AGCTGAGCCA

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GCTGAGCCAG

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

CTGAGCCAGC

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

TGAGCCAGCA

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

GAGCCAGCAG

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

AGCCAGCAGC

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

GCCAGCAGCA

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

CCAGCAGCAG

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CAGCAGCAGA

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

AGCAGCAGAT

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

GCAGCAGATG

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CAGCAGATGG

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

AGCAGATGGG

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GCAGATGGGG

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

CAGATGGGGT

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

AGATGGGGTG

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

GATGGGGTGG

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

ATGGGGTGGG

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TGGGGTGGGA

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

GGGGTGGGAG

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

GGGTGGGAGC

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

GGTGGGAGCA

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GTGGGAGCAG

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

TGGGAGCAGT

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GGGAGCAGTA

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

GGAGCAGTAT

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

GAGCAGTATC

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

AGCAGTATCT

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

GCAGTATCTC

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

CAGTATCTCG

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

AGTATCTCGA

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

GTATCTCGAG

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

TATCTCGAGA

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

ATCTCGAGAC

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TCTCGAGACC

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

CTCGAGACCT

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

TCGAGACCTA

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

CGAGACCTAG

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

GAGACCTAGA

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

AGACCTAGAA

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

GACCTAGAAA

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

ACCTAGAAAA

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

CCTAGAAAAA

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

CTAGAAAAAC

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

TAGAAAAACA

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

AGAAAAACAT

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

GAAAAACATG

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

AAAAACATGG

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

AAAACATGGA

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

AAACATGGAG

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

AACATGGAGC

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

ACATGGAGCA

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

CATGGAGCAA

(2) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

ATGGAGCAAT

(2) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

TGGAGCAATC

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

GGAGCAATCA

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GAGCAATCAC

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

AGCAATCACA

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

GCAATCACAA

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

CAATCACAAG

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

AATCACAAGT

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

ATCACAAGTA

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

TCACAAGTAG

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

CACAAGTAGC

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

ACAAGTAGCA

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

CAAGTAGCAA

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

AAGTAGCAAT

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

AGTAGCAATA

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

GTAGCAATAC

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

TAGCAATACA

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

AGCAATACAG

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

BNSDOCID: <WO___9521912A1_I_>

GCAATACAGC

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

CAATACAGCA

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

AATACAGCAG

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

ATACAGCAGC

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

TACAGCAGCT

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

ACAGCAGCTA

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

CAGCAGCTAA

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

AGCAGCTAAC

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

GCAGCTAACA

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

CAGCTAACAA

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

AGCTAACAAT

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

GCTAACAATG

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

CTAACAATGC

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

TAACAATGCT

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

AACAATGCTG

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

ACAATGCTGC

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

CAATGCTGCT

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

AATGCTGCTT

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

ATGCTGCTTG

(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

TGCTGCTTGT

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

GCTGCTTGTG

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

CTGCTTGTGC

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

TGCTTGTGCC

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

GCTTGTGCCT

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

CTTGTGCCTG

(2) INFORMATION FOR SEQ ID NO:163:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

TTGTGCCTGG

(2) INFORMATION FOR SEQ ID NO:164:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

TGTGCCTGGC

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

GTGCCTGGCT

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

TGCCTGGCTA

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

GCCTGGCTAG

(2) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

CCTGGCTAGA

(2) INFORMATION FOR SEQ ID NO:169:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

CTGGCTAGAA

(2) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

TGGCTAGAAG

(2) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

GGCTAGAAGC

(2) INFORMATION FOR SEQ ID NO:172:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

GCTAGAAGCA

(2) INFORMATION FOR SEQ ID NO:173:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

CTAGAAGCAC

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

TAGAAGCACA

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

AGAAGCACAA

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

GAAGCACAAG

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

AAGCACAAGA

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

AGCACAAGAG

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

GCACAAGAGG

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

CACAAGAGGA

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

ACAAGAGGAG

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

CAAGAGGAGG

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

AAGAGGAGGA

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

AGAGGAGGAA

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

GAGGAGGAAG

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

AGGAGGAAGA

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

GGAGGAAGAG

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

GAGGAAGAGG

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

AGGAAGAGGT

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

GGAAGAGGTG

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GAAGAGGTGG

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

AAGAGGTGGG

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

AGAGGTGGGT

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

GAGGTGGGTT

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

AGGTGGGTTT

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

GGTGGGTTTT

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

GTGGGTTTTC

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

TGGGTTTTCC

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

GGGTTTTCCA

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

GGTTTTCCAG

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

GTTTTCCAGT

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

TTTTCCAGTC

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

TTTCCAGTCA

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

TTCCAGTCAC

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

TCCAGTCACA

(2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

CCAGTCACAC

(2) INFORMATION FOR SEQ ID NO:207:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

CAGTCACACC

(2) INFORMATION FOR SEQ ID NO:208:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

AGTCACACCT

(2) INFORMATION FOR SEQ ID NO:209:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

GTCACACCTC

(2) INFORMATION FOR SEQ ID NO:210:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

TCACACCTCA

(2) INFORMATION FOR SEQ ID NO:211:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

CACACCTCAG

(2) INFORMATION FOR SEQ ID NO:212:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

ACACCTCAGG

(2) INFORMATION FOR SEQ ID NO:213:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

CACCTCAGGT

(2) INFORMATION FOR SEQ ID NO:214:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

ACCTCAGGTA

(2) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

CCTCAGGTAC

(2) INFORMATION FOR SEQ ID NO:216:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

CTCAGGTACC

(2) INFORMATION FOR SEQ ID NO:217:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

TCAGGTACCT

(2) INFORMATION FOR SEQ ID NO:218:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

CAGGTACCTT

(2) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

AGGTACCTTT

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

GGTACCTTTA

(2) INFORMATION FOR SEQ ID NO:221:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

GTACCTTTAA

(2) INFORMATION FOR SEQ ID NO:222:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

TACCTTTAAG

(2) INFORMATION FOR SEQ ID NO:223:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

ACCTTTAAGA

(2) INFORMATION FOR SEQ ID NO:224:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

CCTTTAAGAC

(2) INFORMATION FOR SEQ ID NO:225:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

CTTTAAGACC

(2) INFORMATION FOR SEQ ID NO:226:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

TTTAAGACCA

(2) INFORMATION FOR SEQ ID NO:227:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

TTAAGACCAA

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

TAAGACCAAT

(2) INFORMATION FOR SEQ ID NO:229:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

AAGACCAATG

(2) INFORMATION FOR SEQ ID NO:230:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

AGACCAATGA

(2) INFORMATION FOR SEQ ID NO:231:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

GACCAATGAC

(2) INFORMATION FOR SEQ ID NO:232:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

ACCAATGACT

(2) INFORMATION FOR SEQ ID NO:233:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

CCAATGACTT

(2) INFORMATION FOR SEQ ID NO:234:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

CAATGACTTA

(2) INFORMATION FOR SEQ ID NO:235:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

AATGACTTAC

(2) INFORMATION FOR SEQ ID NO:236:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

ATGACTTACA

(2) INFORMATION FOR SEQ ID NO:237:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

TGACTTACAA

(2) INFORMATION FOR SEQ ID NO:238:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

GACTTACAAG

(2) INFORMATION FOR SEQ ID NO:239:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

ACTTACAAGG

(2) INFORMATION FOR SEQ ID NO:240:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:240:

CTTACAAGGC

(2) INFORMATION FOR SEQ ID NO:241:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:241:

TTACAAGGCA

(2) INFORMATION FOR SEQ ID NO:242:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

TACAAGGCAG

(2) INFORMATION FOR SEQ ID NO:243:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:243:

ACAAGGCAGC

(2) INFORMATION FOR SEQ ID NO:244:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:244:

CAAGGCAGCT

(2) INFORMATION FOR SEQ ID NO:245:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:245:

AAGGCAGCTG

(2) INFORMATION FOR SEQ ID NO:246:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:246:

AGGCAGCTGT

(2) INFORMATION FOR SEQ ID NO:247:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:247:

GGCAGCTGTA

(2) INFORMATION FOR SEQ ID NO:248:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:248:

GCAGCTGTAG

(2) INFORMATION FOR SEQ ID NO:249:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:249:

CAGCTGTAGA

(2) INFORMATION FOR SEQ ID NO:250:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

AGCTGTAGAT

(2) INFORMATION FOR SEQ ID NO:251:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

GCTGTAGATC

(2) INFORMATION FOR SEQ ID NO:252:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:252:

CTGTAGATCT

(2) INFORMATION FOR SEQ ID NO:253:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

TGTAGATCTT

(2) INFORMATION FOR SEQ ID NO:254:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:254:

GTAGATCTTA

(2) INFORMATION FOR SEQ ID NO:255:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:

TAGATCTTAG

(2) INFORMATION FOR SEQ ID NO:256:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:256:

AGATCTTAGC

(2) INFORMATION FOR SEQ ID NO:257:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:257:

GATCTTAGCC

(2) INFORMATION FOR SEQ ID NO:258:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:258:

ATCTTAGCCA

(2) INFORMATION FOR SEQ ID NO:259:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:259:

TCTTAGCCAC

(2) INFORMATION FOR SEQ ID NO:260:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:260:

CTTAGCCACT

(2) INFORMATION FOR SEQ ID NO:261:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

TTAGCCACTT

(2) INFORMATION FOR SEQ ID NO:262:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:262:

TAGCCACTTT

(2) INFORMATION FOR SEQ ID NO:263:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:263:

AGCCACTTTT

(2) INFORMATION FOR SEQ ID NO:264:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:264:

GCCACTTTTT

(2) INFORMATION FOR SEQ ID NO:265:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:265:

CCACTTTTTA

(2) INFORMATION FOR SEQ ID NO:266:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

CACTTTTTAA

(2) INFORMATION FOR SEQ ID NO:267:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

ACTTTTTAAA

(2) INFORMATION FOR SEQ ID NO:268:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:268:

CTTTTTAAAA

(2) INFORMATION FOR SEQ ID NO:269:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

TTTTTAAAAG

(2) INFORMATION FOR SEQ ID NO:270:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:270:

TTTTAAAAGA

(2) INFORMATION FOR SEQ ID NO:271:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

TTTAAAAGAA

(2) INFORMATION FOR SEQ ID NO:272:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:272:

TTAAAAGAAA

(2) INFORMATION FOR SEQ ID NO:273:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

TAAAAGAAAA

(2) INFORMATION FOR SEQ ID NO:274:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:274:

AAAAGAAAAG

(2) INFORMATION FOR SEQ ID NO:275:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:

AAAGAAAAGG

(2) INFORMATION FOR SEQ ID NO:276:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:276:

AAGAAAAGGG

(2) INFORMATION FOR SEQ ID NO:277:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:277:

AGAAAAGGGG

(2) INFORMATION FOR SEQ ID NO:278:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:

GAAAAGGGGG

(2) INFORMATION FOR SEQ ID NO:279:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:279:

AAAAGGGGGG

(2) INFORMATION FOR SEQ ID NO:280:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:280:

AAAGGGGGGA

(2) INFORMATION FOR SEQ ID NO:281:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:

AAGGGGGGAC

(2) INFORMATION FOR SEQ ID NO:282:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:282:

AGGGGGGACT

(2) INFORMATION FOR SEQ ID NO:283:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:

GGGGGGACTG

(2) INFORMATION FOR SEQ ID NO:284:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:

GGGGGACTGG

(2) INFORMATION FOR SEQ ID NO:285:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:285:

GGGGACTGGA

(2) INFORMATION FOR SEQ ID NO:286:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:

GGGACTGGAA

(2) INFORMATION FOR SEQ ID NO:287:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:287:

GGACTGGAAG

(2) INFORMATION FOR SEQ ID NO:288:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:

GACTGGAAGG

(2) INFORMATION FOR SEQ ID NO:289:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:289:

ACTGGAAGGG

(2) INFORMATION FOR SEQ ID NO:290:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:290:

CTGGAAGGGC

(2) INFORMATION FOR SEQ ID NO:291:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:291:

TGGAAGGGCT

(2) INFORMATION FOR SEQ ID NO:292:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:

GGAAGGGCTA

(2) INFORMATION FOR SEQ ID NO:293:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:

GAAGGGCTAA

(2) INFORMATION FOR SEQ ID NO:294:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

AAGGGCTAAT

(2) INFORMATION FOR SEQ ID NO:295:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:295:

AGGGCTAATT

(2) INFORMATION FOR SEQ ID NO:296:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:296:

GGGCTAATTC

(2) INFORMATION FOR SEQ ID NO:297:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:297:

GGCTAATTCA

(2) INFORMATION FOR SEQ ID NO:298:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

GCTAATTCAC

(2) INFORMATION FOR SEQ ID NO:299:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:299:

CTAATTCACT

(2) INFORMATION FOR SEQ ID NO:300:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

TAATTCACTC

(2) INFORMATION FOR SEQ ID NO:301:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

AATTCACTCC

(2) INFORMATION FOR SEQ ID NO:302:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

ATTCACTCCC

(2) INFORMATION FOR SEQ ID NO:303:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:303:

TTCACTCCCA

(2) INFORMATION FOR SEQ ID NO:304:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:304:

TCACTCCCAA

(2) INFORMATION FOR SEQ ID NO:305:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:

CACTCCCAAA

(2) INFORMATION FOR SEQ ID NO:306:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:306:

ACTCCCAAAG

(2) INFORMATION FOR SEQ ID NO:307:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

CTCCCAAAGA

(2) INFORMATION FOR SEQ ID NO:308:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:

TCCCAAAGAA

(2) INFORMATION FOR SEQ ID NO:309:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

CCCAAAGAAG

(2) INFORMATION FOR SEQ ID NO:310:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

CCAAAGAAGA

(2) INFORMATION FOR SEQ ID NO:311:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:311:

CAAAGAAGAC

(2) INFORMATION FOR SEQ ID NO:312:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:312:

AAAGAAGACA

(2) INFORMATION FOR SEQ ID NO:313:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:313:

AAGAAGACAA

(2) INFORMATION FOR SEQ ID NO:314:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:314:

AGAAGACAAG

(2) INFORMATION FOR SEQ ID NO:315:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:315:

GAAGACAAGA

(2) INFORMATION FOR SEQ ID NO:316:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:316:

AAGACAAGAT

(2) INFORMATION FOR SEQ ID NO:317:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:317:

AGACAAGATA

(2) INFORMATION FOR SEQ ID NO:318:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:318:

GACAAGATAT

(2) INFORMATION FOR SEQ ID NO:319:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:319:

ACAAGATATC

(2) INFORMATION FOR SEQ ID NO:320:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:320:

CAAGATATCC

(2) INFORMATION FOR SEQ ID NO:321:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:321:

AAGATATCCT

(2) INFORMATION FOR SEQ ID NO:322:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:322:

AGATATCCTT

(2) INFORMATION FOR SEQ ID NO:323:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:323:

GATATCCTTG

(2) INFORMATION FOR SEQ ID NO:324:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:324:

ATATCCTTGA

(2) INFORMATION FOR SEQ ID NO:325:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:325:

TATCCTTGAT

(2) INFORMATION FOR SEQ ID NO:326:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:326:

ATCCTTGATC

(2) INFORMATION FOR SEQ ID NO:327:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:327:

TCCTTGATCT

(2) INFORMATION FOR SEQ ID NO:328:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:328:

CCTTGATCTG

(2) INFORMATION FOR SEQ ID NO:329:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:329:

CTTGATCTGT

(2) INFORMATION FOR SEQ ID NO:330:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:330:

TTGATCTGTG

(2) INFORMATION FOR SEQ ID NO:331:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:331:

TGATCTGTGG

(2) INFORMATION FOR SEQ ID NO:332:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:332:

GATCTGTGGA

(2) INFORMATION FOR SEQ ID NO:333:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:333:

ATCTGTGGAT

(2) INFORMATION FOR SEQ ID NO:334:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:334:

TCTGTGGATC

(2) INFORMATION FOR SEQ ID NO:335:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:335:

CTGTGGATCT

(2) INFORMATION FOR SEQ ID NO:336:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:336:

TGTGGATCTA

(2) INFORMATION FOR SEQ ID NO:337:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:337:

GTGGATCTAC

(2) INFORMATION FOR SEQ ID NO:338:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:338:

TGGATCTACC

(2) INFORMATION FOR SEQ ID NO:339:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:339:

GGATCTACCA

(2) INFORMATION FOR SEQ ID NO:340:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:340:

GATCTACCAC

(2) INFORMATION FOR SEQ ID NO:341:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:341:

ATCTACCACA

(2) INFORMATION FOR SEQ ID NO:342:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:342:

TCTACCACAC

(2) INFORMATION FOR SEQ ID NO:343:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:343:

CTACCACACA

(2) INFORMATION FOR SEQ ID NO:344:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:344:

TACCACACAC

(2) INFORMATION FOR SEQ ID NO:345:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:345:

ACCACACACA

(2) INFORMATION FOR SEQ ID NO:346:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:346:

CCACACACAA

(2) INFORMATION FOR SEQ ID NO:347:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:347:

CACACACAAG

(2) INFORMATION FOR SEQ ID NO:348:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:348:

ACACACAAGG

(2) INFORMATION FOR SEQ ID NO:349:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:349:

CACACAAGGC

(2) INFORMATION FOR SEQ ID NO:350:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:350:

ACACAAGGCT

(2) INFORMATION FOR SEQ ID NO:351:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:351:

CACAAGGCTA

(2) INFORMATION FOR SEQ ID NO:352:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:352:

ACAAGGCTAC

(2) INFORMATION FOR SEQ ID NO:353:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:353:

CAAGGCTACT

(2) INFORMATION FOR SEQ ID NO:354:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:354:

AAGGCTACTT

(2) INFORMATION FOR SEQ ID NO:355:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:355:

AGGCTACTTC

(2) INFORMATION FOR SEQ ID NO:356:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:356:

GGCTACTTCC

(2) INFORMATION FOR SEQ ID NO:357:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:357:

GCTACTTCCC

(2) INFORMATION FOR SEQ ID NO:358:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:358:

CTACTTCCCT

(2) INFORMATION FOR SEQ ID NO:359:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:359:

TACTTCCCTG

(2) INFORMATION FOR SEQ ID NO:360:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:360:

ACTTCCCTGA

(2) INFORMATION FOR SEQ ID NO:361:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:361:

CTTCCCTGAT

(2) INFORMATION FOR SEQ ID NO:362:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:362:

TTCCCTGATT

(2) INFORMATION FOR SEQ ID NO:363:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:363:

TCCCTGATTG

(2) INFORMATION FOR SEQ ID NO:364:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:364:

CCCTGATTGG

(2) INFORMATION FOR SEQ ID NO:365:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:365:

CCTGATTGGC

(2) INFORMATION FOR SEQ ID NO:366:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:366:

CTGATTGGCA

(2) INFORMATION FOR SEQ ID NO:367:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:367:

TGATTGGCAG

(2) INFORMATION FOR SEQ ID NO:368:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:368:

GATTGGCAGA

(2) INFORMATION FOR SEQ ID NO:369:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:369:

ATTGGCAGAA

(2) INFORMATION FOR SEQ ID NO:370:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:370:

TTGGCAGAAC

(2) INFORMATION FOR SEQ ID NO:371:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:371:

TGGCAGAACT

(2) INFORMATION FOR SEQ ID NO:372:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:372:

GGCAGAACTA

(2) INFORMATION FOR SEQ ID NO:373:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:373:

GCAGAACTAC

(2) INFORMATION FOR SEQ ID NO:374:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:374:

CAGAACTACA

(2) INFORMATION FOR SEQ ID NO:375:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:375:

AGAACTACAC

(2) INFORMATION FOR SEQ ID NO:376:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:376:

GAACTACACA

(2) INFORMATION FOR SEQ ID NO:377:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:377:

AACTACACAC

(2) INFORMATION FOR SEQ ID NO:378:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:378:

ACTACACACC

(2) INFORMATION FOR SEQ ID NO:379:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:379:

CTACACACCA

(2) INFORMATION FOR SEQ ID NO:380:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:380:

TACACACCAG

(2) INFORMATION FOR SEQ ID NO:381:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:381:

ACACACCAGG

(2) INFORMATION FOR SEQ ID NO:382:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:382:

CACACCAGGG

(2) INFORMATION FOR SEQ ID NO:383:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:383:

ACACCAGGGC

(2) INFORMATION FOR SEQ ID NO:384:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:384:

CACCAGGGCC

(2) INFORMATION FOR SEQ ID NO:385:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:385:

ACCAGGGCCA

(2) INFORMATION FOR SEQ ID NO:386:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:386:

CCAGGGCCAG

(2) INFORMATION FOR SEQ ID NO:387:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:387:

CAGGGCCAGG

(2) INFORMATION FOR SEQ ID NO:388:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:388:

AGGGCCAGGG

(2) INFORMATION FOR SEQ ID NO:389:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:389:

GGGCCAGGGG

(2) INFORMATION FOR SEQ ID NO:390:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:390:

GGCCAGGGGT

(2) INFORMATION FOR SEQ ID NO:391:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:391:

GCCAGGGGTC

(2) INFORMATION FOR SEQ ID NO:392:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:392:

CCAGGGGTCA

(2) INFORMATION FOR SEQ ID NO:393:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:393:

CAGGGGTCAG

(2) INFORMATION FOR SEQ ID NO:394:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:394:

AGGGGTCAGA

(2) INFORMATION FOR SEQ ID NO:395:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:395:

GGGGTCAGAT

(2) INFORMATION FOR SEQ ID NO:396:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:396:

GGGTCAGATA

(2) INFORMATION FOR SEQ ID NO:397:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:397:

GGTCAGATAT

(2) INFORMATION FOR SEQ ID NO:398:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:398:

GTCAGATATC

(2) INFORMATION FOR SEQ ID NO:399:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:399:

TCAGATATCC

(2) INFORMATION FOR SEQ ID NO:400:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:400:

CAGATATCCA

(2) INFORMATION FOR SEQ ID NO:401:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:401:

AGATATCCAC

(2) INFORMATION FOR SEQ ID NO:402:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:402:

GATATCCACT

(2) INFORMATION FOR SEQ ID NO:403:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:403:

ATATCCACTG

(2) INFORMATION FOR SEQ ID NO:404:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:404:

TATCCACTGA

(2) INFORMATION FOR SEQ ID NO:405:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:405:

ATCCACTGAC

(2) INFORMATION FOR SEQ ID NO:406:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:406:

TCCACTGACC

(2) INFORMATION FOR SEQ ID NO:407:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:407:

CCACTGACCT

(2) INFORMATION FOR SEQ ID NO:408:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:408:

CACTGACCTT

(2) INFORMATION FOR SEQ ID NO:409:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:409:

ACTGACCTTT

(2) INFORMATION FOR SEQ ID NO:410:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:410:

CTGACCTTTG

(2) INFORMATION FOR SEQ ID NO:411:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:411:

TGACCTTTGG

(2) INFORMATION FOR SEQ ID NO:412:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:412:

GACCTTTGGA

(2) INFORMATION FOR SEQ ID NO:413:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:413:

ACCTTTGGAT

(2) INFORMATION FOR SEQ ID NO:414:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:414:

CCTTTGGATG

(2) INFORMATION FOR SEQ ID NO:415:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:415:

CTTTGGATGG

(2) INFORMATION FOR SEQ ID NO:416:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:416:

TTTGGATGGT

(2) INFORMATION FOR SEQ ID NO:417:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:417:

TTGGATGGTG

(2) INFORMATION FOR SEQ ID NO:418:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:418:

TGGATGGTGC

(2) INFORMATION FOR SEQ ID NO:419:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:419:

GGATGGTGCT

(2) INFORMATION FOR SEQ ID NO:420:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:420:

GATGGTGCTA

(2) INFORMATION FOR SEQ ID NO:421:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:421:

ATGGTGCTAC

(2) INFORMATION FOR SEQ ID NO:422:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:422:

TGGTGCTACA

(2) INFORMATION FOR SEQ ID NO:423:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:423:

GGTGCTACAA

(2) INFORMATION FOR SEQ ID NO:424:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:424:

GTGCTACAAG

(2) INFORMATION FOR SEQ ID NO:425:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:425:

TGCTACAAGC

(2) INFORMATION FOR SEQ ID NO:426:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:426:

GCTACAAGCT

(2) INFORMATION FOR SEQ ID NO:427:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:427:

CTACAAGCTA

(2) INFORMATION FOR SEQ ID NO:428:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:428:

TACAAGCTAG

(2) INFORMATION FOR SEQ ID NO:429:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:429:

ACAAGCTAGT

(2) INFORMATION FOR SEQ ID NO:430:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:430:

CAAGCTAGTA

(2) INFORMATION FOR SEQ ID NO:431:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:431:

AAGCTAGTAC

(2) INFORMATION FOR SEQ ID NO:432:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:432:

AGCTAGTACC

(2) INFORMATION FOR SEQ ID NO:433:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:433:

GCTAGTACCA

(2) INFORMATION FOR SEQ ID NO:434:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:434:

CTAGTACCAG

(2) INFORMATION FOR SEQ ID NO:435:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:435:

TAGTACCAGT

(2) INFORMATION FOR SEQ ID NO:436:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:436:

AGTACCAGTT

(2) INFORMATION FOR SEQ ID NO:437:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:437:

GTACCAGTTG

(2) INFORMATION FOR SEQ ID NO:438:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:438:

TACCAGTTGA

(2) INFORMATION FOR SEQ ID NO:439:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:439:

ACCAGTTGAG

(2) INFORMATION FOR SEQ ID NO:440:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:440:

CCAGTTGAGC

(2) INFORMATION FOR SEQ ID NO:441:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:441:

CAGTTGAGCC

(2) INFORMATION FOR SEQ ID NO:442:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:442:

AGTTGAGCCA

(2) INFORMATION FOR SEQ ID NO:443:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:443:

GTTGAGCCAG

(2) INFORMATION FOR SEQ ID NO:444:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:444:

TTGAGCCAGA

(2) INFORMATION FOR SEQ ID NO:445:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:445:

TGAGCCAGAT

(2) INFORMATION FOR SEQ ID NO:446:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:446:

GAGCCAGATA

(2) INFORMATION FOR SEQ ID NO:447:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:447:

AGCCAGATAA

(2) INFORMATION FOR SEQ ID NO:448:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:448:

GCCAGATAAG

(2) INFORMATION FOR SEQ ID NO:449:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:449:

CCAGATAAGG

(2) INFORMATION FOR SEQ ID NO:450:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:450:

CAGATAAGGT

(2) INFORMATION FOR SEQ ID NO:451:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:451:

AGATAAGGTA

(2) INFORMATION FOR SEQ ID NO:452:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:452:

GATAAGGTAG

(2) INFORMATION FOR SEQ ID NO:453:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:453:

ATAAGGTAGA

(2) INFORMATION FOR SEQ ID NO:454:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:454:

TAAGGTAGAA

(2) INFORMATION FOR SEQ ID NO:455:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:455:

AAGGTAGAAG

(2) INFORMATION FOR SEQ ID NO:456:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:456:

AGGTAGAAGA

(2) INFORMATION FOR SEQ ID NO:457:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:457:

GGTAGAAGAG

(2) INFORMATION FOR SEQ ID NO:458:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:458:

GTAGAAGAGG

(2) INFORMATION FOR SEQ ID NO:459:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:459:

TAGAAGAGGC

(2) INFORMATION FOR SEQ ID NO:460:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:460:

AGAAGAGGCC

(2) INFORMATION FOR SEQ ID NO:461:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:461:

GAAGAGGCCA

(2) INFORMATION FOR SEQ ID NO:462:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:462:

AAGAGGCCAA

(2) INFORMATION FOR SEQ ID NO:463:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:463:

AGAGGCCAAT

(2) INFORMATION FOR SEQ ID NO:464:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:464:

GAGGCCAATA

(2) INFORMATION FOR SEQ ID NO:465:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:465:

AGGCCAATAA

(2) INFORMATION FOR SEQ ID NO:466:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:466:

GGCCAATAAA

(2) INFORMATION FOR SEQ ID NO:467:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:467:

GCCAATAAAG

(2) INFORMATION FOR SEQ ID NO:468:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:468:

CCAATAAAGG

(2) INFORMATION FOR SEQ ID NO:469:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:469:

CAATAAAGGA

(2) INFORMATION FOR SEQ ID NO:470:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:470:

AATAAAGGAG

(2) INFORMATION FOR SEQ ID NO:471:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:471:

ATAAAGGAGA

(2) INFORMATION FOR SEQ ID NO:472:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:472:

TAAAGGAGAG

(2) INFORMATION FOR SEQ ID NO:473:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:473:

AAAGGAGAGA

(2) INFORMATION FOR SEQ ID NO:474:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:474:

AAGGAGAGAA

(2) INFORMATION FOR SEQ ID NO:475:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:475:

AGGAGAGAAC

(2) INFORMATION FOR SEQ ID NO:476:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:476:

GGAGAGAACA

(2) INFORMATION FOR SEQ ID NO:477:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:477:

GAGAGAACAC

(2) INFORMATION FOR SEQ ID NO:478:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:478:

AGAGAACACC

(2) INFORMATION FOR SEQ ID NO:479:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:479:

GAGAACACCA

(2) INFORMATION FOR SEQ ID NO:480:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:480:

AGAACACCAG

(2) INFORMATION FOR SEQ ID NO:481:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:481:

GAACACCAGC

(2) INFORMATION FOR SEQ ID NO:482:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:482:

AACACCAGCT

(2) INFORMATION FOR SEQ ID NO:483:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:483:

ACACCAGCTT

(2) INFORMATION FOR SEQ ID NO:484:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:484:

CACCAGCTTG

(2) INFORMATION FOR SEQ ID NO:485:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:485:

ACCAGCTTGT

(2) INFORMATION FOR SEQ ID NO:486:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:486:

CCAGCTTGTT

(2) INFORMATION FOR SEQ ID NO:487:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:487:

CAGCTTGTTA

(2) INFORMATION FOR SEQ ID NO:488:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:488:

AGCTTGTTAC

(2) INFORMATION FOR SEQ ID NO:489:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:489:

GCTTGTTACA

(2) INFORMATION FOR SEQ ID NO:490:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:490:

CTTGTTACAC

(2) INFORMATION FOR SEQ ID NO:491:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:491:

TTGTTACACC

(2) INFORMATION FOR SEQ ID NO:492:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:492:

TGTTACACCC

(2) INFORMATION FOR SEQ ID NO:493:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:493:

GTTACACCCT

(2) INFORMATION FOR SEQ ID NO:494:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:494:

TTACACCCTG

(2) INFORMATION FOR SEQ ID NO:495:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:495:

TACACCCTGT

(2) INFORMATION FOR SEQ ID NO:496:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:496:

ACACCCTGTG

(2) INFORMATION FOR SEQ ID NO:497:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:497:

CACCCTGTGA

(2) INFORMATION FOR SEQ ID NO:498:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:498:

ACCCTGTGAG

(2) INFORMATION FOR SEQ ID NO:499:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:499:

CCCTGTGAGC

(2) INFORMATION FOR SEQ ID NO:500:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:500:

CCTGTGAGCC

(2) INFORMATION FOR SEQ ID NO:501:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:501:

CTGTGAGCCT

(2) INFORMATION FOR SEQ ID NO:502:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:502:

TGTGAGCCTG

(2) INFORMATION FOR SEQ ID NO:503:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:503:

GTGAGCCTGC

(2) INFORMATION FOR SEQ ID NO:504:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:504:

TGAGCCTGCA

(2) INFORMATION FOR SEQ ID NO:505:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:505:

GAGCCTGCAT

(2) INFORMATION FOR SEQ ID NO:506:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:506:

AGCCTGCATG

(2) INFORMATION FOR SEQ ID NO:507:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:507:

GCCTGCATGG

(2) INFORMATION FOR SEQ ID NO:508:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:508:

CCTGCATGGA

(2) INFORMATION FOR SEQ ID NO:509:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:509:

CTGCATGGAA

(2) INFORMATION FOR SEQ ID NO:510:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:510:

TGCATGGAAT

(2) INFORMATION FOR SEQ ID NO:511:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:511:

GCATGGAATG

(2) INFORMATION FOR SEQ ID NO:512:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:512:

CATGGAATGG

(2) INFORMATION FOR SEQ ID NO:513:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:513:

ATGGAATGGA

(2) INFORMATION FOR SEQ ID NO:514:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:514:

TGGAATGGAT

(2) INFORMATION FOR SEQ ID NO:515:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:515:

GGAATGGATG

(2) INFORMATION FOR SEQ ID NO:516:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:516:

GAATGGATGA

(2) INFORMATION FOR SEQ ID NO:517:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:517:

AATGGATGAC

(2) INFORMATION FOR SEQ ID NO:518:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:518:

ATGGATGACC

(2) INFORMATION FOR SEQ ID NO:519:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:519:

TGGATGACCC

(2) INFORMATION FOR SEQ ID NO:520:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:520:

GGATGACCCT

(2) INFORMATION FOR SEQ ID NO:521:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:521:

GATGACCCTG

(2) INFORMATION FOR SEQ ID NO:522:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:522:

ATGACCCTGA

(2) INFORMATION FOR SEQ ID NO:523:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:523:

TGACCCTGAG

(2) INFORMATION FOR SEQ ID NO:524:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:524:

GACCCTGAGA

(2) INFORMATION FOR SEQ ID NO:525:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:525:

ACCCTGAGAG

(2) INFORMATION FOR SEQ ID NO:526:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:526:

CCCTGAGAGA

(2) INFORMATION FOR SEQ ID NO:527:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:527:

CCTGAGAGAG

(2) INFORMATION FOR SEQ ID NO:528:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:528:

CTGAGAGAGA

(2) INFORMATION FOR SEQ ID NO:529:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:529:

TGAGAGAGAA

(2) INFORMATION FOR SEQ ID NO:530:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:530:

GAGAGAGAAG

(2) INFORMATION FOR SEQ ID NO:531:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:531:

AGAGAGAAGT

(2) INFORMATION FOR SEQ ID NO:532:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:532:

GAGAGAAGTG

(2) INFORMATION FOR SEQ ID NO:533:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:533:

AGAGAAGTGT

(2) INFORMATION FOR SEQ ID NO:534:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:534:

GAGAAGTGTT

(2) INFORMATION FOR SEQ ID NO:535:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:535:

AGAAGTGTTA

(2) INFORMATION FOR SEQ ID NO:536:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:536:

GAAGTGTTAG

(2) INFORMATION FOR SEQ ID NO:537:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:537:

AAGTGTTAGA

(2) INFORMATION FOR SEQ ID NO:538:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:538:

AGTGTTAGAG

(2) INFORMATION FOR SEQ ID NO:539:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:539:

GTGTTAGAGT

(2) INFORMATION FOR SEQ ID NO:540:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:540:

TGTTAGAGTG

(2) INFORMATION FOR SEQ ID NO:541:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:541:

GTTAGAGTGG

(2) INFORMATION FOR SEQ ID NO:542:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:542:

TTAGAGTGGA

(2) INFORMATION FOR SEQ ID NO:543:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:543:

TAGAGTGGAG

(2) INFORMATION FOR SEQ ID NO:544:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:544:

AGAGTGGAGG

(2) INFORMATION FOR SEQ ID NO:545:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:545:

GAGTGGAGGT

(2) INFORMATION FOR SEQ ID NO:546:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:546:

AGTGGAGGTT

(2) INFORMATION FOR SEQ ID NO:547:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:547:

GTGGAGGTTT

(2) INFORMATION FOR SEQ ID NO:548:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:548:

TGGAGGTTTG

(2) INFORMATION FOR SEQ ID NO:549:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:549:

GGAGGTTTGA

(2) INFORMATION FOR SEQ ID NO:550:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:550:

GAGGTTTGAC

(2) INFORMATION FOR SEQ ID NO:551:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:551:

AGGTTTGACA

(2) INFORMATION FOR SEQ ID NO:552:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:552:

GGTTTGACAG

(2) INFORMATION FOR SEQ ID NO:553:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:553:

GTTTGACAGC

(2) INFORMATION FOR SEQ ID NO:554:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:554:

TTTGACAGCC

(2) INFORMATION FOR SEQ ID NO:555:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:555:

TTGACAGCCG

(2) INFORMATION FOR SEQ ID NO:556:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:556:

TGACAGCCGC

(2) INFORMATION FOR SEQ ID NO:557:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:557:

GACAGCCGCC

(2) INFORMATION FOR SEQ ID NO:558:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:558:

ACAGCCGCCT

(2) INFORMATION FOR SEQ ID NO:559:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:559:

CAGCCGCCTA

(2) INFORMATION FOR SEQ ID NO:560:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:560:

AGCCGCCTAG

(2) INFORMATION FOR SEQ ID NO:561:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:561:

GCCGCCTAGC

(2) INFORMATION FOR SEQ ID NO:562:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:562:

CCGCCTAGCA

(2) INFORMATION FOR SEQ ID NO:563:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:563:

CGCCTAGCAT

(2) INFORMATION FOR SEQ ID NO:564:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:564:

GCCTAGCATT

(2) INFORMATION FOR SEQ ID NO:565:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:565:

CCTAGCATTT

(2) INFORMATION FOR SEQ ID NO:566:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:566:

CTAGCATTTC

(2) INFORMATION FOR SEQ ID NO:567:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:567:

TAGCATTTCA

(2) INFORMATION FOR SEQ ID NO:568:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:568:

AGCATTTCAT

(2) INFORMATION FOR SEQ ID NO:569:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:569:

GCATTTCATC

(2) INFORMATION FOR SEQ ID NO:570:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:570:

CATTTCATCA

(2) INFORMATION FOR SEQ ID NO:571:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:571:

ATTTCATCAC

(2) INFORMATION FOR SEQ ID NO:572:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:572:

TTTCATCACG

(2) INFORMATION FOR SEQ ID NO:573:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:573:

TTCATCACGT

(2) INFORMATION FOR SEQ ID NO:574:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:574:

TCATCACGTG

(2) INFORMATION FOR SEQ ID NO:575:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:575:

CATCACGTGG

(2) INFORMATION FOR SEQ ID NO:576:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:576:

ATCACGTGGC

(2) INFORMATION FOR SEQ ID NO:577:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:577:

TCACGTGGCC

(2) INFORMATION FOR SEQ ID NO:578:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:578:

CACGTGGCCC

(2) INFORMATION FOR SEQ ID NO:579:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:579:

ACGTGGCCCG

(2) INFORMATION FOR SEQ ID NO:580:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:580:

CGTGGCCCGA

(2) INFORMATION FOR SEQ ID NO:581:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:581:

GTGGCCCGAG

(2) INFORMATION FOR SEQ ID NO:582:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:582:

TGGCCCGAGA

(2) INFORMATION FOR SEQ ID NO:583:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:583:

GGCCCGAGAG

(2) INFORMATION FOR SEQ ID NO:584:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:584:

GCCCGAGAGC

(2) INFORMATION FOR SEQ ID NO:585:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:585:

CCCGAGAGCT

(2) INFORMATION FOR SEQ ID NO:586:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:586:

CCGAGAGCTG

(2) INFORMATION FOR SEQ ID NO:587:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:587:

CGAGAGCTGC

(2) INFORMATION FOR SEQ ID NO:588:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:588:

GAGAGCTGCA

(2) INFORMATION FOR SEQ ID NO:589:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:589:

AGAGCTGCAT

(2) INFORMATION FOR SEQ ID NO:590:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:590:

GAGCTGCATC

(2) INFORMATION FOR SEQ ID NO:591:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:591:

AGCTGCATCC

(2) INFORMATION FOR SEQ ID NO:592:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:592:

GCTGCATCCG

(2) INFORMATION FOR SEQ ID NO:593:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:593:

CTGCATCCGG

(2) INFORMATION FOR SEQ ID NO:594:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:594:

TGCATCCGGA

(2) INFORMATION FOR SEQ ID NO:595:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:595:

GCATCCGGAG

(2) INFORMATION FOR SEQ ID NO:596:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:596:

CATCCGGAGT

(2) INFORMATION FOR SEQ ID NO:597:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:597:

ATCCGGAGTA

(2) INFORMATION FOR SEQ ID NO:598:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:598:

TCCGGAGTAC

(2) INFORMATION FOR SEQ ID NO:599:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:599:

CCGGAGTACT

(2) INFORMATION FOR SEQ ID NO:600:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:600:

CGGAGTACTT

(2) INFORMATION FOR SEQ ID NO:601:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:601:

GGAGTACTTC

(2) INFORMATION FOR SEQ ID NO:602:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:602:

GAGTACTTCA

(2) INFORMATION FOR SEQ ID NO:603:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:603:

AGTACTTCAA

(2) INFORMATION FOR SEQ ID NO:604:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:604:

GTACTTCAAG

(2) INFORMATION FOR SEQ ID NO:605:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:605:

TACTTCAAGA

(2) INFORMATION FOR SEQ ID NO:606:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:606:

ACTTCAAGAA

(2) INFORMATION FOR SEQ ID NO:607:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:607:

CTTCAAGAAC

(2) INFORMATION FOR SEQ ID NO:608:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:608:

TTCAAGAACT

(2) INFORMATION FOR SEQ ID NO:609:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:609:

TCAAGAACTG

(2) INFORMATION FOR SEQ ID NO:610:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:610:

CAAGAACTGC

(2) INFORMATION FOR SEQ ID NO:611:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:611:

AAGAACTGCT

(2) INFORMATION FOR SEQ ID NO:612:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:612:

AGAACTGCTG

(2) INFORMATION FOR SEQ ID NO:613:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:613:

GAACTGCTGA

(2) INFORMATION FOR SEQ ID NO:614:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1305 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:614:

GAAGAGATTT GGGAGAACAT GACCTGGATG CAGTGGGAAA AAGAAATTCA CAATCACACA 60

AAATACATAT ACTCCTTACT TGAAAAATCG CAGAACCAAC AAGAAAAGAA TGAACAAGAA 120

CTATTGGAAT TGGATCAATG GGCAAGTTTG TGGAATTGGT TTGACATAAC AAAATGGCTG 180

TGGTATATAA AAATATTCAT AATGGTAGTA GGAGGCTTGA TAGGTTTAAG AATAGTTTTT 240

GCTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATACT CACCATTGTC GTTTCAGACC 300

CTCCTCCCAA CCCCGAGGGG ACCCGACAGG CCCGAAGGAA TCGAAGAAGA AGGTGGAGAG 360

AGAGACAGAG ACAGATCCAC TCGATTAGTA CACGGATTCT TAGCACTTTT CTGGGACGAC 420

CTGAGGAGCC TGTGCCTCTT CCTCTACCAC CACTTGAGAG ACTTACTCTT GATTGTAACA 480

AGGATTGTGG AACTTCTGGG ACGCAGGGGA TGGGAAGCCC TCAAATATTG GTGGAACCTC 540

CTAAAGTATT GGAGCCAGGA ACTGCAGAAG AGTGCTGTTA TCTTGCTCAA TGCCACCGCC 600

ATAGCAGTAG CTGAGGGGAC AGATAGAGTT TTAGAAGTAT TACAAAGAGC TTATAGAGCT 660

ATCCTCCACA TACCTAGAAG AATAAGACAG GGCCTCGAAA TGGCTTTGCT ATAAAATGGG 720

TGGCAAGTGA GCAAAAAGTA GTGTAGTCAG ATAGCATGCA TCATAAGGGG TGGGGGCCAA 780

CAACTAACAA TGCTGATCGT GCCTGGCTAG AAGCACAAGA GAAGGAAGAA GCGGGTTTTC 840

CAGTCAAACC TCAGGTAGCT GTAGATCTTA GCCACTTTTT AAAAGAAAAG GGGGGACTGG 900

AAGGGCTAAT TCACTCCCAA AGAAGACAAG ATACACAGTG CTGCAAACTA TTACCAGTGG 960

AGTCAGCGAA GATAGAAGAG GCCAATGGAG GAGAAAACCA CAGATTGTTC TGTTGGGGAC 1020

TTTCCATCCG TTGGGGACTT TCCAAGGCGG CGTGGCCTGG GTGACTAGTT CCGGTGGGGA 1080

CTTTCCAAGA AGGCGCGGCC TGGGCGGGAC TGGGGAGTGG CGAGCCCTCA GATGCTGCAT 1140

ATAAGCAGCT GCTTTCTGCT GTTACTGGGT CTCTCGGGTT AGACCAGATC TGAGCCTGGG 1200

AGCTCTCTGG CTAACTAGGG AACCCACTGC TTAAGCCTCA ATAAAGCTTG CCTTGAGTGC 1260

TTCAAGTAGT GTGTGCCCGT CTGTTGTGTG ACTCTGGTAT CTAGA 1305

(2) INFORMATION FOR SEQ ID NO:615:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1208 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:615:

GAAACAATTT GGGATAACAT GACCTGGATG CAGTGGGAAA GAGAAATTGA CAATTACACA 60

AACATAATAT ACACCTTAAT TGAAGAATCG CAGAACCAAC AAGAAAAAAA TGAACTAGAA 120

TTATTGGAAT TGGATAAATG GGCAAATTTG TGGAATTGGT TTAGTATATC AAACTGGCTA 180

TGGTATATAA AATTATTCAT AATGGTAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT 240

ACTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATACT CACCATTGTC GTTTCAGACC 300

CACCTCCCAA CCCCGAAGGG ACCCGACAGG CCAGAAGGAA TCGAAGAAGA AGGTGGAGAG 360

AGAGACAGAG GCAGCTCCAC TCGATTAGTG CACGGATTCT TAGCACTTTT CTGGGACGAC 420

CTGAGGAGTC TGTGCCTCTT CAGCTACCAC CACTTGAGAG ACTTACTCTT GATTGTAACG 480

AGGATTGTGG AACTTCTGGG ACGCAGGGGA TGGGAAGCCC TCAAATACTG GTGGAATCTC 540

CTGCAGTATT GGAGGCAGGA ACTACAGAAG AGTGCTGTTA GCTTGTTCAA TGGCACGGCC 600

ATAGCAGTAG CTGAGGGGAC AGATAGAGTT ATAGAAGCTT TACGAAGGGC TTATAGAGCT 660

ATTCTCCACA TACCTAGAAG AATAAGACAG GGCTTAGAAA GGGCTTTGCT ATAAAATGGG 720

TGGCAAGTGG TCAGAAAGTA GTGTGGTTAG AAGGCATGTA CCTTTAAGAC AAGGCAGCTA 780

TAGATCTTAG CCGCTTTTTA AAAGAAAAGG GGGGACTGGA AGGGCTAATT CACTCACAGA 840

GAAGATCAGT TGAACCAGAA GAAGATAGAA GAGGCCATGA AGAAGAAAAC AACAGATTGT 900

TCCGTTTGTT CCGTTGGGGA CTTTCCAGGA GACGTGGCCT GAGTGATAAG CCGCTGGGGA 960

CTTTCCGAAG AGGCGTGACG GGACTTTCCA AGGCGACGTG GCCTGGGCGG GACTGGGGAG 1020

TGGCGAGCCC TCAGATGCTG CATATAAGCA GCTGCTTTCT GCCTGTACTG GGTCTCTCTG 1080

GTTAGACCAG ATCTGAGCCT GGGAGCTCTC TGGCTAACTA GGGAACCCAC TGCTTAAGCC 1140

TCAATAAAGC TTGCCTTGAG TGCTTCAAGT AGTGTGTGCC CGTCTGTTGT GTGACTCTGG 1200

TATCTAGA 1208

(2) INFORMATION FOR SEQ ID NO:616:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:616:

TGGAAGGGCT AATTTGGT 18

(2) INFORMATION FOR SEQ ID NO:617:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:617:

ATCTTCCCTA AAAAATTAGC CTGTC 25

(2) INFORMATION FOR SEQ ID NO:618:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:618:

AGGCTCAGAT CTGGTCTAAC 20

(2) INFORMATION FOR SEQ ID NO:619:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:619:

AGCAGCAGGA AGCACTATGG 20

BNSDOCID: <WO___9521912A1_I_>

(2) INFORMATION FOR SEQ ID NO:620:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:620:

TGCTAGAGAT TTTCCACAC 19

(2) INFORMATION FOR SEQ ID NO:621:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:621:

AGTGAATAGA GTTAGGCAGG 20

(2) INFORMATION FOR SEQ ID NO:622:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:622:

GTAAGACAGT ATGATCAGAT A 21

(2) INFORMATION FOR SEQ ID NO:623:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:623:

TTGTAGGGAA TTCCAAATTC C 21

(2) INFORMATION FOR SEQ ID NO:624:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:624:

CAGGATCCTA CACCTGTCAA CATAAT 26

(2) INFORMATION FOR SEQ ID NO:625:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:625:

GGGAATTCCT TATTCCTGCT TG 22

(2) INFORMATION FOR SEQ ID NO:626:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:626:

CCAGAAGTTC CACAATCC 18

(2) INFORMATION FOR SEQ ID NO:627:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:627:

TTCTTCTAGG TATGTGGAG 19

BNSDOCID: <WO___9521912A1_I_>

(2) INFORMATION FOR SEQ ID NO:628:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:628:

AGTGAATTAG CCCTTCCAG 19

(2) INFORMATION FOR SEQ ID NO:629:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:629:

TGCTAGAGAT TTTCCACAC 19

(2) INFORMATION FOR SEQ ID NO:630:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:630:

TGCTCTGGAA AACTCAT 17

(2) INFORMATION FOR SEQ ID NO:631:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:631:

CTTTCTATAG TGAATAGAG 19

(2) INFORMATION FOR SEQ ID NO:632:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:632:

TATTGGAGTC AGGAACT 17

(2) INFORMATION FOR SEQ ID NO:633:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:633:

GGTCTAACCA GAGAGAC 17

(2) INFORMATION FOR SEQ ID NO:634:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:634:

Ala Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:635:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:635:

Pro Thr Ser Gln Ser Arg Gly Asp Pro Thr Gly Pro Lys Glu Lys
1 5 10 15

Lys Lys Val Glu Arg Glu Thr Glu Thr Asp Pro Phe Asp Thr
20 25 30

Asp Pro His
35

(2) INFORMATION FOR SEQ ID NO:636:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:636:

Pro Ser Ser Gln Pro Arg Gly Asp Pro Thr Gly Pro Lys Glu Ser Lys
1 5 10 15

Lys Lys Val Glu Arg Glu Thr Glu Thr Asp Pro Leu Asp Tyr Thr
20 25 30

Asp Ser His
35

(2) INFORMATION FOR SEQ ID NO:637:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:637:

Pro Thr Ser Gln Pro Arg Arg Asp Pro Thr Gly Gln Lys Glu Ser Lys
1 5 10 15

Lys Lys Val Glu Arg Glu Thr Glu Ala Ala Pro Leu Asp Cys Thr
20 25 30

Asp Ser His
35

(2) INFORMATION FOR SEQ ID NO:638:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:638:

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg
1 5 10 15

Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile His Ser Ile Ser Glu
20 25 30

Arg Ile Leu Ser Thr Tyr Leu Gly Arg Ser Ala Glu Pro Val Pro Leu
35 40 45

Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys
50 55 60

Gly Thr Ser Gly Thr Gln Gly Val Gly Ser Pro Gln Ile Leu Val Glu
65 70 75 80

Ser Pro Thr Val Leu Glu Ser Gly Thr Lys Glu Cys Cys Leu
85 90 95

Ala Gln Cys His Ser His Ser Ser Ser Gly Asp Arg
100 105 110

(2) INFORMATION FOR SEQ ID NO:639:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:639:

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg
1 5 10 15

Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Ile His Ser Ile Ser Thr
20 25 30

Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Pro Val Pro Leu
35 40 45

Pro Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Lys Asp Cys
50 55 60

Gly Thr Ser Gly Thr Gln Gly Met Gly Ser Pro Gln Ile Leu Val Glu
65 70 75 80

Pro Pro Lys Val Leu Glu Pro Gly Thr Ala Glu Glu Cys Cys Tyr Leu
85 90 95

Ala Gln Cys His Arg His Ser Ser Ser Gly Asp Arg
100 105 110

(2) INFORMATION FOR SEQ ID NO:640:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 110 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:640:

Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gln Ala Arg Arg Asn Arg
1 5 10 15

Arg Arg Arg Trp Arg Glu Arg Gln Arg Gln Leu His Ser Ile Ser Ala
20 25 30

Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Ser Val Pro Leu
35 40 45

Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys
50 55 60

Gly Thr Ser Gly Thr Gln Gly Met Gly Ser Pro Gln Ile Leu Val Glu
65 70 75 80

Ser Pro Ala Val Leu Glu Ala Gly Thr Thr Glu Glu Cys Cys Leu
85 90 95

BNSDOCID: <WO___9521912A1_I_>

Val Gln Trp His Gly His Ser Ser Ser Gly Asp Arg
100 105 110

(2) INFORMATION FOR SEQ ID NO:641:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:641:

Glu Gln Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp Arg Glu Ile
1 5 10 15

Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn
20 25 30

Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala
35 40 45

Ser Leu Trp Asn Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys
50 55 60

Leu Phe Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe
65 70 75 80

Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
85 90 95

Ser Phe Gln Thr His Leu Pro Ile Pro Arg Gly Pro Asp Arg Pro Glu
100 105 110

Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Asp Arg Ser Ile Arg
115 120 125

Leu Val Asn Gly Ser Leu Ala Leu Ile Trp Asp Asp Leu Arg Ser Leu
130 135 140

Cys Leu Phe Ser Tyr His Arg Leu Arg Asp Leu Leu Leu Ile Val Thr
145 150 155 160

Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
165 170 175

Trp Trp Asn Leu Leu Gln Tyr Trp Ser Gln Glu Leu Lys Asn Ser Ala
180 185 190

Val Asn Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
195 200 205

Arg Val Ile Glu Val Leu Gln Ala Ala Tyr Arg Ala Ile Arg His Ile
210 215 220

Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Ile Leu Leu
225 230 235

(2) INFORMATION FOR SEQ ID NO:642:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:642:

Glu Glu Ile Trp Glu Asn Met Thr Trp Met Gln Trp Glu Lys Glu Ile
1 5 10 15

His Asn His Thr Lys Tyr Ile Tyr Ser Leu Leu Glu Lys Ser Gln Asn
20 25 30

Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Gln Trp Ala
35 40 45

Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr Ile Lys
50 55 60

Ile Phe Ile Met Val Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe
65 70 75 80

Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
85 90 95

Ser Phe Gln Thr Leu Leu Pro Thr Pro Arg Gly Pro Asp Arg Pro Glu
100 105 110

Gly Ile Glu Glu Met Gly Gly Glu Arg Asp Arg Asp Arg Ser Thr Arg
115 120 125

Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu
130 135 140

Cys Leu Phe Leu Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr
145 150 155 160

Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
165 170 175

Trp Trp Asn Leu Leu Lys Tyr Trp Ser Gln Glu Leu Gln Lys Ser Ala
180 185 190

Val Ile Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
195 200 205

Arg Val Leu Glu Val Leu Gln Arg Ala Tyr Arg Ala Ile Leu His Ile
210 215 220

Pro Arg Arg Ile Arg Gln Gly Leu Glu Met Ala Leu Leu
225 230 235

BNSDOCID: <WO___9521912A1_I_>

(2) INFORMATION FOR SEQ ID NO:643:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:643:

```
Glu Thr Ile Trp Asp Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile
1               5                  10                  15

Asp Asn Tyr Thr Asn Ile Ile Tyr Thr Leu Ile Glu Glu Ser Gln Asn
            20                  25                  30

Gln Gln Glu Lys Asn Glu Leu Glu Leu Leu Glu Leu Asp Lys Trp Ala
        35                  40                  45

Asn Leu Trp Asn Trp Phe Ser Ile Ser Asn Trp Leu Trp Tyr Ile Lys
    50                  55                  60

Leu Phe Ile Met Val Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe
65                  70                  75                  80

Thr Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
                85                  90                  95

Ser Phe Gln Thr His Leu Pro Thr Pro Lys Gly Pro Asp Arg Pro Glu
            100                 105                 110

Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Gly Ser Ser Thr Arg
        115                 120                 125

Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu
    130                 135                 140

Cys Leu Phe Ser Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr
145                 150                 155                 160

Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr
                165                 170                 175

Trp Trp Asn Leu Leu Gln Tyr Trp Arg Gln Glu Leu Gln Lys Ser Ala
            180                 185                 190

Val Ser Leu Phe Asn Gly Thr Ala Ile Ala Val Ala Glu Gly Thr Asp
        195                 200                 205

Arg Val Ile Glu Ala Leu Arg Arg Ala Tyr Arg Ala Ile Leu His Ile
    210                 215                 220

Pro Arg Arg Ile Arg Gln Gly Leu Glu Arg Ala Leu Leu
225                 230                 235
```

(2) INFORMATION FOR SEQ ID NO:644:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 207 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:644:

Met Gly Gly Lys Trp Ser Lys Ser Ser Val Ile Gly Trp Pro Ala Val
1 5 10 15

Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala
20 25 30

Val Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr
35 40 45

Ala Ala Asn Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu
50 55 60

Glu Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr
65 70 75 80

Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly
85 90 95

Leu Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu
100 105 110

Trp Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr
115 120 125

Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys
130 135 140

Leu Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu
145 150 155 160

Asn Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro
165 170 175

Glu Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His
180 185 190

His Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys
195 200 205

(2) INFORMATION FOR SEQ ID NO:645:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:645:

Met Gly Gly Lys Ala Lys Ser Ser Val Val Arg His Ala Ser
1 5 10 15

Gly Val Gly Ala Asn Asn Gln Cys
20 25

(2) INFORMATION FOR SEQ ID NO:646:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:646:

Met Gly Gly Lys Trp Ser Glu Ser Ser Val Val Arg Arg His Val Pro
1 5 10 15

Leu Arg Gln Gly Ser Tyr Arg Ser Pro Leu
20 25

(2) INFORMATION FOR SEQ ID NO:647:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 74 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:647:

CTACAAGGGA CTTTCCGCTG GGGACTTTCC AGGGAGGCGT GGCCTGGGCG GGACTGGGGA 60

GTGGCGAGCC CTCA 74

(2) INFORMATION FOR SEQ ID NO:648:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:648:

CTGTTGGGGA CTTTCCATCC GTTGGGGACT TTCCAAGGCG GCGTGGCCTG GGTGACTAGT 60

TCCGGTGGGG ACTTTCCA 78

(2) INFORMATION FOR SEQ ID NO:649:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:649:

CCGTTTGTTC CGTTGGGGAC TTTCCAGGAG ACGTGGCCTG AGTGACTAAG CCGCTGGGGA 60

CTTTCCG 67

(2) INFORMATION FOR SEQ ID NO:650:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 621 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:650:

ATGGGTGGCA AGTGGTCAAA AAGTAGTGTG ATTGGATGGC CTGCTGTAAG GGAAAGAATG 60

AGACGAGCTG AGCCAGCAGC AGATGGGGTG GGAGCAGTAT CTCGAGACCT AGAAAAACAT 120

GGAGCAATCA CAAGTAGCAA TACAGCAGCT AACAATGCTG CTTGTGCCTG GCTAGAAGCA 180

CAAGAGGAGG AAGAGGTGGG TTTTCCAGTC ACACCTCAGG TACCTTTAAG ACCAATGACT 240

TACAAGGCAG CTGTAGATCT TAGCCACTTT TTAAAAGAAA AGGGGGGACT GGAAGGGCTA 300

ATTCACTCCC AAAGAAGACA AGATATCCTT GATCTGTGGA TCTACCACAC ACAAGGCTAC 360

TTCCCTGATT GGCAGAACTA CACACCAGGG CCAGGGGTCA GATATCCACT GACCTTTGGA 420

TGGTGCTACA AGCTAGTACC AGTTGAGCCA GATAAGGTAG AAGAGGCCAA TAAAGGAGAG 480

AACACCAGCT TGTTACACCC TGTGAGCCTG CATGGAATGG ATGACCCTGA GAGAGAAGTG 540

TTAGAGTGGA GGTTTGACAG CCGCCTAGCA TTTCATCACG TGGCCCGAGA GCTGCATCCG 600

GAGTACTTCA AGAACTGCTG A 621

(2) INFORMATION FOR SEQ ID NO:651:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1596 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:651:

GAACAGATTT GGAATAACAT GACCTGGATG GAGTGGGACA GAGAAATTAA CAATTACACA 60

AGCTTAATAC ACTCCTTAAT TGAAGAATCG CAAAACCAGC AAGAAAAGAA TGAACAAGAA 120

TTATTGGAAT TAGATAAATG GGCAAGTTTG TGGAATTGGT TTAACATAAC AAATTGGCTG 180

TGGTATATAA AATTATTCAT AATGATAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT 240

GCTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATATT CACCATTATC GTTTCAGACC 300

CACCTCCCAA TCCCGAGGGG ACCCGACAGG CCCGAAGGAA TAGAAGAAGA AGGTGGAGAG 360

AGAGACAGAG ACAGATCCAT TCGATTAGTG AACGGATCCT TAGCACTTAT CTGGGACGAT 420

CTGCGGAGCC TGTGCCTCTT CAGCTACCAC CGCTTGAGAG ACTTACTCTT GATTGTAACG 480

AGGATTGTGG AACTTCTGGG ACGCAGGGGG TGGGAAGCCC TCAAATATTG GTGGAATCTC 540

CTACAGTATT GGAGTCAGGA ACTAAAGAAT AGTGCTGTTA ACTTGCTCAA TGCCACAGCC 600

ATAGCAGTAG CTGAGGGGAC AGATAGGGTT ATAGAAGTAT TACAAGCAGC TTATAGAGCT 660

ATTCGCCACA TACCTAGAAG AATAAGACAG GGCTTGGAAA GGATTTTGCT ATAAGATGGG 720

TGGCAAGTGG TCAAAAAGTA GTGTGATTGG ATGGCCTGCT GTAAGGGAAA GAATGAGACG 780

AGCTGAGCCA GCAGCAGATG GGGTGGGAGC AGTATCTCGA GACCTAGAAA AACATGGAGC 840

AATCACAAGT AGCAATACAG CAGCTAACAA TGCTGCTTGT GCCTGGCTAG AAGCACAAGA 900

GGAGGAAGAG GTGGGTTTTC CAGTCACACC TCAGGTACCT TTAAGACCAA TGACTTACAA 960

GGCAGCTGTA GATCTTAGCC ACTTTTTAAA AGAAAAGGGG GGACTGGAAG GGCTAATTCA 1020

CTCCCAAAGA AGACAAGATA TCCTTGATCT GTGGATCTAC CACACACAAG GCTACTTCCC 1080

TGATTGGCAG AACTACACAC CAGGGCCAGG GGTCAGATAT CCACTGACCT TTGGATGGTG 1140

CTACAAGCTA GTACCAGTTG AGCCAGATAA GGTAGAAGAG GCCAATAAAG GAGAGAACAC 1200

CAGCTTGTTA CACCCTGTGA GCCTGCATGG AATGGATGAC CCTGAGAGAG AAGTGTTAGA 1260

GTGGAGGTTT GACAGCCGCC TAGCATTTCA TCACGTGGCC CGAGAGCTGC ATCCGGAGTA 1320

CTTCAAGAAC TGCTGACATC GAGCTTGCTA CAAGGGACTT TCCGCTGGGG ACTTTCCAGG 1380

GAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC 1440

TGCTTTTTGC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG 1500

GCTAACTAGG GAACCCACTG CTTAAGCCTC AATAAAGCTT GCCTTGAGTG CTTCAAGTAG 1560

TGTGTGCCCG TCTGTTGTGT GACTCTGGTA ACTAGA 1596

(2) INFORMATION FOR SEQ ID NO:652:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:652:

GCTTTTTGCC

(2) INFORMATION FOR SEQ ID NO:653:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:653:

CTTTTTGCCT

(2) INFORMATION FOR SEQ ID NO:654:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:654:

TTTTTGCCTG

(2) INFORMATION FOR SEQ ID NO:655:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:655:

TTTTGCCTGT

(2) INFORMATION FOR SEQ ID NO:656:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:656:

TTTGCCTGTA

(2) INFORMATION FOR SEQ ID NO:657:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:657:

TTGCCTGTAC

(2) INFORMATION FOR SEQ ID NO:658:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:658:

TGCCTGTACT

(2) INFORMATION FOR SEQ ID NO:659:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:659:

GCCTGTACTG

(2) INFORMATION FOR SEQ ID NO:660:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:660:

CCTGTACTGG

(2) INFORMATION FOR SEQ ID NO:661:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:661:

CTGTACTGGG

(2) INFORMATION FOR SEQ ID NO:662:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:662:

TGTACTGGGT

(2) INFORMATION FOR SEQ ID NO:663:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:663:

GTACTGGGTC

(2) INFORMATION FOR SEQ ID NO:664:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:664:

TACTGGGTCT

(2) INFORMATION FOR SEQ ID NO:665:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:665:

ACTGGGTCTC

(2) INFORMATION FOR SEQ ID NO:666:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:666:

CTGGGTCTCT

(2) INFORMATION FOR SEQ ID NO:667:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:667:

TGGGTCTCTC

(2) INFORMATION FOR SEQ ID NO:668:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:668:

GGGTCTCTCT

(2) INFORMATION FOR SEQ ID NO:669:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:669:

GGTCTCTCTG

(2) INFORMATION FOR SEQ ID NO:670:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:670:

GTCTCTCTGG

(2) INFORMATION FOR SEQ ID NO:671:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:671:

TCTCTCTGGT

(2) INFORMATION FOR SEQ ID NO:672:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:672:

CTCTCTGGTT

(2) INFORMATION FOR SEQ ID NO:673:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:673:

TCTCTGGTTA

(2) INFORMATION FOR SEQ ID NO:674:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:674:

CTCTGGTTAG

(2) INFORMATION FOR SEQ ID NO:675:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:675:

TCTCTGGTTA

(2) INFORMATION FOR SEQ ID NO:676:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:676:

CTGGTTAGAC

(2) INFORMATION FOR SEQ ID NO:677:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:677:

TGGTTAGACC

(2) INFORMATION FOR SEQ ID NO:678:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:678:

GGTTAGACCA

(2) INFORMATION FOR SEQ ID NO:679:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:679:

GTTAGACCAG

(2) INFORMATION FOR SEQ ID NO:680:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:680:

TTAGACCAGA

(2) INFORMATION FOR SEQ ID NO:681:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:681:

TAGACCAGAT

(2) INFORMATION FOR SEQ ID NO:682:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:682:

AGACCAGATC

(2) INFORMATION FOR SEQ ID NO:683:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:683:

GACCAGATCT

(2) INFORMATION FOR SEQ ID NO:684:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:684:

ACCAGATCTG

(2) INFORMATION FOR SEQ ID NO:685:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:685:

CCAGATCTGA

(2) INFORMATION FOR SEQ ID NO:686:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:686:

CAGATCTGAG

(2) INFORMATION FOR SEQ ID NO:687:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:687:

AGATCTGAGC

(2) INFORMATION FOR SEQ ID NO:688:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:688:

GATCTGAGCC

(2) INFORMATION FOR SEQ ID NO:689:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:689:

ATCTGAGCCT

(2) INFORMATION FOR SEQ ID NO:690:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:690:

TCTGAGCCTG

(2) INFORMATION FOR SEQ ID NO:691:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:691:

CTGAGCCTGG

(2) INFORMATION FOR SEQ ID NO:692:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:692:

TGAGCCTGGG

(2) INFORMATION FOR SEQ ID NO:693:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:693:

GAGCCTGGGA

(2) INFORMATION FOR SEQ ID NO:694:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:694:

AGCCTGGGAG

(2) INFORMATION FOR SEQ ID NO:695:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:695:

GCCTGGGAGC

(2) INFORMATION FOR SEQ ID NO:696:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:696:

CCTGGGAGCT

(2) INFORMATION FOR SEQ ID NO:697:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:697:

CTGGGAGCTC

(2) INFORMATION FOR SEQ ID NO:698:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:698:

TGGGAGCTCT

(2) INFORMATION FOR SEQ ID NO:699:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:699:

GGGAGCTCTC

(2) INFORMATION FOR SEQ ID NO:700:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:700:

GGAGCTCTCT

(2) INFORMATION FOR SEQ ID NO:701:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:701:

GAGCTCTCTG

(2) INFORMATION FOR SEQ ID NO:702:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:702:

AGCTCTCTGG

(2) INFORMATION FOR SEQ ID NO:703:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:703:

GCTCTCTGGC

(2) INFORMATION FOR SEQ ID NO:704:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:704:

CTCTCTGGCT

(2) INFORMATION FOR SEQ ID NO:705:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:705:

TCTCTGGCTA

(2) INFORMATION FOR SEQ ID NO:706:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:706:

CTCTGGCTAA

(2) INFORMATION FOR SEQ ID NO:707:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:707:

TCTGGCTAAC

(2) INFORMATION FOR SEQ ID NO:708:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:708:

CTGGCTAACT

(2) INFORMATION FOR SEQ ID NO:709:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:709:

TGGCTAACTA

(2) INFORMATION FOR SEQ ID NO:710:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:710:

GGCTAACTAG

(2) INFORMATION FOR SEQ ID NO:711:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:711:

GCTAACTAGG

(2) INFORMATION FOR SEQ ID NO:712:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:712:

CTAACTAGGG

(2) INFORMATION FOR SEQ ID NO:713:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:713:

TAACTAGGGA

(2) INFORMATION FOR SEQ ID NO:714:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:714:

AACTAGGGAA

(2) INFORMATION FOR SEQ ID NO:715:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:715:

ACTAGGGAAC

(2) INFORMATION FOR SEQ ID NO:716:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:716:

CTAGGGAACC

(2) INFORMATION FOR SEQ ID NO:717:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:717:

TAGGGAACCC

(2) INFORMATION FOR SEQ ID NO:718:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:718:

AGGGAACCCA

(2) INFORMATION FOR SEQ ID NO:719:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:719:

GGGAACCCAC

(2) INFORMATION FOR SEQ ID NO:720:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:720:

GGAACCCACT

(2) INFORMATION FOR SEQ ID NO:721:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:721:

GAACCCACTG

(2) INFORMATION FOR SEQ ID NO:722:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:722:

AACCCACTGC

(2) INFORMATION FOR SEQ ID NO:723:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:723:

ACCCACTGCT

(2) INFORMATION FOR SEQ ID NO:724:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:724:

CCCACTGCTT

(2) INFORMATION FOR SEQ ID NO:725:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:725:

CCACTGCTTA

(2) INFORMATION FOR SEQ ID NO:726:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:726:

CACTGCTTAA

(2) INFORMATION FOR SEQ ID NO:727:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:727:

ACTGCTTAAG

(2) INFORMATION FOR SEQ ID NO:728:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:728:

CTGCTTAAGC

(2) INFORMATION FOR SEQ ID NO:729:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:729:

TGCTTAAGCC

(2) INFORMATION FOR SEQ ID NO:730:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:730:

GCTTAAGCCT

(2) INFORMATION FOR SEQ ID NO:731:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:731:

CTTAAGCCTC

(2) INFORMATION FOR SEQ ID NO:732:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:732:

TTAAGCCTCA

(2) INFORMATION FOR SEQ ID NO:733:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:733:

TAAGCCTCAA

(2) INFORMATION FOR SEQ ID NO:734:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:734:

AAGCCTCAAT

(2) INFORMATION FOR SEQ ID NO:735:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:735:

AGCCTCAATA

(2) INFORMATION FOR SEQ ID NO:736:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:736:

GCCTCAATAA

(2) INFORMATION FOR SEQ ID NO:737:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:737:

CCTCAATAAA

(2) INFORMATION FOR SEQ ID NO:738:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:738:

CTCAATAAAG

(2) INFORMATION FOR SEQ ID NO:739:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:739:

TCAATAAAGC

(2) INFORMATION FOR SEQ ID NO:740:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:740:

CAATAAAGCT

(2) INFORMATION FOR SEQ ID NO:741:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:741:

AATAAAGCTT

(2) INFORMATION FOR SEQ ID NO:742:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:742:

ATAAAGCTTG

(2) INFORMATION FOR SEQ ID NO:743:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:743:

TAAAGCTTGC

(2) INFORMATION FOR SEQ ID NO:744:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:744:

AAAGCTTGCC

(2) INFORMATION FOR SEQ ID NO:745:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:745:

AAGCTTGCCT

(2) INFORMATION FOR SEQ ID NO:746:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:746:

AGCTTGCCTT

(2) INFORMATION FOR SEQ ID NO:747:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:747:

GCTTGCCTTG

(2) INFORMATION FOR SEQ ID NO:748:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:748:

CTTGCCTTGA

(2) INFORMATION FOR SEQ ID NO:749:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:749:

TTGCCTTGAG

(2) INFORMATION FOR SEQ ID NO:750:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:750:

TGCCTTGAGT

(2) INFORMATION FOR SEQ ID NO:751:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:751:

GCCTTGAGTG

(2) INFORMATION FOR SEQ ID NO:752:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:752:

CCTTGAGTGC

(2) INFORMATION FOR SEQ ID NO:753:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:753:

CTTGAGTGCT

(2) INFORMATION FOR SEQ ID NO:754:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:754:

TTGAGTGCTT

(2) INFORMATION FOR SEQ ID NO:755:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:755:

TGAGTGCTTC

(2) INFORMATION FOR SEQ ID NO:756:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:756:

GAGTGCTTCA

(2) INFORMATION FOR SEQ ID NO:757:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:757:

AGTGCTTCAA

(2) INFORMATION FOR SEQ ID NO:758:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:758:

GTGCTTCAAG

(2) INFORMATION FOR SEQ ID NO:759:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:759:

TGCTTCAAGT

(2) INFORMATION FOR SEQ ID NO:760:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:760:

GCTTCAAGTA

(2) INFORMATION FOR SEQ ID NO:761:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:761:

CTTCAAGTAG

(2) INFORMATION FOR SEQ ID NO:762:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:762:

TTCAAGTAGT

(2) INFORMATION FOR SEQ ID NO:763:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:763:

TCAAGTAGTG

(2) INFORMATION FOR SEQ ID NO:764:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:764:

CAAGTAGTGT

(2) INFORMATION FOR SEQ ID NO:765:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:765:

AAGTAGTGTG

(2) INFORMATION FOR SEQ ID NO:766:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:766:

AGTAGTGTGT

(2) INFORMATION FOR SEQ ID NO:767:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:767:

GTAGTGTGTG

(2) INFORMATION FOR SEQ ID NO:768:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:768:

TAGTGTGTGC

(2) INFORMATION FOR SEQ ID NO:769:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:769:

AGTGTGTGCC

(2) INFORMATION FOR SEQ ID NO:770:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:770:

GTGTGTGCCC

(2) INFORMATION FOR SEQ ID NO:771:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:771:

TGTGTGCCCG

(2) INFORMATION FOR SEQ ID NO:772:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:772:

GTGTGCCCGT

(2) INFORMATION FOR SEQ ID NO:773:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:773:

TGTGCCCGTC

(2) INFORMATION FOR SEQ ID NO:774:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:774:

GTGCCCGTCT

(2) INFORMATION FOR SEQ ID NO:775:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:775:

TGCCCGTCTG

(2) INFORMATION FOR SEQ ID NO:776:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:776:

GCCCGTCTGT

(2) INFORMATION FOR SEQ ID NO:777:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:777:

CCCGTCTGTT

(2) INFORMATION FOR SEQ ID NO:778:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:778:

CCGTCTGTTG

(2) INFORMATION FOR SEQ ID NO:779:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:779:

CGTCTGTTGT

(2) INFORMATION FOR SEQ ID NO:780:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:780:

GTCTGTTGTG

(2) INFORMATION FOR SEQ ID NO:781:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:781:

TCTGTTGTGT

(2) INFORMATION FOR SEQ ID NO:782:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:782:

CTGTTGTGTG

(2) INFORMATION FOR SEQ ID NO:783:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:783:

TGTTGTGTGA

(2) INFORMATION FOR SEQ ID NO:784:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:784:

GTTGTGTGAC

(2) INFORMATION FOR SEQ ID NO:785:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:785:

TTGTGTGACT

(2) INFORMATION FOR SEQ ID NO:786:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:786:

TGTGTGACTC

(2) INFORMATION FOR SEQ ID NO:787:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:787:

GTGTGACTCT

(2) INFORMATION FOR SEQ ID NO:788:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:788:

TGTGTGACTC

(2) INFORMATION FOR SEQ ID NO:789:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:789:

GTGTGACTCT

(2) INFORMATION FOR SEQ ID NO:790:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:790:

TGTGACTCTG

(2) INFORMATION FOR SEQ ID NO:791:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:791:

GTGACTCTGG

(2) INFORMATION FOR SEQ ID NO:792:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:792:

TGACTCTGGT

(2) INFORMATION FOR SEQ ID NO:793:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:793:

GACTCTGGTA

(2) INFORMATION FOR SEQ ID NO:794:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:794:

ACTCTGGTAA

(2) INFORMATION FOR SEQ ID NO:795:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:795:

CTCTGGTAAC

(2) INFORMATION FOR SEQ ID NO:796:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:796:

TCTGGTAACT

(2) INFORMATION FOR SEQ ID NO:797:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:797:

CTGGTAACTA

(2) INFORMATION FOR SEQ ID NO:798:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:798:

TGGTAACTAG

(2) INFORMATION FOR SEQ ID NO:799:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:799:

GGTAACTAGA

BNSDOCID: <WO___9521912A1_I_>

(2) INFORMATION FOR SEQ ID NO:800:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9207 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:800:

TGGAAGGGCT AATTCACTCA CGGAAAAGAC CAGTTGAACC AGAAGAAGAT AGAAGAGGCC 60

ATGAAGAAGA AAACAACAGA TTGTTCTGCT TGCTCAGCTG GGGACTTTCC AGAAGGCGCG 120

GCCTGAGTGA CTAAGCCCCG TTGGGGACTT TCCGAAGAGG CATGAAGGGA CTTTCCAAGG 180

CAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC 240

TGCTTTCTGC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG 300

GCTAGCTAGG GAACCCACTG CTTAAGCCTC AATAAAGCTT GCCTTGAGTG CTTCAAGTAG 360

TGTGTGCCCG TCTGTTGTGT GACTCTGGTA TCTAGAGATC CCTCAGACCA TTTTAGTCCG 420

TGTGGAAAAT CTCTAGCAGT GGCGCCCGAA CAGGGACTTG AAAGCGAAAG GAAAACCAGA 480

GGAGCTCTCT CGACGCAGGA CTCGGCTTGC TGAAGCGCGC ACGGCAAGAG GCGAGGGGCG 540

GCGACTGGTG AGTACGCCGA AAATTTTGAC TAGCGGAGGC TAGAAGGAGA GAGATGGGTG 600

CGAGAGCGTC AATATTAAGC GGGGGAAAAT TAGATAGATG GGAGAAAATT CGGTTAAGGC 660

CAGGAGGAAA GAAAAAGTAT AAATTAAAAC ATATAGTATG GGCAAGCAGG GAGCTAGAAC 720

GATTCGCAGT CAATCCTGGC CTGTTGGAAA CATCAGAAGG CTGTAGACAA ATACTGGGAC 780

AGTTACACCC GTCCCTTCAG ACAGGATCAG AAGAACTTAA ATCAGTATAT AATGCAGTAG 840

CAGTCCTCTA TTGTGTGCAT CAAAACATAG ACATAAAGGA CACCAAGGAA GCTTTAGAAA 900

AGATAGAGGA AGAGCAAAAC AAATGTAAGA AAAAAGCACA GCAAGCAGCA GCACAGCAAG 960

CAGCAGCTGG CACAGGAAAC AGCAACCCGG TCAGCCAAAA TTACCCTATA GTACAGAACA 1020

TGCAGGGGCA AATGGTACAT CAGGCCATAT CACCTAGAAC TTTAAATGCA TGGGTAAAAG 1080

TAATAGAAGA GAAGGCTTTC AGCCCAGAGG TAATACCCAT GTTTTCAGCA TTATCAGAAG 1140

GAGCCACCCC ACAAGATTTA AACACCATGC TAAACACAGT GGGGGGACAT CAAGCAGCTA 1200

TGCAAATGTT AAAAGAGACC ATCAATGAGG AAGCTGCAGA ATGGGATAGA TTACATCCAG 1260

CGCAGGCAGG GCCTGTTGCA CCAGGCCAGA TGAGAGACCC AAGGGGAAGT GACATAGCAG 1320

GAACTACTAG TACCCTTCAG GAACAAATAG GATGGATGAC AGGTAATCCA GCTATCCCAG 1380

TAGGAGAAAT CTATAAAAGA TGGATAATCC TGGGATTAAA TAAAATAGTA AGGATGTATA 1440

GCCCTATCAG CATTCTGGAC ATAAAACAAG GACCAAAGGA ACCCTTTAGA GACTATGTAG 1500

ACCGGTTCTA TAAAACTCTA AGAGCCGAGC AAGCTACACA GGAGGTAAAA AATTGGATGA 1560

CAGAAACCTT GTTGGTCCAA AATGCAAACC CAGATTGTAA GACTATTTTA AAAGCATTGG 1620

GACCAGCAGC TACACTAGAA GAAATGATGA CAGCATGTCA GGGAGTGGGA GGACCCAGCC 1680

ATAAAGCAAG AGTTTTGGCA GAAGCAATGA GCCAAGCAAC AAATGCAGCT ACTGTAATGA 1740

TGCAGAGAAG CAATTTTAGA AACCAAAGAA AGAATGTTAA GTGTTTCAAT TGTGGCAAAG 1800

AAGGGCACAT AGCCAGAAAT TGCAGGGCTC CTAGGAAAAG GGGCTGTTGG AAATGTGGAA 1860

AGGAAGGACA CCAAATGAAA GATTGTACTG AGAGACAGGC TAATTTTTTA GGGAAAATCT 1920

GGCCTTCCCA CAAGGGGAGG CCAGGGAACT TTCTTCAGAG CAGGCCAGAA CCAACAGCCC 1980

CTCTCCAGGG CAGGCCGGAG CCATCAGCCC CGCCAGAAGA GAGCTTCAGG TTTGGGGAGG 2040

AGACAACAAC TCCCTCTCAG AAGCAGGAGC CGATAGACAG GGACAGGGAT CTGTATCCTT 2100

TAGCTTCCCT CAGATCACTC TTTGGCAACG ACCCCTCGTC ACAATAAAGA TAGGGGGGCA 2160

GCTGAAGGAA GCTCTATTAG ATACAGGAGC AGATGATACA GTATTAGAAG ACATGCATTT 2220

GCCAGGAAAA TGGAAACCAA AAATGATAGG GGGAATTGGA GGTTTTATCA AAGTAAAACA 2280

ATATGATGAA ATTCTTGTAG AAATCTGTGG ACATAAAGCT ATAGGTACAG TATTAGTAGG 2340

ACCTACACCT GTCAACATAA TTGGAAGAAA TCTGTTGACT CAGATTGGTT GCACTTTAAA 2400

TTTTCCCATT AGTCCTATTG AAACTGTACC AGTACAATTA AAGCCAGGAA TGGATGGCCC 2460

AAAGGTTAAA CAATGGCCAT TGACAGAAGA GAAAATAAAA GCATTAGTAG AAATTTGTAC 2520

AGAAATGGAA AAGGAAGGAA AGATTTCAAA AATTGGGCCT GAAAATCCAT ACAATACTCC 2580

AGTATTTGCC ATAAAGAAAA AAGATGGTAC TAAATGGAGA AAATTAGTAG ATTTCAGAGA 2640

CCTTAATAAG AGAACTCAAG ACTTCTGGGA AGTTCAATTA GGAATACCAC ATCCCTCAGG 2700

ATTAAAAAAG AAAAAATCAG TAACAGTACT GGATGTGGGT GATGCATACT TTTCAGTTCC 2760

CTTAGATGAA AACTTCAGGA AGTATACTGC ATTTACCATA CCTAGTATAA ATAATGAGAC 2820

ACCAGGGATT AGATATCAGT ACAATGTGCT TCCACAGGGA TGGAAAGGAT CACCAGCAAT 2880

ATTCCAAAGT AGCATGACAA GAATCTTAGA GCCTTTTAGA AGACAAAATC CAGACATAGT 2940

TATCTATCAA TACATGGATG ACTTGTATGT AGGATCTGAT TTAGAAATAG GACAGCATAG 3000

AATAAAAATA GAGGAACTGA GACAACATCT GTTGAAGTGG GGATTTACCA CACCAGACAA 3060

AAAGCATCAG AAAGAACCCC CATTCCTTTG GATGGGTTAT GAACTCCATC CTGATAAATG 3120

GACAGTGCAA CCTATAGTAC TGCCAGAAAA AGACAGCTGG ACTGTCAATG ACATACAGAA 3180

GTTAGTGGGT AAATTAAATT GGGCAAGTCA GATTTACCCA GGAATTAAAG TAAGGCAATT 3240

ATGTAAACTC CTTAGGGGAA CCAAAGCACT AACAGAAGTA ATACCACTAA CAGAAGAAGC 3300

AGAGCTAGAA CTGGCAGAAA ACAGGGAAAT TCTAAGAGAA CCAGTACATG GAGTGTATTA 3360

TGACCCATCA AAAGACTTAA TAGCAGAAAT ACAGAAGCAG GAGCAAGGCC AATGGACATA 3420

TCAAATTTAT CAAGATCAAT TTAAAAATCT AAAAACAGGA AAGTATGCAA GATTGAGGGG 3480

TGCCCACACT AATGATGTAA AACAATTTCC AGAGGCAGTG CAAAAAATAG CCACAGAAAG 3540

CATAGTAATA TGGGGAAAGA CTCCTAAATT TAGACTACCC ATACAAAAAG AAACATGGGA 3600

CGCATGGTGG ACAGAGTATT GGCAAGCCAC CTGGATTCCT GAGTGGGAGT TTGTCAATAC 3660

BNSDOCID: <WO___9521912A1_I_>

CCCTCCCCTA GTAAAATTAT GGTACCAGTT AGAAAAAGAA CCCATAATAG GAGCAGAAAC 3720

TTTCTATGTA GATGGGGCAG CTAACAGAGA GACTAAATTA GGAAAAGCAG GATATGTTAC 3780

TGACAGAGGA AGACAAAAAG TTGTCTCCCT AACTGACACA ACAAATCAGA AGACTGAGTT 3840

ACAAGCAATT CATCTAGCTT TGCAGGATTC AGGATTAGAA GTAAACATAG TAACAGACTC 3900

ACAGTATGCA TTAGGAATCA TTCAAGCACA ACCAGATAAA AGTGAATCAG AAATAGTCAA 3960

TCAAATAATA GAGCAATTAA TAAAAAAGGA AAAGGTCTAC CTGGCATGGG TACCAGCACA 4020

CAAAGGAATT GGAGGGAATG AACAAGTAGA TAAATTAGTC AGTGCTGGAA TCAGGAAAAT 4080

ACTATTTTTA GATGGAATAG ATAAGGCACA AGAAGGCCAT GAGAAATATC ACAGTAATTG 4140

GAGAGCAATG GCTAGTGGTT TTAACCTGCC ACCTATAGTA GCAAAAGAAA TAGTAGCCAG 4200

CTGTGATAAA TGTCAGCTAA AAGGAGAAGC CATGCATGGA CAAGTAGACT GTAGTCCAGG 4260

AATATGGCAA CTAGATTGTA CACATCTAGA AGGAAAAATT ATCCTGGTAG CAGTTCATGT 4320

AGCCAGTGGA TATATAGAAG CAGAAGTTAT TCCAGCAGAG ACAGGGCAGG AAACAGCATA 4380

CTTTATCTTA AAATTAGCAG GAAGGTGGCC AGTAAACACA ATACATACAG ACAATGGCGG 4440

CAATTTCATC AGTACCACGG TTAAGGCCGC CTGTTGGTGG GCAGGGATCA AGCAGGAATT 4500

TGGCATTCCC TACAATCCCC AAAGCCAAGG AGTAGTGGAA TCTATGAATA GAGAATTAAA 4560

GAAAATTATA GGACAGGTAA GAGATCAGGC TGAACATCTT AAGACAGCAG TACAAATGGC 4620

AGTATTCATC CACAATTTTA AAAGAAAAGG GGGGATTGGG GGATACAGTG CAGGGGAAAG 4680

AATAGTAGAC ATAATAGCAA CAGACATACA AACTAAAGAA TTACAAAAGC AAATTACAAA 4740

AATTCAAAAT TTTCGGGTTT ATTACAGGGA CAGCAGAGAT CCACTTTGGA AAGGACCAGC 4800

AAAACTTCTC TGGAAAGGCG AAGGGGCAGT AGTAATACAA GATAATAGTG ACATAAAAGT 4860

AGTGCCAAGA AGAAAAGTAA AGATCATTAG GGATTATGGA AAACAGATGG CAGGTGATGA 4920

TTGTGTGGCA AGTAGACAGG ATGAGGATTA GAACATGGAA CAGTTTAGTG AAACACCATA 4980

TGTATGTTTC AAAGAAAGCT AAGGGATGGA TTTATAGACA TCACTATGAA AACACTCATC 5040

CAAAAATAAG CTCAGAAGTA CACATCCCAC TAGGGGAAGC TAGATTGGTA ATAACAACAT 5100

ATTGGGGTCT ACATACAGGA GAAAGAGACT GGCATTTGGG TCAGGGAGTC TCCATAGAAT 5160

GGAGGGAAAG GACATATAGA ACACAAGTAG ACCCCGAACT AGCAGACCAA CTAATTCATA 5220

TACATTACTT TGATTGTTTT TCAGAATCTG CCATAAGAAG TGCCATATTA GGATATAGAG 5280

TTAGGCATAG GTGTGAATAT CAAGCAGGAC ATAACAAGGT AGGATCTCTA CAGTACTTGG 5340

CACTAACAGC ATTAATAACA CCAAAGAAGA TAAAGCCACC TTTGCCTAGT GTTGCGAAAC 5400

TGACAGAGGA TAGATGGAAC AAGCCCCAGA AGACCAAGGG CCACAGAGGC AGCCATACAA 5460

TGAATGGACA CTAGAACTTT TAGAGGAGCT TAAGAATGAA GCTGTTAGGC ATTTTCCTAG 5520

GGTATGGCTC CATGGCTTAG GGCAACATAT CTATGAAACT TATGGGGATA CTTGGGAAGG 5580

AGTGGAGGCC ATAACAAGAA CTCTGCAACA ACTGCTGTTT ATTCATTTCA GAATTGGGTG 5640

TCAACATAGC AGAATAGGCA TTATTCGACA GAGGAGAGCA AGAAATGGAG CCAGTAGATC 5700

CTAGACTAGA GCCCTGGAAG CATCCAGGAA GTCAGCCTAA GACTGCGTGT ACCACTTGCT 5760

ATTGTAAAAA GTGCTGCTTT CATTGCCAAG TTTGTTTTAT GACAAAAGGC TTAGGCATCT 5820

CCTATGGCAG GAAGAAGCGG AGACAGCGAC GAAGAGCTCC TCAAGACAGT CAGACTCATC 5880

AAGCTTATCT ATCAAAGCAG TAAGTAATAT ATGTAATGCA ACCTTTACAA ATAGTAGCAA 5940

TAGTAGCATT AGTAGTAGCA GGAATAATAG CAATAGTTGT GTGGACCATA GTATTCATAG 6000

AATATAAGAA AATATTAAGA CAAAGAAAAA TAGACAGGTT GATTGATAGA ATAAGAGAAA 6060

GAGCAGAAGA CAGTGGCAAT GACAGTGAAG GGGATCAGGA AGAATTATCG GCACTTGTGG 6120

ACATGGGGCA CCATGATCCT TGGGATATTA ATGATCTGTA GAGCTGCAAA CAATTTGTGG 6180

GTCACAGTCT ATTATGGGGT ACCTGTGTGG AGAGAAGCAA CCACCACTCT ATTTTGTGCA 6240

TCAGATGCCA AGGCATATGA TGCAGAGGTA CATAATGTTT GGGCCACACA TGCCTGTGTA 6300

CCCACAGACC CTAACCCACA AGAAGTAGAA TTGAAAAATG TGACAGAAAA TTTTAACATG 6360

TGGAAAAATA ACATGGTAGA ACAGATGCAT GAGGATATAA TCAGTTTATG GGATCAAAGC 6420

CTGAAGCCAT GTGTAAAATT AACCCCACTC TGTGTTTCTT TAAATTGCAC TGATGCTACT 6480

AATACCACTA ATAGTAATAC CACTAGCAGC AGCGAGAAAC CGAAGGGGAC AGGGGAAATA 6540

AAAAACTGCT CTTTCAATAT CACCACAAGC ATAAGAGATA AGGTGCAGAA ACAATATGCA 6600

CTTTTTTATA GCCTTGATGT AGTACCAATG GATGATAATG ATAATAGTAC AAGCTATAGG 6660

TTAATAAGTT GTAACACCTC AATCATTACA CAGGCCTGTC CAAAGATATC CTTTGAGCCA 6720

ATTCCCATAC ATTATTGTGC CCCGGCTGGT TTTGCGATTC TAAAGTGTAA AGATAAAAGG 6780

TTCAATGGAA AAGGACCATG TACAAGTGTC AGCACAGTAC AGTGTACACA TGGAATTAGG 6840

CCAGTAGTAT CAACTCAACT GTTGTTAAAT GGCAGTCTAG CAGAAGAAGA GGTAGTAATT 6900

AGATCTGACA ATTTTACGAA CAATGCTAAA ACCATAATAG TACAGCTGAG CAAATCTGTA 6960

GAAATTACTT GTGTAAGACC CAACAACAAT ACAAGAAAAA GTATAAGTAT GGGACCAGGG 7020

AGAGCATTTT ATACAACAGA AATAATAGGA GATATAAGAC AAGCATATTG TAACATTAGT 7080

AAAGCAAACT GGACTGACAC TTTAGAACAG ATAGCTAGAA AATTAAGAGA ACAATTTGAG 7140

AATAAAACAA TAGTCTTTAA GCCATCCTCA GGAGGGGACC CAGAAATTGT AACACAGTTT 7200

TACAGTTTTA ATTGTGGAGG GGAATTTTTC TACTGTAATT CAACACAACT GTTTAATGGT 7260

ACTTGGAATG GTACTTGGGT TAATGGTACT TGGAGTAGTA ATAATACGAC TGATACTGCA 7320

AATATCACAC TCCCATGCAG AATAAAACAA TTTATAAACA TGTGGCAGGA AGTAGGAAAA 7380

GCAATGTATG CCCCTCCCAT CAAAGGACAA ATTAAATGTA CATCAAATAT TACAGGGCTG 7440

ATATTAACAA GAGATGGTGG TAACAATAAC ACCACGAACG ACAACGAGAC CGAGACCTTC 7500

AGACCTGGAG GAGGAGATAT GAGGGACAAT TGGAGAAGTG AATTATATAA ATATAAAGTA 7560

GTACAAGTTG AACCATTAGG AGTAGCACCC ACCAAGGCAA AGAGAAGAGT GGTGCAAAGA 7620

GAAAAAAGAG CAGTGGGAAT AGGAGCTATG TTCCTTGGGT TCTTAGGAGC AGCAGGAAGC 7680

ACTATGGGCG CAGCGTCAGT GACGCTGACG GTACAAGCCA GACAATTATT GTCTGGTATA 7740

GTGCAGCAGC AGAACAATCT GCTGAGGGCT ATTGAGGCGC AACAGCATCT GTTGCAACTC 7800

ACAGTCTGGG GCATCAAACA GCTCCAGGCA AGAGTCCTGG CTGTGGAAAG ATACCTAAGG 7860

GATCAACAGC TCCTGGGACT TTGGGGTTGC TCTGGAAAAC TCATTTGCAC CACTACTGTG 7920

CCTTGGAACA ATAGCTGGAG TAATAAATCT CTGGAAACAA TTTGGGATAA CATGACCTGG 7980

ATGCAGTGGG AAAGAGAAAT TGACAATTAC ACAAACATAA TATACACCTT AATTGAAGAA 8040

TCGCAGAACC AACAAGAAAA AAATGAACTA GAATTATTGG AATTGGATAA ATGGGCAAAT 8100

TTGTGGAATT GGTTTAGTAT ATCAAACTGG CTATGGTATA TAAAATTATT CATAATGGTA 8160

GTAGGAGGCT TGGTAGGTTT AAGAATAGTT TTTACTGTAC TTTCTATAGT TAATAGAGTT 8220

AGGCAGGGAT ACTCACCATT ATCGTTTCAG ACCCACCTCC CAACCCCGAA GGGACCCGAC 8280

AGGCCAGAAG GAATCGAAGA AGAAGGTGGA GAGAGAGACA GAGGCAGCTC CACTCGATTA 8340

GTGCACGGAT TCTTAGCACT TTTCTGGGAC GACCTGAGGA GTCTGTGCCT CTTCAGCTAC 8400

CACCACTTGA GAGACTTACT CTTGATTGTA ACGAGGATTG TGGAACTTCT GGGACGCAGG 8460

GGATGGGAAG CCCTCAAATA CTGGTGGAAT CTCCTGCAGT ATTGGAGGCA GGAACTACAG 8520

AAGAGTGCTG TTAGCTTGTT CAATGGCACG GCCATAGCAG TAGCTGAGGG GACAGATAGA 8580

GTTATAGAAG CTTTACGAAG GGCTTATAGA GCTATTCTCC ACATACCTAG AAGAATAAGA 8640

CAGGGCTTAG AAAGGGCTTT GCTATAAAAT GGGTGGCAAG TGGTCAGAAA GTAGTGTGGT 8700

TAGAAGGCAT GTACCTTTAA GACAAGGCAG CTATAGATCT TAGCCGCTTT TTAAAAGAAA 8760

AGGGGGGACT GGAAGGGCTA ATTCACTCAC GGAAAAGACC AGTTGAACCA GAAGAAGATA 8820

GAAGAGGCCA TGAAGAAGAA AACAACAGAT TGTTCTGCTT GCTCAGCTGG GGACTTTCCA 8880

GAAGGCGCGG CCTGAGTGAC TAAGCCCCGT TGGGGACTTT CCGAAGAGGC ATGAAGGGAC 8940

TTTCCAAGGC AGGCGTGGCC TGGGCGGGAC TGGGGAGTGG CGAGCCCTCA GATGCTGCAT 9000

ATAAGCAGCT GCTTTCTGCC TGTACTGGGT CTCTCTGGTT AGACCAGATC TGAGCCTGGG 9060

AGCTCTCTGG CTAGCTAGGG AACCCACTGC TTAAGCCTCA ATAAAGCTTG CCTTGAGTGC 9120

TTCAAGTAGT GTGTGCCCGT CTGTTGTGTG ACTCTGGTAT CTAGAGATCC CTCAGACCAT 9180

TTTAGTCCGT GTGGAAAATC TCTAGCA 9207

CLAIMS:

1. An isolated HIV-1 strain or a component, part, fragment or derivative thereof which is substantially non-pathogenic.

2. A strain of HIV-1 according to claim 1 wherein said strain is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.

3. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1 or results in reduced synthesis of said polypeptide or protein.

4. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.

5. A strain of HIV-1 according to claim 3 or 4 wherein said strain carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

6. A strain of HIV-1 according to claim 5 wherein said strain is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.

7. A strain of HIV-1 according to claim 6 wherein said strain is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.

8. A strain of HIV-1 according to claim 7 wherein said strain carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

9. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

10. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

11. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

12. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224
	(xiv)	9389-9395; and
	(xv)	9281-9366.

13. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2); TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4); GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6); TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8); GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10); AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12); GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14); GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16); TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18); AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20); AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22); AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24); TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26); GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28); GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30); GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32); TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34); GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36); ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38); GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40); CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42); TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44); CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46); GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48); AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50); GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52); GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54); AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56); GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58); ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60); GAGACGAGCT (SEQ ID NO:61);

BNSDOCID: <WO___9521912A1_I_>

AGACGAGCTG (SEQ ID NO:62); GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64); CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66); AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68); CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70); GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72); GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74); CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76); GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78); AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80); CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82); GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84); TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86); GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88); GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90); GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92); GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94); GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96); AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98); TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100); TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102); TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104); GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106); GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108); CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110); TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112); GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114); AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116); AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118); CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120); TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122); GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124); GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126); AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128); TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130); ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132); AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134); GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136); AGCAATACAG (SEQ ID NO:137);

GCAATACAGC (SEQ ID NO:138); CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140); ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142); ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144); AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146); CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148); GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150); TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152); ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154); AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156); TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158); CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160); GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162); TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164); GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166); GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168); CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170); GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172); CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174); AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176); AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178); GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180); ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182); AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184); GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186); GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188); AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190); GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192); AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194); AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196); GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198); GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200); GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202); TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204); TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206); CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208); GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210); CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212); CACCTCAGGT (SEQ ID NO:213);

BNSDOCID: <WO___9521912A1_I_>

ACCTCAGGTA (SEQ ID NO:214); CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216); TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218); AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220); GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222); ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224); CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226); TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228); AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230); GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232); CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234); AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236); TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238); ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240); TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242); ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244); AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246); GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248); CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250); GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252); TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254); TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256); GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258); TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260); TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262); AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264); CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266); ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268); TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270); TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272); TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274); AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276); AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278); AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280); AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282); GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284); GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286); GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288); ACTGGAAGGG (SEQ ID NO:289);

CTGGAAGGGC (SEQ ID NO:290); TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292); GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294); AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296); GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298); CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300); AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302); TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304); CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306); CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308); CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310); CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312); AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314); GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316); AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318); ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320); AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322); GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324); TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326); TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328); CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330); TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332); ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334); CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336); GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338); GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340); ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342); CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344); ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346); CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348); CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350); CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352); CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354); AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356); GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358); TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360); CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362); TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364); CCTGATTGGC (SEQ ID NO:365);

BNSDOCID: <WO___9521912A1_I_>

CTGATTGGCA (SEQ ID NO:366); TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368); ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370); TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372); GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374); AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376); AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378); CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380); ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382); ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384); ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386); CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388); GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390); GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392); CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394); GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396); GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398); TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400); AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402); ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404); ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406); CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408); ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410); TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412); ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414); CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416); TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418); GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420); ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422); GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424); TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426); CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428); ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430); AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432); GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434); TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436); GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438); ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440); CAGTTGAGCC (SEQ ID NO:441);

AGTTGAGCCA (SEQ ID NO:442); GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444); TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446); AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448); CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450); AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452); ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454); AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456); GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458); TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460); GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462); AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464); AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466); GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468); CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470); ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472); AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474); AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476); GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478); GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480); GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482); ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484); ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486); CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488); GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490); TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492); GTTACACCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494); TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496); CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498); CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500); CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502); GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504); GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506); GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508); CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510); GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512); ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514); GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516); AATGGATGAC (SEQ ID NO:517);

ATGGATGACC (SEQ ID NO:518); TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520); GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522); TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524); ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526); CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528); TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530); AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532); AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534); AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536); AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538); GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540); GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542); TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544); GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546); GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548); GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550); AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552); GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554); TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556); GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558); CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560); GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562); CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564); CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTC (SEQ ID NO:566); TAGCATTTCA (SEQ ID NO:567);
AGCATTTCAT (SEQ ID NO:568); GCATTTCATC (SEQ ID NO:569);
CATTTCATCA (SEQ ID NO:570); ATTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572); TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574); CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576); TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578); ACGTGGCCCG (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580); GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582); GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584); CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586); CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588); AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590); AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592); CTGCATCCGG (SEQ ID NO:593);

TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

14. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);
CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);
CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);

GGAGCTCTCT (SEQ ID NO:700); GAGCTCTCTG (SEQ ID NO:701);
AGCTCTCTGG (SEQ ID NO:702); GCTCTCTGGC (SEQ ID NO:703);
CTCTCTGGCT (SEQ ID NO:704); TCTCTGGCTA (SEQ ID NO:705);
CTCTGGCTAA (SEQ ID NO:706); TCTGGCTAAC (SEQ ID NO:707);
CTGGCTAACT (SEQ ID NO:708); TGGCTAACTA (SEQ ID NO:709);
GGCTAACTAG (SEQ ID NO:710); GCTAACTAGG (SEQ ID NO:711);
CTAACTAGGG (SEQ ID NO:712); TAACTAGGGA (SEQ ID NO:713);
AACTAGGGAA (SEQ ID NO:714); ACTAGGGAAC (SEQ ID NO:715);
CTAGGGAACC (SEQ ID NO:716); TAGGGAACCC (SEQ ID NO:717);
AGGGAACCCA (SEQ ID NO:718); GGGAACCCAC (SEQ ID NO:719);
GGAACCCACT (SEQ ID NO:720); GAACCCACTG (SEQ ID NO:721);
AACCCACTGC (SEQ ID NO:722); ACCCACTGCT (SEQ ID NO:723);
CCCACTGCTT (SEQ ID NO:724); CCACTGCTTA (SEQ ID NO:725);
CACTGCTTAA (SEQ ID NO:726); ACTGCTTAAG (SEQ ID NO:727);
CTGCTTAAGC (SEQ ID NO:728); TGCTTAAGCC (SEQ ID NO:729);
GCTTAAGCCT (SEQ ID NO:730); CTTAAGCCTC (SEQ ID NO:731);
TTAAGCCTCA (SEQ ID NO:732); TAAGCCTCAA (SEQ ID NO:733);
AAGCCTCAAT (SEQ ID NO:734); AGCCTCAATA (SEQ ID NO:735);
GCCTCAATAA (SEQ ID NO:736); CCTCAATAAA (SEQ ID NO:737);
CTCAATAAAG (SEQ ID NO:738); TCAATAAAGC (SEQ ID NO:739);
CAATAAAGCT (SEQ ID NO:740); AATAAAGCTT (SEQ ID NO:741);
ATAAAGCTTG (SEQ ID NO:742); TAAAGCTTGC (SEQ ID NO:743);
AAAGCTTGCC (SEQ ID NO:744); AAGCTTGCCT (SEQ ID NO:745);
AGCTTGCCTT (SEQ ID NO:746); GCTTGCCTTG (SEQ ID NO:747);
CTTGCCTTGA (SEQ ID NO:748); TTGCCTTGAG (SEQ ID NO:749);
TGCCTTGAGT (SEQ ID NO:750); GCCTTGAGTG (SEQ ID NO:751);
CCTTGAGTGC (SEQ ID NO:752); CTTGAGTGCT (SEQ ID NO:753);
TTGAGTGCTT (SEQ ID NO:754); TGAGTGCTTC (SEQ ID NO:755);
GAGTGCTTCA (SEQ ID NO:756); AGTGCTTCAA (SEQ ID NO:757);
GTGCTTCAAG (SEQ ID NO:758); TGCTTCAAGT (SEQ ID NO:759);
GCTTCAAGTA (SEQ ID NO:760); CTTCAAGTAG (SEQ ID NO:761);
TTCAAGTAGT (SEQ ID NO:762); TCAAGTAGTG (SEQ ID NO:763);
CAAGTAGTGT (SEQ ID NO:764); AAGTAGTGTG (SEQ ID NO:765);
AGTAGTGTGT (SEQ ID NO:766); GTAGTGTGTG (SEQ ID NO:767);
TAGTGTGTGC (SEQ ID NO:768); AGTGTGTGCC (SEQ ID NO:769);
GTGTGTGCCC (SEQ ID NO:770); TGTGTGCCCG (SEQ ID NO:771);
GTGTGCCCGT (SEQ ID NO:772); TGTGCCCGTC (SEQ ID NO:773);
GTGCCCGTCT (SEQ ID NO:774); TGCCCGTCTG (SEQ ID NO:775);

GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
CTGTTGTGTG (SEQ ID NO:782); TGTTGTGTGA (SEQ ID NO:783);
GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);
TGACTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);
TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799).

15. A strain of HIV-1 according to claim 8 having the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

16. An isolated strain of HIV-1 which is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

17. An isolated strain of HIV-1 according to claim 16 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.

18. A nucleic acid molecule or a part, fragment or derivative thereof from an HIV-1 isolate defined in any one of claims 1 to 16.

19. A molecular infectious clone comprising a nucleic acid molecule according to claim 18.

20. A method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate

BNSDOCID: <WO___9521912A1_I_>

target cells carrying DNA derived from said non-pathogenic HIV-1.

21. A method according to claim 20 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.

22. A method according to claim 21 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1.

23. A method according to claim 17 wherein said isolate carries one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.

24. A method according to claim 22 or 23 wherein said HIV-1 isolate carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

25. A method according to claim 24 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.

26. A method according to claim 25 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.

27. A method according to claim 26 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

28. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

29. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

30. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

31. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

32. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43:

ATGGGTGGCA (SEQ ID NO:2); TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4); GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6); TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8); GCAAGTGGTC (SEQ ID NO:9);

BNSDOCID: <WO___9521912A1_I_>

CAAGTGGTCA (SEQ ID NO:10); AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12); GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14); GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16); TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18); AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20); AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22); AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24); TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26); GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28); GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30); GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32); TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34); GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36); ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38); GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40); CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42); TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44); CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46); GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48); AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50); GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52); GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54); AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56); GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58); ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60); GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62); GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64); CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66); AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68); CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70); GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72); GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74); CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76); GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78); AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80); CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82); GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84); TGGGGTGGGA (SEQ ID NO:85);

GGGGTGGGAG (SEQ ID NO:86); GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88); GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90); GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92); GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94); GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96); AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98); TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100); TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102); TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104); GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106); GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108); CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110); TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112); GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114); AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116); AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118); CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120); TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122); GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124); GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126); AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128); TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130); ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132); AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134); GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136); AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138); CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140); ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142); ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144); AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146); CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148); GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150); TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152); ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154); AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156); TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158); CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160); GCTTGTGCCT (SEQ ID NO:161);

BNSDOCID: <WO___9521912A1_I_>

CTTGTGCCTG (SEQ ID NO:162); TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164); GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166); GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168); CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170); GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172); CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174); AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176); AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178); GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180); ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182); AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184); GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186); GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188); AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190); GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192); AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194); AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196); GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198); GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200); GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202); TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204); TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206); CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208); GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210); CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212); CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214); CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216); TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218); AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220); GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222); ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224); CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226); TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228); AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230); GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232); CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234); AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236); TGACTTACAA (SEQ ID NO:237);

GACTTACAAG (SEQ ID NO:238); ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240); TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242); ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244); AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246); GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248); CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250); GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252); TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254); TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256); GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258); TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260); TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262); AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264); CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266); ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268); TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270); TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272); TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274); AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276); AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278); AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280); AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282); GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284); GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286); GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288); ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290); TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292); GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294); AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296); GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298); CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300); AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302); TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304); CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306); CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308); CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310); CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312); AAGAAGACAA (SEQ ID NO:313);

BNSDOCID: <WO___9521912A1_I_>

AGAAGACAAG (SEQ ID NO:314); GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316); AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318); ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320); AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322); GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324); TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326); TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328); CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330); TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332); ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334); CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336); GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338); GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340); ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342); CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344); ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346); CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348); CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350); CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352); CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354); AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356); GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358); TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360); CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362); TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364); CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366); TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368); ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370); TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372); GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374); AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376); AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378); CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380); ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382); ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384); ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386); CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388); GGGCCAGGGG (SEQ ID NO:389);

GGCCAGGGGT (SEQ ID NO:390); GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392); CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394); GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396); GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398); TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400); AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402); ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404); ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406); CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408); ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410); TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412); ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414); CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416); TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418); GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420); ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422); GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424); TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426); CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428); ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430); AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432); GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434); TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436); GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438); ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440); CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442); GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444); TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446); AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448); CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450); AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452); ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454); AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456); GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458); TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460); GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462); AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464); AGGCCAATAA (SEQ ID NO:465);

BNSDOCID: <WO___9521912A1_I_>

GGCCAATAAA (SEQ ID NO:466); GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468); CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470); ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472); AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474); AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476); GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478); GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480); GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482); ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484); ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486); CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488); GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490); TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492); GTTACACCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494); TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496); CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498); CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500); CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502); GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504); GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506); GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508); CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510); GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512); ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514); GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516); AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518); TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520); GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522); TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524); ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526); CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528); TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530); AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532); AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534); AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536); AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538); GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540); GTTAGAGTGG (SEQ ID NO:541);

TTAGAGTGGA (SEQ ID NO:542); TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544); GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546); GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548); GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550); AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552); GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554); TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556); GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558); CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560); GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562); CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564); CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTC (SEQ ID NO:566); TAGCATTTCA (SEQ ID NO:567);
AGCATTTCAT (SEQ ID NO:568); GCATTTCATC (SEQ ID NO:569);
CATTTCATCA (SEQ ID NO:570); ATTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572); TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574); CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576); TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578); ACGTGGCCCG (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580); GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582); GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584); CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586); CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588); AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590); AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592); CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

BNSDOCID: <WO___9521912A1_I_>

33. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);
CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);
CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);
GGAGCTCTCT (SEQ ID NO:700); GAGCTCTCTG (SEQ ID NO:701);
AGCTCTCTGG (SEQ ID NO:702); GCTCTCTGGC (SEQ ID NO:703);
CTCTCTGGCT (SEQ ID NO:704); TCTCTGGCTA (SEQ ID NO:705);
CTCTGGCTAA (SEQ ID NO:706); TCTGGCTAAC (SEQ ID NO:707);
CTGGCTAACT (SEQ ID NO:708); TGGCTAACTA (SEQ ID NO:709);
GGCTAACTAG (SEQ ID NO:710); GCTAACTAGG (SEQ ID NO:711);
CTAACTAGGG (SEQ ID NO:712); TAACTAGGGA (SEQ ID NO:713);
AACTAGGGAA (SEQ ID NO:714); ACTAGGGAAC (SEQ ID NO:715);
CTAGGGAACC (SEQ ID NO:716); TAGGGAACCC (SEQ ID NO:717);
AGGGAACCCA (SEQ ID NO:718); GGGAACCCAC (SEQ ID NO:719);

GGAACCCACT (SEQ ID NO:720); GAACCCACTG (SEQ ID NO:721);
AACCCACTGC (SEQ ID NO:722); ACCCACTGCT (SEQ ID NO:723);
CCCACTGCTT (SEQ ID NO:724); CCACTGCTTA (SEQ ID NO:725);
CACTGCTTAA (SEQ ID NO:726); ACTGCTTAAG (SEQ ID NO:727);
CTGCTTAAGC (SEQ ID NO:728); TGCTTAAGCC (SEQ ID NO:729);
GCTTAAGCCT (SEQ ID NO:730); CTTAAGCCTC (SEQ ID NO:731);
TTAAGCCTCA (SEQ ID NO:732); TAAGCCTCAA (SEQ ID NO:733);
AAGCCTCAAT (SEQ ID NO:734); AGCCTCAATA (SEQ ID NO:735);
GCCTCAATAA (SEQ ID NO:736); CCTCAATAAA (SEQ ID NO:737);
CTCAATAAAG (SEQ ID NO:738); TCAATAAAGC (SEQ ID NO:739);
CAATAAAGCT (SEQ ID NO:740); AATAAAGCTT (SEQ ID NO:741);
ATAAAGCTTG (SEQ ID NO:742); TAAAGCTTGC (SEQ ID NO:743);
AAAGCTTGCC (SEQ ID NO:744); AAGCTTGCCT (SEQ ID NO:745);
AGCTTGCCTT (SEQ ID NO:746); GCTTGCCTTG (SEQ ID NO:747);
CTTGCCTTGA (SEQ ID NO:748); TTGCCTTGAG (SEQ ID NO:749);
TGCCTTGAGT (SEQ ID NO:750); GCCTTGAGTG (SEQ ID NO:751);
CCTTGAGTGC (SEQ ID NO:752); CTTGAGTGCT (SEQ ID NO:753);
TTGAGTGCTT (SEQ ID NO:754); TGAGTGCTTC (SEQ ID NO:755);
GAGTGCTTCA (SEQ ID NO:756); AGTGCTTCAA (SEQ ID NO:757);
GTGCTTCAAG (SEQ ID NO:758); TGCTTCAAGT (SEQ ID NO:759);
GCTTCAAGTA (SEQ ID NO:760); CTTCAAGTAG (SEQ ID NO:761);
TTCAAGTAGT (SEQ ID NO:762); TCAAGTAGTG (SEQ ID NO:763);
CAAGTAGTGT (SEQ ID NO:764); AAGTAGTGTG (SEQ ID NO:765);
AGTAGTGTGT (SEQ ID NO:766); GTAGTGTGTG (SEQ ID NO:767);
TAGTGTGTGC (SEQ ID NO:768); AGTGTGTGCC (SEQ ID NO:769);
GTGTGTGCCC (SEQ ID NO:770); TGTGTGCCCG (SEQ ID NO:771);
GTGTGCCCGT (SEQ ID NO:772); TGTGCCCGTC (SEQ ID NO:773);
GTGCCCGTCT (SEQ ID NO:774); TGCCCGTCTG (SEQ ID NO:775);
GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
CTGTTGTGTG (SEQ ID NO:782); TGTTGTGTGA (SEQ ID NO:783);
GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);
TGACTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);

BNSDOCID: <WO___9521912A1_I_>

TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799).

34. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

35. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

36. A method according to claim 35 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.

37. A method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying DNA derived from said non-pathogenic HIV-1.

38. A method according to claim 37 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject.

39. A method according to claim 38 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1.

40. A method according to claim 17 wherein said isolate carried one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1.

41. A method according to claim 39 or 40 wherein said HIV-1 isolate carries a mutation in its *nef* gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome.

42. A method according to claim 40 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gp120 and/or gp160 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the *nef* gene and/or LTR region of pathogenic HIV-1.

43. A method according to claim 42 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of *gag*, *pol* and/or *env*.

44. A method according to claim 43 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

45. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

46. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;

BNSDOCID: <WO___9521912A1_I_>

(vii) 9105-9224; and

(viii) 9271-9370.

47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide (ix) 8882-8928;

(x) 8850-9006;

(xi) 8792-9041; and

(xii) 9112-9204.

47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of:

nucleotide (xiii) 9105-9224;

(xiv) 9389-9395; and

(xv) 9281-9366.

48. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43:

ATGGGTGGCA (SEQ ID NO:2); TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4); GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6); TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8); GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10); AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12); GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14); GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16); TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18); AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20); AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22); AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24); TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26); GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28); GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30); GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32); TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34); GGATGGCCTG (SEQ ID NO:35);

GATGGCCTGC (SEQ ID NO:36); ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38); GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40); CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42); TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44); CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46); GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48); AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50); GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52); GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54); AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56); GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58); ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60); GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62); GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64); CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66); AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68); CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70); GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72); GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74); CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76); GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78); AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80); CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82); GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84); TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86); GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88); GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90); GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92); GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94); GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96); AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98); TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100); TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102); TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104); GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106); GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108); CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110); TAGAAAAACA (SEQ ID NO:111);

BNSDOCID: <WO___9521912A1_I_>

AGAAAAACAT (SEQ ID NO:112); GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114); AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116); AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118); CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120); TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122); GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124); GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126); AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128); TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130); ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132); AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134); GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136); AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138); CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140); ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142); ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144); AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146); CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148); GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150); TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152); ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154); AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156); TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158); CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160); GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162); TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164); GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166); GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168); CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170); GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172); CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174); AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176); AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178); GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180); ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182); AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184); GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186); GGAGGAAGAG (SEQ ID NO:187);

GAGGAAGAGG (SEQ ID NO:188); AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190); GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192); AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194); AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196); GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198); GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200); GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202); TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204); TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206); CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208); GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210); CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212); CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214); CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216); TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218); AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220); GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222); ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224); CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226); TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228); AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230); GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232); CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234); AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236); TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238); ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240); TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242); ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244); AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246); GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248); CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250); GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252); TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254); TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256); GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258); TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260); TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262); AGCCACTTTT (SEQ ID NO:263);

GCCACTTTTT (SEQ ID NO:264); CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266); ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268); TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270); TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272); TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274); AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276); AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278); AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280); AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282); GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284); GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286); GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288); ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290); TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292); GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294); AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296); GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298); CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300); AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302); TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304); CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306); CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308); CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310); CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312); AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314); GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316); AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318); ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320); AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322); GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324); TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326); TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328); CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330); TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332); ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334); CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336); GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338); GGATCTACCA (SEQ ID NO:339);

GATCTACCAC (SEQ ID NO:340); ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342); CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344); ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346); CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348); CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350); CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352); CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354); AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356); GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358); TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360); CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362); TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364); CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366); TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368); ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370); TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372); GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374); AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376); AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378); CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380); ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382); ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384); ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386); CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388); GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390); GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392); CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394); GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396); GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398); TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400); AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402); ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404); ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406); CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408); ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410); TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412); ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414); CTTTGGATGG (SEQ ID NO:415);

BNSDOCID: <WO___9521912A1_|_>

TTTGGATGGT (SEQ ID NO:416); TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418); GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420); ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422); GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424); TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426); CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428); ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430); AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432); GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434); TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436); GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438); ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440); CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442); GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444); TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446); AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448); CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450); AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452); ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454); AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456); GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458); TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460); GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462); AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464); AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466); GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468); CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470); ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472); AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474); AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476); GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478); GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480); GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482); ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484); ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486); CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488); GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490); TTGTTACACC (SEQ ID NO:491);

TGTTACACCC (SEQ ID NO:492); GTTACACCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494); TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496); CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498); CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500); CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502); GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504); GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506); GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508); CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510); GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512); ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514); GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516); AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518); TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520); GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522); TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524); ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526); CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528); TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530); AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532); AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534); AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536); AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538); GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540); GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542); TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544); GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546); GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548); GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550); AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552); GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554); TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556); GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558); CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560); GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562); CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564); CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTC (SEQ ID NO:566); TAGCATTTCA (SEQ ID NO:567);

BNSDOCID: <WO___9521912A1_I_>

AGCATTTCAT (SEQ ID NO:568); GCATTTCATC (SEQ ID NO:569);
CATTTCATCA (SEQ ID NO:570); ATTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572); TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574); CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576); TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578); ACGTGGCCCG (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580); GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582); GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584); CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586); CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588); AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590); AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592); CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

49. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);

CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);
CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);
GGAGCTCTCT (SEQ ID NO:700); GAGCTCTCTG (SEQ ID NO:701);
AGCTCTCTGG (SEQ ID NO:702); GCTCTCTGGC (SEQ ID NO:703);
CTCTCTGGCT (SEQ ID NO:704); TCTCTGGCTA (SEQ ID NO:705);
CTCTGGCTAA (SEQ ID NO:706); TCTGGCTAAC (SEQ ID NO:707);
CTGGCTAACT (SEQ ID NO:708); TGGCTAACTA (SEQ ID NO:709);
GGCTAACTAG (SEQ ID NO:710); GCTAACTAGG (SEQ ID NO:711);
CTAACTAGGG (SEQ ID NO:712); TAACTAGGGA (SEQ ID NO:713);
AACTAGGGAA (SEQ ID NO:714); ACTAGGGAAC (SEQ ID NO:715);
CTAGGGAACC (SEQ ID NO:716); TAGGGAACCC (SEQ ID NO:717);
AGGGAACCCA (SEQ ID NO:718); GGGAACCCAC (SEQ ID NO:719);
GGAACCCACT (SEQ ID NO:720); GAACCCACTG (SEQ ID NO:721);
AACCCACTGC (SEQ ID NO:722); ACCCACTGCT (SEQ ID NO:723);
CCCACTGCTT (SEQ ID NO:724); CCACTGCTTA (SEQ ID NO:725);
CACTGCTTAA (SEQ ID NO:726); ACTGCTTAAG (SEQ ID NO:727);
CTGCTTAAGC (SEQ ID NO:728); TGCTTAAGCC (SEQ ID NO:729);
GCTTAAGCCT (SEQ ID NO:730); CTTAAGCCTC (SEQ ID NO:731);
TTAAGCCTCA (SEQ ID NO:732); TAAGCCTCAA (SEQ ID NO:733);
AAGCCTCAAT (SEQ ID NO:734); AGCCTCAATA (SEQ ID NO:735);
GCCTCAATAA (SEQ ID NO:736); CCTCAATAAA (SEQ ID NO:737);
CTCAATAAAG (SEQ ID NO:738); TCAATAAAGC (SEQ ID NO:739);
CAATAAAGCT (SEQ ID NO:740); AATAAAGCTT (SEQ ID NO:741);
ATAAAGCTTG (SEQ ID NO:742); TAAAGCTTGC (SEQ ID NO:743);
AAAGCTTGCC (SEQ ID NO:744); AAGCTTGCCT (SEQ ID NO:745);
AGCTTGCCTT (SEQ ID NO:746); GCTTGCCTTG (SEQ ID NO:747);
CTTGCCTTGA (SEQ ID NO:748); TTGCCTTGAG (SEQ ID NO:749);

TGCCTTGAGT (SEQ ID NO:750); GCCTTGAGTG (SEQ ID NO:751);
CCTTGAGTGC (SEQ ID NO:752); CTTGAGTGCT (SEQ ID NO:753);
TTGAGTGCTT (SEQ ID NO:754); TGAGTGCTTC (SEQ ID NO:755);
GAGTGCTTCA (SEQ ID NO:756); AGTGCTTCAA (SEQ ID NO:757);
GTGCTTCAAG (SEQ ID NO:758); TGCTTCAAGT (SEQ ID NO:759);
GCTTCAAGTA (SEQ ID NO:760); CTTCAAGTAG (SEQ ID NO:761);
TTCAAGTAGT (SEQ ID NO:762); TCAAGTAGTG (SEQ ID NO:763);
CAAGTAGTGT (SEQ ID NO:764); AAGTAGTGTG (SEQ ID NO:765);
AGTAGTGTGT (SEQ ID NO:766); GTAGTGTGTG (SEQ ID NO:767);
TAGTGTGTGC (SEQ ID NO:768); AGTGTGTGCC (SEQ ID NO:769);
GTGTGTGCCC (SEQ ID NO:770); TGTGTGCCCG (SEQ ID NO:771);
GTGTGCCCGT (SEQ ID NO:772); TGTGCCCGTC (SEQ ID NO:773);
GTGCCCGTCT (SEQ ID NO:774); TGCCCGTCTG (SEQ ID NO:775);
GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
CTGTTGTGTG (SEQ ID NO:782); TGTTGTGTGA (SEQ ID NO:783);
GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);
TGACTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);
TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799).

50. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number _____.

51. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of *gag*, *pol* and/or *env* and which is incapable of directing synthesis of a *nef* gene product or a full length *nef* gene product.

52. A method according to claim 51 wherein the glycoprotein is at least one of gp41-45, gp120 and/or gp160.

53. A method for obtaining a preparation of non-pathogenic HIV-1 from a biological sample, said method comprising co-culturing PBMCs from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid.

54. A method according to claim 53 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication.

55. A method according to claim 54 wherein the cytokine is M-CSF.

56. A method according to claim 53 or 54 or 55 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2.

57. A method according to claim 53 wherein the PBMCs from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs.

58. A method according to claim 53 or 57 wherein the cocultured cells are subjected to UV irradiation.

59. A method for obtaining a preparation of non-pathogenic HIV-1 from a biological sample, said method comprising co-culturing monocytes from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the monocytes and PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid.

BNSDOCID: <WO___9521912A1_I_>

60. A method according to claim 59 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication.

61. A method according to claim 60 wherein the cytokine is M-CSF.

62. A method according to claim 59 or 60 or 61 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2.

63. A method according to claim 59 wherein the monocytes from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs.

64. A method according to claim 59 or 63 wherein the cocultured cells are subjected to UV irradiation.

65. A method for identifying or screening for compounds capable of reducing or otherwise interfering with HIV-1 replication, said method comprising contacting a compound to be tested with a cell or cell extract containing or capable of containing a *nef* gene product fused to a reporter molecule capable of giving an identifiable signal and screening for a compound which inhibits said signal.

66. A method according to claim 65 wherein the compound is an antibody to *nef* gene product or a part thereof.

67. A method according to claim 65 wherein the compound is a DNA targeting agent and inhibits transcription of the *nef* gene.

68. A compound capable of inhibiting *nef* gene product function or *nef* gene transcription.

69. A compound capable of inhibiting *nef* gene product function or *nef* gene transcription identified according to the method of claim 65 or 66 or 67.

70. A therapeutic composition useful for inhibiting or reducing productive infection by a pathogenic strain of HIV-1 and/or for vaccinating an individual against the development of AIDS or AIDS-related diseases, said composition comprising a non-pathogenic strain of HIV-1 according to any one of claims 1 to 16 and one or more pharmaceutical acceptable carriers and/or diluents.

71. A therapeutic composition according to claim 70 wherein said HIV-1 isolate comprises genetic material that directs expression of antisense or ribozyme nucleotide sequences which inhibit production of one or more proteins encoded by a pathogenic strain of HIV-1.

72. A viral isolate which:

(i) is genetically or immunologically related to a pathogenic strain of HIV-1;

(ii) is substantially non-pathogenic in human subjects;

(iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and

(iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down-regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1.

73. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *gag* or *pol*.

74. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *env* or *tat*.

75. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *rev* or *vpu*.

BNSDOCID: <WO___9521912A1_I_>

76. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of *vpr*, *vif* or *nef*.

77. A viral isolate according to claim 72 wherein the targeted protein is *nef*.

78. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in the genome of said HIV-1 wherein said deletion mutation results in said genome being unable to synthesise a polypeptide or protein from a pathogenic strain of HIV-1 or directing the synthesis of a truncated form of said polypeptide or protein wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV-1.

79. The method according to claim 78 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3.

80. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(i)	8830-8862;
	(ii)	9009-9035;
	(iii)	9019-9029; and
	(iv)	9033-9049.

81. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(v)	9281-9371;
	(vi)	9281-9362;
	(vii)	9105-9224; and
	(viii)	9271-9370.

82. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(ix)	8882-8928;
	(x)	8850-9006;
	(xi)	8792-9041; and
	(xii)	9112-9204.

83. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide	(xiii)	9105-9224;
	(xiv)	9389-9395; and
	(xv)	9281-9366.

84. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2);	TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4);	GGTGGCAAGT (SEQ ID NO:5);
GTGGCAAGTG (SEQ ID NO:6);	TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8);	GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10);	AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12);	GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14);	GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16);	TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18);	AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20);	AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22);	AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24);	TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26);	GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28);	GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30);	GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32);	TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34);	GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36);	ATGGCCTGCT (SEQ ID NO:37);

BNSDOCID: <WO___9521912A1_I_>

TGGCCTGCTG (SEQ ID NO:38); GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40); CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42); TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44); CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46); GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48); AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50); GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52); GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54); AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56); GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58); ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60); GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62); GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64); CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66); AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68); CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70); GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72); GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74); CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76); GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78); AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80); CAGATGGGGT (SEQ ID NO:81);
AGATGGGGTG (SEQ ID NO:82); GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84); TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86); GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88); GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90); GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92); GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94); GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96); AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98); TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100); TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102); TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104); GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106); GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108); CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110); TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112); GAAAAACATG (SEQ ID NO:113);

AAAAACATGG (SEQ ID NO:114); AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116); AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118); CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120); TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122); GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124); GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126); AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128); TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130); ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132); AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134); GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136); AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138); CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140); ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142); ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144); AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146); CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148); GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150); TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152); ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154); AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156); TGCTGCTTGT (SEQ ID NO:157);
GCTGCTTGTG (SEQ ID NO:158); CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160); GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162); TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164); GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166); GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168); CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170); GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172); CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174); AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176); AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178); GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180); ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182); AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184); GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186); GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188); AGGAAGAGGT (SEQ ID NO:189);

GGAAGAGGTG (SEQ ID NO:190); GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192); AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194); AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196); GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198); GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200); GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202); TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204); TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206); CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208); GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210); CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212); CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214); CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216); TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218); AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220); GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222); ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224); CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226); TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228); AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230); GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232); CCAATGACTT (SEQ ID NO:233);
CAATGACTTA (SEQ ID NO:234); AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236); TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238); ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240); TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242); ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244); AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246); GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248); CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250); GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252); TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254); TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256); GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258); TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260); TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262); AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264); CCACTTTTTA (SEQ ID NO:265);

CACTTTTTAA (SEQ ID NO:266); ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268); TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270); TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272); TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274); AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276); AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278); AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280); AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282); GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284); GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286); GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288); ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290); TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292); GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294); AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296); GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298); CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300); AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302); TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304); CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306); CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308); CCCAAAGAAG (SEQ ID NO:309);
CCAAAGAAGA (SEQ ID NO:310); CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312); AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314); GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316); AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318); ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320); AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322); GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324); TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326); TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328); CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330); TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332); ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334); CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336); GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338); GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340); ATCTACCACA (SEQ ID NO:341);

TCTACCACAC (SEQ ID NO:342); CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344); ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346); CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348); CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350); CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352); CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354); AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356); GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358); TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360); CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362); TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364); CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366); TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368); ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370); TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372); GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374); AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376); AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378); CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380); ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382); ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384); ACCAGGGCCA (SEQ ID NO:385);
CCAGGGCCAG (SEQ ID NO:386); CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388); GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390); GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392); CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394); GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396); GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398); TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400); AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402); ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404); ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406); CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408); ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410); TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412); ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414); CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416); TTGGATGGTG (SEQ ID NO:417);

TGGATGGTGC (SEQ ID NO:418); GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420); ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422); GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424); TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426); CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428); ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430); AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432); GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434); TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436); GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438); ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440); CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442); GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444); TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446); AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448); CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450); AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452); ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454); AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456); GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458); TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460); GAAGAGGCCA (SEQ ID NO:461);
AAGAGGCCAA (SEQ ID NO:462); AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464); AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466); GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468); CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470); ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472); AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474); AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476); GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478); GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480); GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482); ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484); ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486); CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488); GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490); TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492); GTTACACCCT (SEQ ID NO:493);

BNSDOCID: <WO___9521912A1_I_>

TTACACCCTG (SEQ ID NO:494); TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496); CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498); CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500); CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502); GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504); GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506); GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508); CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510); GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512); ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514); GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516); AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518); TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520); GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522); TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524); ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526); CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528); TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530); AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532); AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534); AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536); AAGTGTTAGA (SEQ ID NO:537);
AGTGTTAGAG (SEQ ID NO:538); GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540); GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542); TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544); GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546); GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548); GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550); AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552); GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554); TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556); GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558); CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560); GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562); CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564); CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTC (SEQ ID NO:566); TAGCATTTCA (SEQ ID NO:567);
AGCATTTCAT (SEQ ID NO:568); GCATTTCATC (SEQ ID NO:569);

CATTTCATCA (SEQ ID NO:570); ATTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572); TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574); CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576); TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578); ACGTGGCCCG (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580); GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582); GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584); CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586); CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588); AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590); AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592); CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

85. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);
CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);

BNSDOCID: <WO___9521912A1_I_>

CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);
GGAGCTCTCT (SEQ ID NO:700); GAGCTCTCTG (SEQ ID NO:701);
AGCTCTCTGG (SEQ ID NO:702); GCTCTCTGGC (SEQ ID NO:703);
CTCTCTGGCT (SEQ ID NO:704); TCTCTGGCTA (SEQ ID NO:705);
CTCTGGCTAA (SEQ ID NO:706); TCTGGCTAAC (SEQ ID NO:707);
CTGGCTAACT (SEQ ID NO:708); TGGCTAACTA (SEQ ID NO:709);
GGCTAACTAG (SEQ ID NO:710); GCTAACTAGG (SEQ ID NO:711);
CTAACTAGGG (SEQ ID NO:712); TAACTAGGGA (SEQ ID NO:713);
AACTAGGGAA (SEQ ID NO:714); ACTAGGGAAC (SEQ ID NO:715);
CTAGGGAACC (SEQ ID NO:716); TAGGGAACCC (SEQ ID NO:717);
AGGGAACCCA (SEQ ID NO:718); GGGAACCCAC (SEQ ID NO:719);
GGAACCCACT (SEQ ID NO:720); GAACCCACTG (SEQ ID NO:721);
AACCCACTGC (SEQ ID NO:722); ACCCACTGCT (SEQ ID NO:723);
CCCACTGCTT (SEQ ID NO:724); CCACTGCTTA (SEQ ID NO:725);
CACTGCTTAA (SEQ ID NO:726); ACTGCTTAAG (SEQ ID NO:727);
CTGCTTAAGC (SEQ ID NO:728); TGCTTAAGCC (SEQ ID NO:729);
GCTTAAGCCT (SEQ ID NO:730); CTTAAGCCTC (SEQ ID NO:731);
TTAAGCCTCA (SEQ ID NO:732); TAAGCCTCAA (SEQ ID NO:733);
AAGCCTCAAT (SEQ ID NO:734); AGCCTCAATA (SEQ ID NO:735);
GCCTCAATAA (SEQ ID NO:736); CCTCAATAAA (SEQ ID NO:737);
CTCAATAAAG (SEQ ID NO:738); TCAATAAAGC (SEQ ID NO:739);
CAATAAAGCT (SEQ ID NO:740); AATAAAGCTT (SEQ ID NO:741);
ATAAAGCTTG (SEQ ID NO:742); TAAAGCTTGC (SEQ ID NO:743);
AAAGCTTGCC (SEQ ID NO:744); AAGCTTGCCT (SEQ ID NO:745);
AGCTTGCCTT (SEQ ID NO:746); GCTTGCCTTG (SEQ ID NO:747);
CTTGCCTTGA (SEQ ID NO:748); TTGCCTTGAG (SEQ ID NO:749);
TGCCTTGAGT (SEQ ID NO:750); GCCTTGAGTG (SEQ ID NO:751);

CCTTGAGTGC (SEQ ID NO:752); CTTGAGTGCT (SEQ ID NO:753);
TTGAGTGCTT (SEQ ID NO:754); TGAGTGCTTC (SEQ ID NO:755);
GAGTGCTTCA (SEQ ID NO:756); AGTGCTTCAA (SEQ ID NO:757);
GTGCTTCAAG (SEQ ID NO:758); TGCTTCAAGT (SEQ ID NO:759);
GCTTCAAGTA (SEQ ID NO:760); CTTCAAGTAG (SEQ ID NO:761);
TTCAAGTAGT (SEQ ID NO:762); TCAAGTAGTG (SEQ ID NO:763);
CAAGTAGTGT (SEQ ID NO:764); AAGTAGTGTG (SEQ ID NO:765);
AGTAGTGTGT (SEQ ID NO:766); GTAGTGTGTG (SEQ ID NO:767);
TAGTGTGTGC (SEQ ID NO:768); AGTGTGTGCC (SEQ ID NO:769);
GTGTGTGCCC (SEQ ID NO:770); TGTGTGCCCG (SEQ ID NO:771);
GTGTGCCCGT (SEQ ID NO:772); TGTGCCCGTC (SEQ ID NO:773);
GTGCCCGTCT (SEQ ID NO:774); TGCCCGTCTG (SEQ ID NO:775);
GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
CTGTTGTGTG (SEQ ID NO:782); TGTTGTGTGA (SEQ ID NO:783);
GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);
TGACTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);
TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799).

86. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3 wherein the presence of said deletion mutation is indicative of the presence of a non-pathogenic strain of HIV-1.

87. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide (i) 8830-8862;
(ii) 9009-9035;
(iii) 9019-9029; and
(iv) 9033-9049.

88. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide (v) 9281-9371;
(vi) 9281-9362;
(vii) 9105-9224; and
(viii) 9271-9370.

89. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide (ix) 8882-8928;
(x) 8850-9006;
(xi) 8792-9041; and
(xii) 9112-9204.

90. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of:

nucleotide (xiii) 9105-9224;
(xiv) 9389-9395; and
(xv) 9281-9366.

91. A strain of HIV-1 according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the *nef* gene of HIV-1 strain NL4-3:

ATGGGTGGCA (SEQ ID NO:2); TGGGTGGCAA (SEQ ID NO:3);
GGGTGGCAAG (SEQ ID NO:4); GGTGGCAAGT (SEQ ID NO:5);

GTGGCAAGTG (SEQ ID NO:6); TGGCAAGTGG (SEQ ID NO:7);
GGCAAGTGGT (SEQ ID NO:8); GCAAGTGGTC (SEQ ID NO:9);
CAAGTGGTCA (SEQ ID NO:10); AAGTGGTCAA (SEQ ID NO:11);
AGTGGTCAAA (SEQ ID NO:12); GTGGTCAAAA (SEQ ID NO:13);
TGGTCAAAAA (SEQ ID NO:14); GGTCAAAAAG (SEQ ID NO:15);
GTCAAAAAGT (SEQ ID NO:16); TCAAAAAGTA (SEQ ID NO:17);
CAAAAAGTAG (SEQ ID NO:18); AAAAAGTAGT (SEQ ID NO:19);
AAAAGTAGTG (SEQ ID NO:20); AAAGTAGTGT (SEQ ID NO:21);
AAGTAGTGTG (SEQ ID NO:22); AGTAGTGTGA (SEQ ID NO:23);
GTAGTGTGAT (SEQ ID NO:24); TAGTGTGATT (SEQ ID NO:25);
AGTGTGATTG (SEQ ID NO:26); GTGTGATTGG (SEQ ID NO:27);
TGTGATTGGA (SEQ ID NO:28); GTGATTGGAT (SEQ ID NO:29);
TGATTGGATG (SEQ ID NO:30); GATTGGATGG (SEQ ID NO:31);
ATTGGATGGC (SEQ ID NO:32); TTGGATGGCC (SEQ ID NO:33);
TGGATGGCCT (SEQ ID NO:34); GGATGGCCTG (SEQ ID NO:35);
GATGGCCTGC (SEQ ID NO:36); ATGGCCTGCT (SEQ ID NO:37);
TGGCCTGCTG (SEQ ID NO:38); GGCCTGCTGT (SEQ ID NO:39);
GCCTGCTGTA (SEQ ID NO:40); CCTGCTGTAA (SEQ ID NO:41);
CTGCTGTAAG (SEQ ID NO:42); TGCTGTAAGG (SEQ ID NO:43);
GCTGTAAGGG (SEQ ID NO:44); CTGTAAGGGA (SEQ ID NO:45);
TGTAAGGGAA (SEQ ID NO:46); GTAAGGGAAA (SEQ ID NO:47);
TAAGGGAAAG (SEQ ID NO:48); AAGGGAAAGA (SEQ ID NO:49);
AGGGAAAGAA (SEQ ID NO:50); GGGAAAGAAT (SEQ ID NO:51);
GGAAAGAATG (SEQ ID NO:52); GAAAGAATGA (SEQ ID NO:53);
AAAGAATGAG (SEQ ID NO:54); AAGAATGAGA (SEQ ID NO:55);
AGAATGAGAC (SEQ ID NO:56); GAATGAGACG (SEQ ID NO:57);
AATGAGACGA (SEQ ID NO:58); ATGAGACGAG (SEQ ID NO:59);
TGAGACGAGC (SEQ ID NO:60); GAGACGAGCT (SEQ ID NO:61);
AGACGAGCTG (SEQ ID NO:62); GACGAGCTGA (SEQ ID NO:63);
ACGAGCTGAG (SEQ ID NO:64); CGAGCTGAGC (SEQ ID NO:65);
GAGCTGAGCC (SEQ ID NO:66); AGCTGAGCCA (SEQ ID NO:67);
GCTGAGCCAG (SEQ ID NO:68); CTGAGCCAGC (SEQ ID NO:69);
TGAGCCAGCA (SEQ ID NO:70); GAGCCAGCAG (SEQ ID NO:71);
AGCCAGCAGC (SEQ ID NO:72); GCCAGCAGCA (SEQ ID NO:73);
CCAGCAGCAG (SEQ ID NO:74); CAGCAGCAGA (SEQ ID NO:75);
AGCAGCAGAT (SEQ ID NO:76); GCAGCAGATG (SEQ ID NO:77);
CAGCAGATGG (SEQ ID NO:78); AGCAGATGGG (SEQ ID NO:79);
GCAGATGGGG (SEQ ID NO:80); CAGATGGGGT (SEQ ID NO:81);

AGATGGGGTG (SEQ ID NO:82); GATGGGGTGG (SEQ ID NO:83);
ATGGGGTGGG (SEQ ID NO:84); TGGGGTGGGA (SEQ ID NO:85);
GGGGTGGGAG (SEQ ID NO:86); GGGTGGGAGC (SEQ ID NO:87);
GGTGGGAGCA (SEQ ID NO:88); GTGGGAGCAG (SEQ ID NO:89);
TGGGAGCAGT (SEQ ID NO:90); GGGAGCAGTA (SEQ ID NO:91);
GGAGCAGTAT (SEQ ID NO:92); GAGCAGTATC (SEQ ID NO:93);
AGCAGTATCT (SEQ ID NO:94); GCAGTATCTC (SEQ ID NO:95);
CAGTATCTCG (SEQ ID NO:96); AGTATCTCGA (SEQ ID NO:97);
GTATCTCGAG (SEQ ID NO:98); TATCTCGAGA (SEQ ID NO:99);
ATCTCGAGAC (SEQ ID NO:100); TCTCGAGACC (SEQ ID NO:101);
CTCGAGACCT (SEQ ID NO:102); TCGAGACCTA (SEQ ID NO:103);
CGAGACCTAG (SEQ ID NO:104); GAGACCTAGA (SEQ ID NO:105);
AGACCTAGAA (SEQ ID NO:106); GACCTAGAAA (SEQ ID NO:107);
ACCTAGAAAA (SEQ ID NO:108); CCTAGAAAAA (SEQ ID NO:109);
CTAGAAAAAC (SEQ ID NO:110); TAGAAAAACA (SEQ ID NO:111);
AGAAAAACAT (SEQ ID NO:112); GAAAAACATG (SEQ ID NO:113);
AAAAACATGG (SEQ ID NO:114); AAAACATGGA (SEQ ID NO:115);
AAACATGGAG (SEQ ID NO:116); AACATGGAGC (SEQ ID NO:117);
ACATGGAGCA (SEQ ID NO:118); CATGGAGCAA (SEQ ID NO:119);
ATGGAGCAAT (SEQ ID NO:120); TGGAGCAATC (SEQ ID NO:121);
GGAGCAATCA (SEQ ID NO:122); GAGCAATCAC (SEQ ID NO:123);
AGCAATCACA (SEQ ID NO:124); GCAATCACAA (SEQ ID NO:125);
CAATCACAAG (SEQ ID NO:126); AATCACAAGT (SEQ ID NO:127);
ATCACAAGTA (SEQ ID NO:128); TCACAAGTAG (SEQ ID NO:129);
CACAAGTAGC (SEQ ID NO:130); ACAAGTAGCA (SEQ ID NO:131);
CAAGTAGCAA (SEQ ID NO:132); AAGTAGCAAT (SEQ ID NO:133);
AGTAGCAATA (SEQ ID NO:134); GTAGCAATAC (SEQ ID NO:135);
TAGCAATACA (SEQ ID NO:136); AGCAATACAG (SEQ ID NO:137);
GCAATACAGC (SEQ ID NO:138); CAATACAGCA (SEQ ID NO:139);
AATACAGCAG (SEQ ID NO:140); ATACAGCAGC (SEQ ID NO:141);
TACAGCAGCT (SEQ ID NO:142); ACAGCAGCTA (SEQ ID NO:143);
CAGCAGCTAA (SEQ ID NO:144); AGCAGCTAAC (SEQ ID NO:145);
GCAGCTAACA (SEQ ID NO:146); CAGCTAACAA (SEQ ID NO:147);
AGCTAACAAT (SEQ ID NO:148); GCTAACAATG (SEQ ID NO:149);
CTAACAATGC (SEQ ID NO:150); TAACAATGCT (SEQ ID NO:151);
AACAATGCTG (SEQ ID NO:152); ACAATGCTGC (SEQ ID NO:153);
CAATGCTGCT (SEQ ID NO:154); AATGCTGCTT (SEQ ID NO:155);
ATGCTGCTTG (SEQ ID NO:156); TGCTGCTTGT (SEQ ID NO:157);

GCTGCTTGTG (SEQ ID NO:158); CTGCTTGTGC (SEQ ID NO:159);
TGCTTGTGCC (SEQ ID NO:160); GCTTGTGCCT (SEQ ID NO:161);
CTTGTGCCTG (SEQ ID NO:162); TTGTGCCTGG (SEQ ID NO:163);
TGTGCCTGGC (SEQ ID NO:164); GTGCCTGGCT (SEQ ID NO:165);
TGCCTGGCTA (SEQ ID NO:166); GCCTGGCTAG (SEQ ID NO:167);
CCTGGCTAGA (SEQ ID NO:168); CTGGCTAGAA (SEQ ID NO:169);
TGGCTAGAAG (SEQ ID NO:170); GGCTAGAAGC (SEQ ID NO:171);
GCTAGAAGCA (SEQ ID NO:172); CTAGAAGCAC (SEQ ID NO:173);
TAGAAGCACA (SEQ ID NO:174); AGAAGCACAA (SEQ ID NO:175);
GAAGCACAAG (SEQ ID NO:176); AAGCACAAGA (SEQ ID NO:177);
AGCACAAGAG (SEQ ID NO:178); GCACAAGAGG (SEQ ID NO:179);
CACAAGAGGA (SEQ ID NO:180); ACAAGAGGAG (SEQ ID NO:181);
CAAGAGGAGG (SEQ ID NO:182); AAGAGGAGGA (SEQ ID NO:183);
AGAGGAGGAA (SEQ ID NO:184); GAGGAGGAAG (SEQ ID NO:185);
AGGAGGAAGA (SEQ ID NO:186); GGAGGAAGAG (SEQ ID NO:187);
GAGGAAGAGG (SEQ ID NO:188); AGGAAGAGGT (SEQ ID NO:189);
GGAAGAGGTG (SEQ ID NO:190); GAAGAGGTGG (SEQ ID NO:191);
AAGAGGTGGG (SEQ ID NO:192); AGAGGTGGGT (SEQ ID NO:193);
GAGGTGGGTT (SEQ ID NO:194); AGGTGGGTTT (SEQ ID NO:195);
GGTGGGTTTT (SEQ ID NO:196); GTGGGTTTTC (SEQ ID NO:197);
TGGGTTTTCC (SEQ ID NO:198); GGGTTTTCCA (SEQ ID NO:199);
GGTTTTCCAG (SEQ ID NO:200); GTTTTCCAGT (SEQ ID NO:201);
TTTTCCAGTC (SEQ ID NO:202); TTTCCAGTCA (SEQ ID NO:203);
TTCCAGTCAC (SEQ ID NO:204); TCCAGTCACA (SEQ ID NO:205);
CCAGTCACAC (SEQ ID NO:206); CAGTCACACC (SEQ ID NO:207);
AGTCACACCT (SEQ ID NO:208); GTCACACCTC (SEQ ID NO:209);
TCACACCTCA (SEQ ID NO:210); CACACCTCAG (SEQ ID NO:211);
ACACCTCAGG (SEQ ID NO:212); CACCTCAGGT (SEQ ID NO:213);
ACCTCAGGTA (SEQ ID NO:214); CCTCAGGTAC (SEQ ID NO:215);
CTCAGGTACC (SEQ ID NO:216); TCAGGTACCT (SEQ ID NO:217);
CAGGTACCTT (SEQ ID NO:218); AGGTACCTTT (SEQ ID NO:219);
GGTACCTTTA (SEQ ID NO:220); GTACCTTTAA (SEQ ID NO:221);
TACCTTTAAG (SEQ ID NO:222); ACCTTTAAGA (SEQ ID NO:223);
CCTTTAAGAC (SEQ ID NO:224); CTTTAAGACC (SEQ ID NO:225);
TTTAAGACCA (SEQ ID NO:226); TTAAGACCAA (SEQ ID NO:227);
TAAGACCAAT (SEQ ID NO:228); AAGACCAATG (SEQ ID NO:229);
AGACCAATGA (SEQ ID NO:230); GACCAATGAC (SEQ ID NO:231);
ACCAATGACT (SEQ ID NO:232); CCAATGACTT (SEQ ID NO:233);

CAATGACTTA (SEQ ID NO:234); AATGACTTAC (SEQ ID NO:235);
ATGACTTACA (SEQ ID NO:236); TGACTTACAA (SEQ ID NO:237);
GACTTACAAG (SEQ ID NO:238); ACTTACAAGG (SEQ ID NO:239);
CTTACAAGGC (SEQ ID NO:240); TTACAAGGCA (SEQ ID NO:241);
TACAAGGCAG (SEQ ID NO:242); ACAAGGCAGC (SEQ ID NO:243);
CAAGGCAGCT (SEQ ID NO:244); AAGGCAGCTG (SEQ ID NO:245);
AGGCAGCTGT (SEQ ID NO:246); GGCAGCTGTA (SEQ ID NO:247);
GCAGCTGTAG (SEQ ID NO:248); CAGCTGTAGA (SEQ ID NO:249);
AGCTGTAGAT (SEQ ID NO:250); GCTGTAGATC (SEQ ID NO:251);
CTGTAGATCT (SEQ ID NO:252); TGTAGATCTT (SEQ ID NO:253);
GTAGATCTTA (SEQ ID NO:254); TAGATCTTAG (SEQ ID NO:255);
AGATCTTAGC (SEQ ID NO:256); GATCTTAGCC (SEQ ID NO:257);
ATCTTAGCCA (SEQ ID NO:258); TCTTAGCCAC (SEQ ID NO:259);
CTTAGCCACT (SEQ ID NO:260); TTAGCCACTT (SEQ ID NO:261);
TAGCCACTTT (SEQ ID NO:262); AGCCACTTTT (SEQ ID NO:263);
GCCACTTTTT (SEQ ID NO:264); CCACTTTTTA (SEQ ID NO:265);
CACTTTTTAA (SEQ ID NO:266); ACTTTTTAAA (SEQ ID NO:267);
CTTTTTAAAA (SEQ ID NO:268); TTTTTAAAAG (SEQ ID NO:269);
TTTTAAAAGA (SEQ ID NO:270); TTTAAAAGAA (SEQ ID NO:271);
TTAAAAGAAA (SEQ ID NO:272); TAAAAGAAAA (SEQ ID NO:273);
AAAAGAAAAG (SEQ ID NO:274); AAAGAAAAGG (SEQ ID NO:275);
AAGAAAAGGG (SEQ ID NO:276); AGAAAAGGGG (SEQ ID NO:277);
GAAAAGGGGG (SEQ ID NO:278); AAAAGGGGGG (SEQ ID NO:279);
AAAGGGGGGA (SEQ ID NO:280); AAGGGGGGAC (SEQ ID NO:281);
AGGGGGGACT (SEQ ID NO:282); GGGGGGACTG (SEQ ID NO:283);
GGGGGACTGG (SEQ ID NO:284); GGGGACTGGA (SEQ ID NO:285);
GGGACTGGAA (SEQ ID NO:286); GGACTGGAAG (SEQ ID NO:287);
GACTGGAAGG (SEQ ID NO:288); ACTGGAAGGG (SEQ ID NO:289);
CTGGAAGGGC (SEQ ID NO:290); TGGAAGGGCT (SEQ ID NO:291);
GGAAGGGCTA (SEQ ID NO:292); GAAGGGCTAA (SEQ ID NO:293);
AAGGGCTAAT (SEQ ID NO:294); AGGGCTAATT (SEQ ID NO:295);
GGGCTAATTC (SEQ ID NO:296); GGCTAATTCA (SEQ ID NO:297);
GCTAATTCAC (SEQ ID NO:298); CTAATTCACT (SEQ ID NO:299);
TAATTCACTC (SEQ ID NO:300); AATTCACTCC (SEQ ID NO:301);
ATTCACTCCC (SEQ ID NO:302); TTCACTCCCA (SEQ ID NO:303);
TCACTCCCAA (SEQ ID NO:304); CACTCCCAAA (SEQ ID NO:305);
ACTCCCAAAG (SEQ ID NO:306); CTCCCAAAGA (SEQ ID NO:307);
TCCCAAAGAA (SEQ ID NO:308); CCCAAAGAAG (SEQ ID NO:309);

CCAAAGAAGA (SEQ ID NO:310); CAAAGAAGAC (SEQ ID NO:311);
AAAGAAGACA (SEQ ID NO:312); AAGAAGACAA (SEQ ID NO:313);
AGAAGACAAG (SEQ ID NO:314); GAAGACAAGA (SEQ ID NO:315);
AAGACAAGAT (SEQ ID NO:316); AGACAAGATA (SEQ ID NO:317);
GACAAGATAT (SEQ ID NO:318); ACAAGATATC (SEQ ID NO:319);
CAAGATATCC (SEQ ID NO:320); AAGATATCCT (SEQ ID NO:321);
AGATATCCTT (SEQ ID NO:322); GATATCCTTG (SEQ ID NO:323);
ATATCCTTGA (SEQ ID NO:324); TATCCTTGAT (SEQ ID NO:325);
ATCCTTGATC (SEQ ID NO:326); TCCTTGATCT (SEQ ID NO:327);
CCTTGATCTG (SEQ ID NO:328); CTTGATCTGT (SEQ ID NO:329);
TTGATCTGTG (SEQ ID NO:330); TGATCTGTGG (SEQ ID NO:331);
GATCTGTGGA (SEQ ID NO:332); ATCTGTGGAT (SEQ ID NO:333);
TCTGTGGATC (SEQ ID NO:334); CTGTGGATCT (SEQ ID NO:335);
TGTGGATCTA (SEQ ID NO:336); GTGGATCTAC (SEQ ID NO:337);
TGGATCTACC (SEQ ID NO:338); GGATCTACCA (SEQ ID NO:339);
GATCTACCAC (SEQ ID NO:340); ATCTACCACA (SEQ ID NO:341);
TCTACCACAC (SEQ ID NO:342); CTACCACACA (SEQ ID NO:343);
TACCACACAC (SEQ ID NO:344); ACCACACACA (SEQ ID NO:345);
CCACACACAA (SEQ ID NO:346); CACACACAAG (SEQ ID NO:347);
ACACACAAGG (SEQ ID NO:348); CACACAAGGC (SEQ ID NO:349);
ACACAAGGCT (SEQ ID NO:350); CACAAGGCTA (SEQ ID NO:351);
ACAAGGCTAC (SEQ ID NO:352); CAAGGCTACT (SEQ ID NO:353);
AAGGCTACTT (SEQ ID NO:354); AGGCTACTTC (SEQ ID NO:355);
GGCTACTTCC (SEQ ID NO:356); GCTACTTCCC (SEQ ID NO:357);
CTACTTCCCT (SEQ ID NO:358); TACTTCCCTG (SEQ ID NO:359);
ACTTCCCTGA (SEQ ID NO:360); CTTCCCTGAT (SEQ ID NO:361);
TTCCCTGATT (SEQ ID NO:362); TCCCTGATTG (SEQ ID NO:363);
CCCTGATTGG (SEQ ID NO:364); CCTGATTGGC (SEQ ID NO:365);
CTGATTGGCA (SEQ ID NO:366); TGATTGGCAG (SEQ ID NO:367);
GATTGGCAGA (SEQ ID NO:368); ATTGGCAGAA (SEQ ID NO:369);
TTGGCAGAAC (SEQ ID NO:370); TGGCAGAACT (SEQ ID NO:371);
GGCAGAACTA (SEQ ID NO:372); GCAGAACTAC (SEQ ID NO:373);
CAGAACTACA (SEQ ID NO:374); AGAACTACAC (SEQ ID NO:375);
GAACTACACA (SEQ ID NO:376); AACTACACAC (SEQ ID NO:377);
ACTACACACC (SEQ ID NO:378); CTACACACCA (SEQ ID NO:379);
TACACACCAG (SEQ ID NO:380); ACACACCAGG (SEQ ID NO:381);
CACACCAGGG (SEQ ID NO:382); ACACCAGGGC (SEQ ID NO:383);
CACCAGGGCC (SEQ ID NO:384); ACCAGGGCCA (SEQ ID NO:385);

CCAGGGCCAG (SEQ ID NO:386); CAGGGCCAGG (SEQ ID NO:387);
AGGGCCAGGG (SEQ ID NO:388); GGGCCAGGGG (SEQ ID NO:389);
GGCCAGGGGT (SEQ ID NO:390); GCCAGGGGTC (SEQ ID NO:391);
CCAGGGGTCA (SEQ ID NO:392); CAGGGGTCAG (SEQ ID NO:393);
AGGGGTCAGA (SEQ ID NO:394); GGGGTCAGAT (SEQ ID NO:395);
GGGTCAGATA (SEQ ID NO:396); GGTCAGATAT (SEQ ID NO:397);
GTCAGATATC (SEQ ID NO:398); TCAGATATCC (SEQ ID NO:399);
CAGATATCCA (SEQ ID NO:400); AGATATCCAC (SEQ ID NO:401);
GATATCCACT (SEQ ID NO:402); ATATCCACTG (SEQ ID NO:403);
TATCCACTGA (SEQ ID NO:404); ATCCACTGAC (SEQ ID NO:405);
TCCACTGACC (SEQ ID NO:406); CCACTGACCT (SEQ ID NO:407);
CACTGACCTT (SEQ ID NO:408); ACTGACCTTT (SEQ ID NO:409);
CTGACCTTTG (SEQ ID NO:410); TGACCTTTGG (SEQ ID NO:411);
GACCTTTGGA (SEQ ID NO:412); ACCTTTGGAT (SEQ ID NO:413);
CCTTTGGATG (SEQ ID NO:414); CTTTGGATGG (SEQ ID NO:415);
TTTGGATGGT (SEQ ID NO:416); TTGGATGGTG (SEQ ID NO:417);
TGGATGGTGC (SEQ ID NO:418); GGATGGTGCT (SEQ ID NO:419);
GATGGTGCTA (SEQ ID NO:420); ATGGTGCTAC (SEQ ID NO:421);
TGGTGCTACA (SEQ ID NO:422); GGTGCTACAA (SEQ ID NO:423);
GTGCTACAAG (SEQ ID NO:424); TGCTACAAGC (SEQ ID NO:425);
GCTACAAGCT (SEQ ID NO:426); CTACAAGCTA (SEQ ID NO:427);
TACAAGCTAG (SEQ ID NO:428); ACAAGCTAGT (SEQ ID NO:429);
CAAGCTAGTA (SEQ ID NO:430); AAGCTAGTAC (SEQ ID NO:431);
AGCTAGTACC (SEQ ID NO:432); GCTAGTACCA (SEQ ID NO:433);
CTAGTACCAG (SEQ ID NO:434); TAGTACCAGT (SEQ ID NO:435);
AGTACCAGTT (SEQ ID NO:436); GTACCAGTTG (SEQ ID NO:437);
TACCAGTTGA (SEQ ID NO:438); ACCAGTTGAG (SEQ ID NO:439);
CCAGTTGAGC (SEQ ID NO:440); CAGTTGAGCC (SEQ ID NO:441);
AGTTGAGCCA (SEQ ID NO:442); GTTGAGCCAG (SEQ ID NO:443);
TTGAGCCAGA (SEQ ID NO:444); TGAGCCAGAT (SEQ ID NO:445);
GAGCCAGATA (SEQ ID NO:446); AGCCAGATAA (SEQ ID NO:447);
GCCAGATAAG (SEQ ID NO:448); CCAGATAAGG (SEQ ID NO:449);
CAGATAAGGT (SEQ ID NO:450); AGATAAGGTA (SEQ ID NO:451);
GATAAGGTAG (SEQ ID NO:452); ATAAGGTAGA (SEQ ID NO:453);
TAAGGTAGAA (SEQ ID NO:454); AAGGTAGAAG (SEQ ID NO:455);
AGGTAGAAGA (SEQ ID NO:456); GGTAGAAGAG (SEQ ID NO:457);
GTAGAAGAGG (SEQ ID NO:458); TAGAAGAGGC (SEQ ID NO:459);
AGAAGAGGCC (SEQ ID NO:460); GAAGAGGCCA (SEQ ID NO:461);

AAGAGGCCAA (SEQ ID NO:462); AGAGGCCAAT (SEQ ID NO:463);
GAGGCCAATA (SEQ ID NO:464); AGGCCAATAA (SEQ ID NO:465);
GGCCAATAAA (SEQ ID NO:466); GCCAATAAAG (SEQ ID NO:467);
CCAATAAAGG (SEQ ID NO:468); CAATAAAGGA (SEQ ID NO:469);
AATAAAGGAG (SEQ ID NO:470); ATAAAGGAGA (SEQ ID NO:471);
TAAAGGAGAG (SEQ ID NO:472); AAAGGAGAGA (SEQ ID NO:473);
AAGGAGAGAA (SEQ ID NO:474); AGGAGAGAAC (SEQ ID NO:475);
GGAGAGAACA (SEQ ID NO:476); GAGAGAACAC (SEQ ID NO:477);
AGAGAACACC (SEQ ID NO:478); GAGAACACCA (SEQ ID NO:479);
AGAACACCAG (SEQ ID NO:480); GAACACCAGC (SEQ ID NO:481);
AACACCAGCT (SEQ ID NO:482); ACACCAGCTT (SEQ ID NO:483);
CACCAGCTTG (SEQ ID NO:484); ACCAGCTTGT (SEQ ID NO:485);
CCAGCTTGTT (SEQ ID NO:486); CAGCTTGTTA (SEQ ID NO:487);
AGCTTGTTAC (SEQ ID NO:488); GCTTGTTACA (SEQ ID NO:489);
CTTGTTACAC (SEQ ID NO:490); TTGTTACACC (SEQ ID NO:491);
TGTTACACCC (SEQ ID NO:492); GTTACACCCT (SEQ ID NO:493);
TTACACCCTG (SEQ ID NO:494); TACACCCTGT (SEQ ID NO:495);
ACACCCTGTG (SEQ ID NO:496); CACCCTGTGA (SEQ ID NO:497);
ACCCTGTGAG (SEQ ID NO:498); CCCTGTGAGC (SEQ ID NO:499);
CCTGTGAGCC (SEQ ID NO:500); CTGTGAGCCT (SEQ ID NO:501);
TGTGAGCCTG (SEQ ID NO:502); GTGAGCCTGC (SEQ ID NO:503);
TGAGCCTGCA (SEQ ID NO:504); GAGCCTGCAT (SEQ ID NO:505);
AGCCTGCATG (SEQ ID NO:506); GCCTGCATGG (SEQ ID NO:507);
CCTGCATGGA (SEQ ID NO:508); CTGCATGGAA (SEQ ID NO:509);
TGCATGGAAT (SEQ ID NO:510); GCATGGAATG (SEQ ID NO:511);
CATGGAATGG (SEQ ID NO:512); ATGGAATGGA (SEQ ID NO:513);
TGGAATGGAT (SEQ ID NO:514); GGAATGGATG (SEQ ID NO:515);
GAATGGATGA (SEQ ID NO:516); AATGGATGAC (SEQ ID NO:517);
ATGGATGACC (SEQ ID NO:518); TGGATGACCC (SEQ ID NO:519);
GGATGACCCT (SEQ ID NO:520); GATGACCCTG (SEQ ID NO:521);
ATGACCCTGA (SEQ ID NO:522); TGACCCTGAG (SEQ ID NO:523);
GACCCTGAGA (SEQ ID NO:524); ACCCTGAGAG (SEQ ID NO:525);
CCCTGAGAGA (SEQ ID NO:526); CCTGAGAGAG (SEQ ID NO:527);
CTGAGAGAGA (SEQ ID NO:528); TGAGAGAGAA (SEQ ID NO:529);
GAGAGAGAAG (SEQ ID NO:530); AGAGAGAAGT (SEQ ID NO:531);
GAGAGAAGTG (SEQ ID NO:532); AGAGAAGTGT (SEQ ID NO:533);
GAGAAGTGTT (SEQ ID NO:534); AGAAGTGTTA (SEQ ID NO:535);
GAAGTGTTAG (SEQ ID NO:536); AAGTGTTAGA (SEQ ID NO:537);

AGTGTTAGAG (SEQ ID NO:538); GTGTTAGAGT (SEQ ID NO:539);
TGTTAGAGTG (SEQ ID NO:540); GTTAGAGTGG (SEQ ID NO:541);
TTAGAGTGGA (SEQ ID NO:542); TAGAGTGGAG (SEQ ID NO:543);
AGAGTGGAGG (SEQ ID NO:544); GAGTGGAGGT (SEQ ID NO:545);
AGTGGAGGTT (SEQ ID NO:546); GTGGAGGTTT (SEQ ID NO:547);
TGGAGGTTTG (SEQ ID NO:548); GGAGGTTTGA (SEQ ID NO:549);
GAGGTTTGAC (SEQ ID NO:550); AGGTTTGACA (SEQ ID NO:551);
GGTTTGACAG (SEQ ID NO:552); GTTTGACAGC (SEQ ID NO:553);
TTTGACAGCC (SEQ ID NO:554); TTGACAGCCG (SEQ ID NO:555);
TGACAGCCGC (SEQ ID NO:556); GACAGCCGCC (SEQ ID NO:557);
ACAGCCGCCT (SEQ ID NO:558); CAGCCGCCTA (SEQ ID NO:559);
AGCCGCCTAG (SEQ ID NO:560); GCCGCCTAGC (SEQ ID NO:561);
CCGCCTAGCA (SEQ ID NO:562); CGCCTAGCAT (SEQ ID NO:563);
GCCTAGCATT (SEQ ID NO:564); CCTAGCATTT (SEQ ID NO:565);
CTAGCATTTC (SEQ ID NO:566); TAGCATTTCA (SEQ ID NO:567);
AGCATTTCAT (SEQ ID NO:568); GCATTTCATC (SEQ ID NO:569);
CATTTCATCA (SEQ ID NO:570); ATTTCATCAC (SEQ ID NO:571);
TTTCATCACG (SEQ ID NO:572); TTCATCACGT (SEQ ID NO:573);
TCATCACGTG (SEQ ID NO:574); CATCACGTGG (SEQ ID NO:575);
ATCACGTGGC (SEQ ID NO:576); TCACGTGGCC (SEQ ID NO:577);
CACGTGGCCC (SEQ ID NO:578); ACGTGGCCCG (SEQ ID NO:579);
CGTGGCCCGA (SEQ ID NO:580); GTGGCCCGAG (SEQ ID NO:581);
TGGCCCGAGA (SEQ ID NO:582); GGCCCGAGAG (SEQ ID NO:583);
GCCCGAGAGC (SEQ ID NO:584); CCCGAGAGCT (SEQ ID NO:585);
CCGAGAGCTG (SEQ ID NO:586); CGAGAGCTGC (SEQ ID NO:587);
GAGAGCTGCA (SEQ ID NO:588); AGAGCTGCAT (SEQ ID NO:589);
GAGCTGCATC (SEQ ID NO:590); AGCTGCATCC (SEQ ID NO:591);
GCTGCATCCG (SEQ ID NO:592); CTGCATCCGG (SEQ ID NO:593);
TGCATCCGGA (SEQ ID NO:594); GCATCCGGAG (SEQ ID NO:595);
CATCCGGAGT (SEQ ID NO:596); ATCCGGAGTA (SEQ ID NO:597);
TCCGGAGTAC (SEQ ID NO:598); CCGGAGTACT (SEQ ID NO:599);
CGGAGTACTT (SEQ ID NO:600); GGAGTACTTC (SEQ ID NO:601);
GAGTACTTCA (SEQ ID NO:602); AGTACTTCAA (SEQ ID NO:603);
GTACTTCAAG (SEQ ID NO:604); TACTTCAAGA (SEQ ID NO:605);
ACTTCAAGAA (SEQ ID NO:606); CTTCAAGAAC (SEQ ID NO:607);
TTCAAGAACT (SEQ ID NO:608); TCAAGAACTG (SEQ ID NO:609);
CAAGAACTGC (SEQ ID NO:610); AAGAACTGCT (SEQ ID NO:611);
AGAACTGCTG (SEQ ID NO:612); GAACTGCTGA (SEQ ID NO:613).

92. A method according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3:

GCTTTTTGCC (SEQ ID NO:652); CTTTTTGCCT (SEQ ID NO:653);
TTTTTGCCTG (SEQ ID NO:654); TTTTGCCTGT (SEQ ID NO:655);
TTTGCCTGTA (SEQ ID NO:656); TTGCCTGTAC (SEQ ID NO:657);
TGCCTGTACT (SEQ ID NO:658); GCCTGTACTG (SEQ ID NO:659);
CCTGTACTGG (SEQ ID NO:660); CTGTACTGGG (SEQ ID NO:661);
TGTACTGGGT (SEQ ID NO:662); GTACTGGGTC (SEQ ID NO:663);
TACTGGGTCT (SEQ ID NO:664); ACTGGGTCTC (SEQ ID NO:665);
CTGGGTCTCT (SEQ ID NO:666); TGGGTCTCTC (SEQ ID NO:667);
GGGTCTCTCT (SEQ ID NO:668); GGTCTCTCTG (SEQ ID NO:669);
GTCTCTCTGG (SEQ ID NO:670); TCTCTCTGGT (SEQ ID NO:671);
CTCTCTGGTT (SEQ ID NO:672); TCTCTGGTTA (SEQ ID NO:673);
CTCTGGTTAG (SEQ ID NO:674); TCTCTGGTTA (SEQ ID NO:675);
CTGGTTAGAC (SEQ ID NO:676); TGGTTAGACC (SEQ ID NO:677);
GGTTAGACCA (SEQ ID NO:678); GTTAGACCAG (SEQ ID NO:679);
TTAGACCAGA (SEQ ID NO:680); TAGACCAGAT (SEQ ID NO:681);
AGACCAGATC (SEQ ID NO:682); GACCAGATCT (SEQ ID NO:683);
ACCAGATCTG (SEQ ID NO:684); CCAGATCTGA (SEQ ID NO:685);
CAGATCTGAG (SEQ ID NO:686); AGATCTGAGC (SEQ ID NO:687);
GATCTGAGCC (SEQ ID NO:688); ATCTGAGCCT (SEQ ID NO:689);
TCTGAGCCTG (SEQ ID NO:690); CTGAGCCTGG (SEQ ID NO:691);
TGAGCCTGGG (SEQ ID NO:692); GAGCCTGGGA (SEQ ID NO:693);
AGCCTGGGAG (SEQ ID NO:694); GCCTGGGAGC (SEQ ID NO:695);
CCTGGGAGCT (SEQ ID NO:696); CTGGGAGCTC (SEQ ID NO:697);
TGGGAGCTCT (SEQ ID NO:698); GGGAGCTCTC (SEQ ID NO:699);
GGAGCTCTCT (SEQ ID NO:700); GAGCTCTCTG (SEQ ID NO:701);
AGCTCTCTGG (SEQ ID NO:702); GCTCTCTGGC (SEQ ID NO:703);
CTCTCTGGCT (SEQ ID NO:704); TCTCTGGCTA (SEQ ID NO:705);
CTCTGGCTAA (SEQ ID NO:706); TCTGGCTAAC (SEQ ID NO:707);
CTGGCTAACT (SEQ ID NO:708); TGGCTAACTA (SEQ ID NO:709);
GGCTAACTAG (SEQ ID NO:710); GCTAACTAGG (SEQ ID NO:711);
CTAACTAGGG (SEQ ID NO:712); TAACTAGGGA (SEQ ID NO:713);
AACTAGGGAA (SEQ ID NO:714); ACTAGGGAAC (SEQ ID NO:715);
CTAGGGAACC (SEQ ID NO:716); TAGGGAACCC (SEQ ID NO:717);
AGGGAACCCA (SEQ ID NO:718); GGGAACCCAC (SEQ ID NO:719);

BNSDOCID: <WO___9521912A1_I_>

GGAACCCACT (SEQ ID NO:720); GAACCCACTG (SEQ ID NO:721);
AACCCACTGC (SEQ ID NO:722); ACCCACTGCT (SEQ ID NO:723);
CCCACTGCTT (SEQ ID NO:724); CCACTGCTTA (SEQ ID NO:725);
CACTGCTTAA (SEQ ID NO:726); ACTGCTTAAG (SEQ ID NO:727);
CTGCTTAAGC (SEQ ID NO:728); TGCTTAAGCC (SEQ ID NO:729);
GCTTAAGCCT (SEQ ID NO:730); CTTAAGCCTC (SEQ ID NO:731);
TTAAGCCTCA (SEQ ID NO:732); TAAGCCTCAA (SEQ ID NO:733);
AAGCCTCAAT (SEQ ID NO:734); AGCCTCAATA (SEQ ID NO:735);
GCCTCAATAA (SEQ ID NO:736); CCTCAATAAA (SEQ ID NO:737);
CTCAATAAAG (SEQ ID NO:738); TCAATAAAGC (SEQ ID NO:739);
CAATAAAGCT (SEQ ID NO:740); AATAAAGCTT (SEQ ID NO:741);
ATAAAGCTTG (SEQ ID NO:742); TAAAGCTTGC (SEQ ID NO:743);
AAAGCTTGCC (SEQ ID NO:744); AAGCTTGCCT (SEQ ID NO:745);
AGCTTGCCTT (SEQ ID NO:746); GCTTGCCTTG (SEQ ID NO:747);
CTTGCCTTGA (SEQ ID NO:748); TTGCCTTGAG (SEQ ID NO:749);
TGCCTTGAGT (SEQ ID NO:750); GCCTTGAGTG (SEQ ID NO:751);
CCTTGAGTGC (SEQ ID NO:752); CTTGAGTGCT (SEQ ID NO:753);
TTGAGTGCTT (SEQ ID NO:754); TGAGTGCTTC (SEQ ID NO:755);
GAGTGCTTCA (SEQ ID NO:756); AGTGCTTCAA (SEQ ID NO:757);
GTGCTTCAAG (SEQ ID NO:758); TGCTTCAAGT (SEQ ID NO:759);
GCTTCAAGTA (SEQ ID NO:760); CTTCAAGTAG (SEQ ID NO:761);
TTCAAGTAGT (SEQ ID NO:762); TCAAGTAGTG (SEQ ID NO:763);
CAAGTAGTGT (SEQ ID NO:764); AAGTAGTGTG (SEQ ID NO:765);
AGTAGTGTGT (SEQ ID NO:766); GTAGTGTGTG (SEQ ID NO:767);
TAGTGTGTGC (SEQ ID NO:768); AGTGTGTGCC (SEQ ID NO:769);
GTGTGTGCCC (SEQ ID NO:770); TGTGTGCCCG (SEQ ID NO:771);
GTGTGCCCGT (SEQ ID NO:772); TGTGCCCGTC (SEQ ID NO:773);
GTGCCCGTCT (SEQ ID NO:774); TGCCCGTCTG (SEQ ID NO:775);
GCCCGTCTGT (SEQ ID NO:776); CCCGTCTGTT (SEQ ID NO:777);
CCGTCTGTTG (SEQ ID NO:778); CGTCTGTTGT (SEQ ID NO:779);
GTCTGTTGTG (SEQ ID NO:780); TCTGTTGTGT (SEQ ID NO:781);
CTGTTGTGTG (SEQ ID NO:782); TGTTGTGTGA (SEQ ID NO:783);
GTTGTGTGAC (SEQ ID NO:784); TTGTGTGACT (SEQ ID NO:785);
TGTGTGACTC (SEQ ID NO:786); GTGTGACTCT (SEQ ID NO:787);
TGTGTGACTC (SEQ ID NO:788); GTGTGACTCT (SEQ ID NO:789);
TGTGACTCTG (SEQ ID NO:790); GTGACTCTGG (SEQ ID NO:791);

TGACTCTGGT (SEQ ID NO:792); GACTCTGGTA (SEQ ID NO:793);
ACTCTGGTAA (SEQ ID NO:794); CTCTGGTAAC (SEQ ID NO:795);
TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797);
TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799).

1/47

FIGURE 1


2/47
3/47
4/47
5/47
6/47
7/47
8/47
9/47
10/47
11/47
12/47
13/47
14/47
15/47
16/47
17/47
18/47
19/47

BNSDOCID: <WO___9521912A1_I>

FIGURE 1

```
          8072
NL43      GAACAGATTTGGAATAACATGACCTGGATGGAGTGGGACAGAGAAATTAA  8121
          *** ******** * *************** ******* * ******* *
D36P      GAAGAGATTTGGGAGAACATGACCTGGATGCAGTGGGAAAAAGAAATTCA
          ***   ****** ****************** ******* ********* *
C18S      GAAACAATTTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGA
          ***   ****** ****************** ******* ********* *
C18M      GAAACAATTTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGA
                                                  ********
C98H                                              GAAATTAA


NL43      CAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGC  8171
          **** ******  *  *** ******** ***** ******* ***** *
D36P      CAATCACACAAAATACATATACTCCTTACTTGAAAAATCGCAGAACCAAC
          ********** * ***** ** ******************** ***** *
C18S      CAATTACACAAACATAATATACACCTTAATTGAAGAATCGCAGAACCAAC
          **********   ***** ** ******************** ***** *
C18M      CAATTACACAAACATAATATACACCTTAATTGAAGAATCGCAGAACCAAC
          ********** ****** **  ******************** ***** *
C98H      CAATTACACAAGATTAATATACAACTTAATTGAAGAATCGCAGAACCAAC
```

SUBSTITUTE SHEET (Rule 26)

FIGURE 1

```
NL43    AAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTG  8221
        ********************* ********** *** ************
D36P    AAGAAAAGAATGAACAAGAACTATTGGAATTGGATCAATGGGCAAGTTTG
        ******* ******* **************** ************* ****
C18S    AAGAAAAAAATGAACTAGAATTATTGGAATTGGATAAATGGGCAAATTTG
        ******* ******* **************** ************* ****
C18M    AAGAAAAAAATGAACTAGAATTATTGGAATTGGATAAATGGGCAAATTTG
        ******************** ******************************
C98H    AAGAAAAGAATGAACAAGACTTATTGGAATTAGATAAATGGGCAAGTTTG


NL43    TGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCAT  8271
        ************ ********** ******************** *******
D36P    TGGAATTGGTTTGACATAACAAAATGGCTGTGGTATATAAAATATTCAT
        *************  *** **** ***** **********************
C18S    TGGAATTGGTTTAGTATATCAAACTGGCTATGGTATATAAAATTATTCAT
        *************** *** **** ***** **********************
C18M    TGGAATTGGTTTAGTATATCAAACTGGCTATGGTATATAAAATTATTCAT
        ************ ********* ******************************
C98H    TGGAATTGGTTTGACATAACAAGTGGGCTGTGGTATATAAAATTATTCAT
```

BNSDOCID: <WO___9521912A1_I_>

SUBSTITUTE SHEET (Rule 26)

FIGURE 1

```
NL43    AATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTT  8321
        **** ************** ****************************
D36P    AATGGTAGTAGGAGGCTTGATAGGTTTAAGAATAGTTTTTGCTGTACTTT
        **** ********************************** *********
C18S    AATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTACTGTACTTT
        **** ********************************** *********
C18M    AATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTACTGTACTTT
        ************************************** **********
C98H    AATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTAGCTGTACTTT

                          SA8  SA9                    SA10

NL43    CTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACC  8371
        ***************************** ******** ************
D36P    CTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCGTTTCAGACC
        ******* ********************* ***********************
C18S    CTATAGTTAATAGAGTTAGGCAGGGATACTCACCATTATCGTTTCAGACC
        ******* ********************* ***********************
C18M    CTATAGTTAATAGAGTTAGGCAGGGATACTCACCATTATCGTTTCAGACC
        ***************************** ***********************
C98H    CTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTATCGTTTCAGACC
```

FIGURE 1

Tat termination NL43

```
NL43    CACCTCCCAATCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGA  8421
        * ******** ********************************** ********
D36P    CTCCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA
        ********** ***** ***************** ******** ********
C18S    CACCTCCCAACCCCGAAGGGACCCGACAGGCCAGAAGGAATCGAAGAAGA
        *********  ********************** ******** ********
C18M    CACCTCCCAACCCCGAGGGGACCCGACAGGCCAGAAGGAATCGAAGAAGA
        ********** ********************************** ********
C98H    CACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGA
```

```
NL43    AGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCT  8471
        **************************** *********  ****** **
D36P    AGGTGGAGAGAGAGACAGAGACAGATCCACTCGATTAGTACACGGATTCT
        ********************* *** **** ********** ****** **
C18S    AGGTGGAGAGAGAGACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCT
        ************** ***** *** **** ********** ****** **
C18M    AGGTGGAGAGAGAGGCAGAGGCAGCTCCACTCGATTAGTGCACGGATTCT
        **************************** ********** ****** **
C98H    AGGTGGAGAGAGAGACAGAGACAGATCCAGTCGATTAGTGCACGGATTCT
```

D36P, C18S,C18M & C98H Tat termination

BNSDOCID: <WO___9521912A1_I_>

SUBSTITUTE SHEET (RULE 26)

FIGURE 1

```
NL43    TAGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCAC  8521
        ******** ********** *** ******************  *******
D36P    TAGCACTTTTCTGGGACGACCTGAGGAGCCTGTGCCTCTTCCTCTACCAC
        ******** ********** *** **** **********************
C18S    TAGCACTTTTCTGGGACGACCTGAGGAGTCTGTGCCTCTTCAGCTACCAC
        ******** ****** *** *** **** **********************
C18M    TAGCACTTTTCTGGGTCGACCTGAGGAGTCTGTGCCTCTTCAGCTACCAC
        ******** ****** *** *** ****************************
C98H    TAGCACTTTTCTGGGTCGACCTGAGGAGCCTGTGCCTCTTCAGCTACCAC


NL43    CGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGG  8571
        * ************************** **********************
D36P    CACTTGAGAGACTTACTCTTGATTGTAACAAGGATTGTGGAACTTCTGGG
        * ****************************************************
C18S    CACTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGG
        ****************************************************
C18M    CGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGG
        ****************************************************
C98H    CGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGG
```

FIGURE 1

```
NL43    ACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGTATT  8621
        ********* ************************** ****** ******
D36P    ACGCAGGGGATGGGAAGCCCTCAAATATTGGTGGAACCTCCTAAAGTATT
        ********* ****************** ************** *******
C18S    ACGCAGGGGATGGGAAGCCCTCAAATACTGGTGGAATCTCCTGCAGTATT
        **** **** ****************** ************** *******
C18M    ACGCGGGGGATGGGAAGCCCTCAAATACTGGTGGAATCTCCTGCAGTATT
        ************************************************ ****
C98H    ACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAATATT
```

NL43 Rev termination

```
NL43    GGAGTCAGGAACTAAAGAATAGTGCTGTTAACTTGCTCAATGCCACAGCC  8671
        **** ********  **** ********** **************** ***
D36P    GGAGCCAGGAACTGCAGAAGAGTGCTGTTATCTTGCTCAATGCCACCGCC
        **** ********* **** ********** **** ****** *** ***
C18S    GGAGGCAGGAACTACAGAAGAGTGCTGTTAGCTTGTTCAATGGCACGGCC
        **** ********* **** ***** **** **** **************
C18M    GGAGACAGGAACTACAGAAGAGTGCAGTTAGCTTGTTCAATGCCATAGCC
        ************* ***** ****** *** **** ********** ***
C98H    GGAGTCAGGAACTCAAGAAGAGTGCTATTAGCTTGTTCAATGCCACCGCC
```

C18S, C18M & C98H Rev termination

BNSDOCID: <WO__9521912A1_I_>

FIGURE 1

```
NL43    ATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTATTACAAGCAGC  8721
        ************************** *** ************** ***
D36P    ATAGCAGTAGCTGAGGGGACAGATAGAGTTTTAGAAGTATTACAAAGAGC
        ************************** ********** **** *  **
C18S    ATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGCTTTACGAAGGGC
        ************************** * ******** *******  ***
C18M    ATAGCAGTAGCTGAGGGGACAGATAGAGCTATAGAAGGATTACAAAGAGC
        ************************** ******************  ***
C98H    ATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGTATTACAAAGAGC
                  D36P Rev termination
```

```
NL43    TTATAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAA  8771
        ************ * ***************************** * ****
D36P    TTATAGAGCTATCCTCCACATACCTAGAAGAATAAGACAGGGCCTCGAAA
        ************** ******************************** ****
C18S    TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAA
        ************** ******************************** ****
C18M    TTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAA
        ** ******* *** ******************************** ****
C98H    TTGTAGAGCTGTTCTCCACATACCTAGAAGAATAAGACAGGGCTTCGAAA
```

FIGURE 1


Env termination
Nef start
NL43
GGATTTTGCTATAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGG 8821
D36P
TGGCTTTGCTATAAAATGGGTGGCAAGTGAGCAAAAAGTAGTGTAGTCAG
C18S
GGGCTTTGCTATAAAATGGGTGGCAAGTGGTCAGAAAGTAGTGTGGTTAG
C18M
GGGCTTTGCTGTAAAATGGG----------
C98H
GGGCTATGCTATAAAATGGGTGGCAAGTGGTTAAAAAGTAGTATGGTTAG
D36P Nef termination
nef duplication region
NL43
ATGGCCTGCTGTAAGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATG 8871
D36P
ATAGCATG----------CATCATAAG
C18S
AAGGCATG----------
C18M

C98H
ATGGCCTGCTGTAAGGGAAAAAATGAAACAAGCTGAGCCAGCAGCAGAAG

BNSDOCID: <WO__9521912A1_I_>

FIGURE 1

```
NL43    GGGTGGGAGCAGTATCTCGAGACCTAGAAAAACATGGAGCAATCACAAGT  8921
        ******* **
D36P    GGGTGGGGGC----------------------------------------
C18S    ----------------------------------------------------
C18M    ----------------------------------------------------
        ********** ********** ********** *****
C98H    GGGTGGGAGCAATATCTCGAGACCTAGGAAAACATGGAGCAATCCCAAGT
```

$SIV_{mac}239$ IPTC

```
NL43    AGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAAGCACAAGA  8971
          ** ** ********** * **********
D36P    -------CAACAACTAACAATGCTGATCGTGCCTGGCTAGAAGCACAAGA
C18S    ----------------------------------------------------
C18M    ----------------------------------------------------
        ********* ** **********  **********
C98H    AGCAATACAACAACTAACAATGCTAATTGTGCCTGGCTAGAAGCACAAGA
```

SUBSTITUTE SHEET (Rule 26)

FIGURE 1

NL43 GGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAA 9021
D36P GAAGGAAGAAGCGGGTTTTCCAGTCAAACCTCAGGTA----------
C18S ----------TACCTTTAAGAC---
C18M ----------
C98H GGAGGAGGAAGTGGGTTTTCCAGTCAAACCTCAGGTACCTTTAAGACCAA
Poly purine tract
NL43 TGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGG 9071
D36P ----------GCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGG
C18S ---------AAGGCAGCTATAGATCTTAGCCGCTTTTTAAAAGAAAAGGGG
C18M ----------GATCTTAGCCACTTTTTAAAAGAAAAGGGG
C98H TGACTTACAAG----------GCCACTTTTTAAAAAGAAAGGGG
C54P AGCCACTTTTTAAAAAGAAAGGGG
C18S & C18F nef termination
C18M and C98H nef Termination

BNSDOCID: <WO___9521912A1_I_>

FIGURE 1



SUBSTITUTE SHEET (Rule 26)

FIGURE 1


[NRE -->
NL43 CAGGGCCAGGGGTCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTA 9221
D36P ----------CACAGTGCTGCAAACTA
C18S ----------
C18M ----------
C98H ----------ATCCACTGACTTTTGG,TGGTGCTTCAAATTA
C54P CAGGGCCAGGGACCAGATATCCACTGACCTTTGGATGGTGCTGCAAACGA
myb
NF-AT
NL43 GTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACAC 9271
D36P TTACCAGTGGAGTCAGCGAAGATAGAAGAGGCCAATGGAGGAGAAAACCA
C18S ---TCAGTTGAACCAGAAGAAGATAGAAGAGGCCATGAAGAAGAAAACAA
C18M ---TCAGTTGAACCAGAAGAAGAATGAAGAGGCCATGAAGAAGAAAACAA
C98H GTACCAGTGGANCCAGA--AGAGAGAAGAGACCAATGGAGGAGAGAACA-
C54P GTGCCAGTGGAAACAGAGAAGATAGAAGAGGCCAATGGAGGAGAAAACAA
(myb)

BNSDOCID: <WO__9521912A1_I_>

FIGURE 1



SUBSTITUTE SHEET (RULE 26)

FIGURE 1

TCF-1α



D36P, C18S, C18M, & C98H extra NFKB

D36P & C98H extra NFKB

SUBSTITUTE SHEET (RULE 26)

BNSDOCID: <WO__9521912A1_I_>

FIGURE 1



SUBSTITUTE SHEET (Rule 26)

FIGURE 1


Sp1
Sp1
TATA box
NL43 CTGGGCGGGACTGGGGAGTGGCGAGCCC,TCAGATGCTGCATATAAGCAG 9510
D36P CTGGGCGGGACTGGGGAGTGGCGAGCCC,TCAGATGCTGCATATAAGCAG
C18S CTGGGCGGGACTGGGGAGTGGCGAGCCC,TCAGATGCTGCATATAAGCAG
C18M CTGGGCGGGACTGGGGAGTGGCGAGCCC,TCAGATGCTGCATATAAGCAG
C98H CTGGGCGGA-CTGGGGAGTGC-GAGCC-,TCAGATGCTGCATATAGGCAG
C54P CTGGGCGGGACTGGGGAGGGGCGAGCCC,TCAGATGCTGCATATAAGCAG
Sp1
Sp1
U3
R
TAR
NL43 CTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG 9560
D36P CTGCTTTCTGCTGTTACTGGGTCTCTCGGGTTAGACCAGATCTGAGCCTG
C18S CTGCTTTCTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG
C18M CTGCTTTCTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG
C98H CTGCTTTCTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG
C54P CTGCTTTCTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTG

BNSDOCID: <WO___9521912A1_I_>

FIGURE 1

```
                                                    Polyadenylation

                 ____________________________________                 ________
NL43     GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCT  9610
         **************************************************
D36P     GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCT
         **************************************************
C18S     GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCT
         **
C18M     GGAGCTCTCTGGCTAGCTAGGGGACCCACTCCTTAAGCCTCAATAAAGCT
         **************************************************
C98H     GGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCT
         *
C54P     G    incomplete


           R       ][      U5
NL43     TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT  9660
         **************************************************
D36P     TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT
         **************************************************
C18S     TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT
         **************************************************
C18M     TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT
         **************************************************
C98H     TGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT
```

SUBSTITUTE SHEET (Rule 26)

FIGURE 1

```
NL43     AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA   9709
         * *****
D36P     ATCTAGA        1305
         * *****
C18S     ATCTAGA        1209
         * ***************************** ********************
C18M     ATCTAGAGATCCCTCAGACCATTTTAGTCCGTGTGGAAAATCTCTAGCA   END
         * *****
C98H     ATCTAGA        1399
```

20/47

FIGURE 2



BNSDOCID: <WO___9521912A1_I_>

FIGURE 2A

NL43	73	PTSQSRGDPTGPKE#	86
D36PBMC		PSSQPRGDPTGPKESKKKVERETETDPLD#	
C18 HIV_{StV}		PTSQPRRDPTGQKESKKKVERETEAAPLD#	
C18 HIV_{MBC}		PTSQPRRDPTGQKESKKKVERETEAAPLD#	
C98 HIV		PTSQPRRDPTGQKESKKKVERETETDPVD#	

FIGURE 2B

NL43	26	DPPPNPEGTRQARRNRRRRWRERQRQIHSISERILSTYLG	65
D36PBMC		DPPPNPEGTRQARRNRRRRWRERQRQIHSISTRILSTFLG	
C18 HIV_{StV}		DPPPNPEGTRQARRNRRRRWRERQRQLHSISARILSTFLG	
C18 HIV_{MBC}		DPPPNPEGTRQARRNRRRRWRERQRQLHSISARILSTFLG	
C98 HIV		DPPPNPEGTRQARRNRRRRWRERQRQIQSISARILSTFLG	

BNSDOCID: <WO__9521912A1_I_>

FIGURE 2B

NL43	RSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVE	105
D36 PBMC	RPEEPVPLPLPPLERLTLDCNKDCGTSGTQGMGSPQILVE	
C18 HIV_{StV}	RPEESVPLQLPPLERLTLDCNEDCGTSGTQGMGSPQILVE	
C18 HIV_{MBC}	RPEESVPLQLPPLERLTLDCNEDCGTSGTQGMGSPQILVE	
C98 HIV	RPEEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVE	

NL43	SPTVLESGTKE#	116
D36PBMC	PPKVLEPGTAEECCYLAQCHRHSSS#	
C18 HIV_{StV}	SPAVLEAGTTEECC#	
C18 HIV_{MBC}	SPAVLEAGTTEECC#	
C98 HIV	SPTILESGTQEECY#	

SUBSTITUTE SHEET (RULE 26)

FIGURE 3



BNSDOCID: <WO___9521912A1_I_>

FIGURE 3

NL43	EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASL	639
D36PBMC	EEIWENMTWMQWEKEIHNHTKYIYSLLEKSQNQQEKNEQELLELDQWASL	
C18 HIV_{StV}	ETIWDNMTWMQWEREIDNYTNIIYTLIEESQNQQEKNELELLELDKWANL	
C18 HIV_{MBC}		
C98 HIV	EINNYTRTIYNLIEESQNQQEKNEQDLLELDKWASL	

NL43	WNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQT	689
D36 PBMC	WNWFDITKWLWYIKIFIMVVGGLIGLRIVFAVLSIVNRVRQGYSPLSFQT	
C18 HIV_{StV}	WNWFSISNWLWYIKLFIMVVGGLVGLRIVFTVLSIVNRVRQGYSPLSFQT	
C18 HIV_{MBC}		
C98 HIV	WNWFDITSGLWYIKLFIMIVGGLVGLRIVLAVLSIVNRVRQGYSPLSFQT	

SUBSTITUTE SHEET (RULE 26)

FIGURE 3

NL43	HLPIPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYH	739
D36 PBMC	LLPTPRGPDRPEGIEEEGGERDRDRSTRLVHGFLALFWDDLRSLCLFLYH	
C18 HIV_{StV}	HLPTPKGPDRPEGIEEEGGERDRGSSTRLVHGFLALFWDDLRSLCLFSYH	
C18 HIV_{MBC}		
C98 HIV	HLPTPRGPDRPEGIEEEGGERDRDRSSRLVHGFLALFWVDLRSLCLFSYH	
NL43	RLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVNLLNATA	789
D36 PBMC	HLRDLLLIVTRIVELLGRRGWEALKYWWNLLKYWSQELQKSAVILLNATA	
C18 HIV_{StV}	HLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWRQELQKSAVSLFNGTA	
C18 HIV_{MBC}		
C98 HIV	RLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKKSAISLFNATA	
NL43	IAVAEGTDRVIEVLQAAYRAIRHIPRRIRQGLERILL#	839
D36 PBMC	IAVAEGTDRVLEVLQRAYRAILHIPRRIRQGLEMALL#	
C18 HIV_{StV}	IAVAEGTDRVIEALRRAYRAILHIPRRIRQGLERALL#	
C18 HIV_{MBC}		
C98 HIV	IAVAEGTDRVIEVLQRACRAVLHIPRRIRQGFERAML#	

SUBSTITUTE SHEET (Rule 26)

BNSDOCID: <WO___9521912A1_I_>

FIGURE 4

```
NL43          MGGKWSKSSVIGWPAVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAA      50
              ****
D36 PBMC      MGGK#                                                    4
              ****** ***
C18.HIV StV   MGGKWSESSVVRRHVPLRQGSYRS#                              24
              *
C18 HIV MBC   MRILATF#                                                 7
              ***** ***   ****** *  ***** **** **** ***** ****
C98 HIV       MGGKWLKSSMVRWPAVREKMKQAEPAAEGVGAISRDLGKHGAIPSSNTTT      50

NL43          NNAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL      100
              *** ***************** ************
C98 HIV       NNANCAWLEAQEEEEVGFPVKPQVPLRPMTYKATF#                    85

NL43          IHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEP      150

NL43          DKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHP      200

NL43          EYFKNC*                                                 206
```

SUBSTITUTE SHEET (Rule 26)

FIGURE 5


NFkB
NFkKB
9419
NL43 CGAGCTTGCTACAAGGGACTTTCC,,,,GCTGGGGACTTTCCAGGGA
D36 PBMC ΔCTGTTGGGGACTTTCCATCCGTTGGGGACTTTCCAAGGC
C18 HIVStV ΔCCGTTTGTTCCGTTGGGGACTTTCCA-GGA
C18 HIVMBC ΔCTGCTTGCTCAGCTGGGGACTTTCCA-GAA
C98 HIV ΔACAGAGTGTGGGGACTCTCCACAACAGAGTGTGGGGACTTTCCAAGGA
C54 PBMC ΔCCGTTGGGGACTTTCCAAGGA
NFkB
NFkB
Sp1
Sp1
Sp1
9492
NL43 GGCGTGGCCTGGGCGGGACTGGGGAGTGGCG-AGCCCTCA
DC36 PBMC GGCGTGGCCTGGGTGACTAGTTCCGGTGGGG-ACTTTCCA
C18 HIVStV GACGTGGCCTGAGTGACTAAG-CCGCTGGGG-ACTTTCCG
C18 HIVMBC GGCGCGGCCTGAGTGACTAAGCCCCGTTGGG-ACTTTCCG
C98 HIV GGCGTGGCCTGAGTGACTAAGTTCCGTTGGGGACTTTCCA
C54 PBMC GGCGTGGCCTGAGTGACTAAGTTCCGTTGGGACTTTCCAA
Sp1
3' half NFkB
NFkB



FIG 6

BNSDOCID: <WO___9521912A1_I_>

FIG 7


Replication of Sydney Asymptomatic
Patient Isolates in non-PHA stimulated PBMCS
PHA activation
228200
C98
C18
Mock
RT Activity (cpm/150µl)
80000
60000
40000
20000
0
0 2 4 6 8 10 12 14 16 18 20 22
Days PI



FIG 8

BNSDOCID: <WO___9521912A1_I_>

31/47

FIGURE 9



FIGURE 9

TGGAAGGGCTAATTCACTCACGGAAAAGACCAGTTGAACCAG
AAGAAGATAGAAGAGGCCATGAAGAAGAAAACAACAGATTGT
TCTGCTTGCTCAGCTGGGGACTTTCCAGAAGGCGCGGCCTGA
GTGACTAAGCCCCGTTGGGGACTTTCCGAAGAGGCATGAAGG
GACTTTCCAAGGCAGGCGTGGCCTGGGCGGGACTGGGGAGTG
GCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGCCT
GTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGC
TCTCTGGCTAGCTAGGGAACCCACTGCTTAAGCCTCAATAAA
GCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGT
GTGACTCTGGTATCTAGAGATCCCTCAGACCATTTTAGTCCG
TGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAA
AGCGAAAGGAAAACCAGAGGAGCTCTCTCGACGCAGGACTCG
GCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACT
GGTGAGTACGCCGAAAATTTTGACTAGCGGAGGCTAGAAGGA
GAGAGATGGGTGCGAGAGCGTCAATATTAAGCGGGGGAAAAT
TAGATAGATGGGAGAAAATTCGGTTAAGGCCAGGAGGAAAGA
AAAAGTATAAATTAAAACATATAGTATGGGCAAGCAGGGAGC
TAGAACGATTCGCAGTCAATCCTGGCCTGTTGGAAACATCAG
AAGGCTGTAGACAAATACTGGGACAGTTACACCCGTCCCTTC
AGACAGGATCAGAAGAACTTAAATCAGTATATAATGCAGTAG
CAGTCCTCTATTGTGTGCATCAAAACATAGACATAAAGGACA
CCAAGGAAGCTTTAGAAAAGATAGAGGAAGAGCAAAACAAAT
GTAAGAAAAAAGCACAGCAAGCAGCAGCACAGCAAGCAGCAG
CTGGCACAGGAAACAGCAACCCGGTCAGCCAAAATTACCCTA
TAGTACAGAACATGCAGGGGCAAATGGTACATCAGGCCATAT
CACCTAGAACTTTAAATGCATGGGTAAAAGTAATAGAAGAGA
AGGCTTTCAGCCCAGAGGTAATACCCATGTTTTCAGCATTAT
CAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACA
CAGTGGGGGGACATCAAGCAGCTATGCAAATGTTAAAAGAGA
CCATCAATGAGGAAGCTGCAGAATGGGATAGATTACATCCAG
CGCAGGCAGGGCCTGTTGCACCAGGCCAGATGAGAGACCCAA
GGGGAAGTGACATAGCAGGAACTACTAGTACCCTTCAGGAAC
AAATAGGATGGATGACAGGTAATCCAGCTATCCCAGTAGGAG
AAATCTATAAAAGATGGATAATCCTGGGATTAAATAAAATAG
TAAGGATGTATAGCCCTATCAGCATTCTGGACATAAAACAAG
GACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATA
AAACTCTAAGAGCCGAGCAAGCTACACAGGAGGTAAAAAATT
GGATGACAGAAACCTTGTTGGTCCAAAATGCAAACCCAGATT
GTAAGACTATTTTAAAAGCATTGGGACCAGCAGCTACACTAG

BNSDOCID: <WO___9521912A1_I_>

FIGURE 9

AAGAAATGATGACAGCATGTCAGGGAGTGGGAGGACCCAGCC
ATAAAGCAAGAGTTTTGGCAGAAGCAATGAGCCAAGCAACAA
ATGCAGCTACTGTAATGATGCAGAGAAGCAATTTTAGAAACC
AAAGAAAGAATGTTAAGTGTTTCAATTGTGGCAAAGAAGGGC
ACATAGCCAGAAATTGCAGGGCTCCTAGGAAAAGGGGCTGTT
GGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTG
AGAGACAGGCTAATTTTTTAGGGAAAATCTGGCCTTCCCACA
AGGGGAGGCCAGGGAACTTTCTTCAGAGCAGGCCAGAACCAA
CAGCCCCTCTCCAGGGCAGGCCGGAGCCATCAGCCCCGCCAG
AAGAGAGCTTCAGGTTTGGGGAGGAGACAACAACTCCCTCTC
AGAAGCAGGAGCCGATAGACAGGGACAGGGATCTGTATCCTT
TAGCTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCAC
AATAAAGATAGGGGGGCAGCTGAAGGAAGCTCTATTAGATAC
AGGAGCAGATGATACAGTATTAGAAGACATGCATTTGCCAGG
AAAATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTAT
CAAAGTAAAACAATATGATGAAATTCTTGTAGAAATCTGTGG
ACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGT
CAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCAC
TTTAAATTTTCCCATTAGTCCTATTGAAACTGTACCAGTACA
ATTAAAGCCAGGAATGGATGGCCCAAAGGTTAAACAATGGCC
ATTGACAGAAGAGAAAATAAAAGCATTAGTAGAAATTTGTAC
AGAAATGGAAAAGGAAGGAAAGATTTCAAAAATTGGGCCTGA
AAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGA
TGGTACTAAATGGAGAAAATTAGTAGATTTCAGAGACCTTAA
TAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACC
ACATCCCTCAGGATTAAAAAAGAAAAAATCAGTAACAGTACT
GGATGTGGGTGATGCATACTTTTCAGTTCCCTTAGATGAAAA
CTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAATAA
TGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACA
GGGATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGAC
AAGAATCTTAGAGCCTTTTAGAAGACAAAATCCAGACATAGT
TATCTATCAATACATGGATGACTTGTATGTAGGATCTGATTT
AGAAATAGGACAGCATAGAATAAAAATAGAGGAACTGAGACA
ACATCTGTTGAAGTGGGGATTTACCACACCAGACAAAAAGCA
TCAGAAAGAACCCCCATTCCTTTGGATGGGTTATGAACTCCA
TCCTGATAAATGGACAGTGCAACCTATAGTACTGCCAGAAAA
AGACAGCTGGACTGTCAATGACATACAGAAGTTAGTGGGTAA
ATTAAATTGGGCAAGTCAGATTTACCCAGGAATTAAAGTAAG
GCAATTATGTAAACTCCTTAGGGGAACCAAAGCACTAACAGA

FIGURE 9 34/47

AGTAATACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGA
AAACAGGGAAATTCTAAGAGAACCAGTACATGGAGTGTATTA
TGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGA
GCAAGGCCAATGGACATATCAAATTTATCAAGATCAATTTAA
AAATCTAAAAACAGGAAAGTATGCAAGATTGAGGGGTGCCCA
CACTAATGATGTAAAACAATTTCCAGAGGCAGTGCAAAAAAT
AGCCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATT
TAGACTACCCATACAAAAAGAAACATGGGACGCATGGTGGAC
AGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGT
CAATACCCCTCCCCTAGTAAAATTATGGTACCAGTTAGAAAA
AGAACCCATAATAGGAGCAGAAACTTTCTATGTAGATGGGGC
AGCTAACAGAGAGACTAAATTAGGAAAAGCAGGATATGTTAC
TGACAGAGGAAGACAAAAAGTTGTCTCCCTAACTGACACAAC
AAATCAGAAGACTGAGTTACAAGCAATTCATCTAGCTTTGCA
GGATTCAGGATTAGAAGTAAACATAGTAACAGACTCACAGTA
TGCATTAGGAATCATTCAAGCACAACCAGATAAAAGTGAATC
AGAAATAGTCAATCAAATAATAGAGCAATTAATAAAAAAGGA
AAAGGTCTACCTGGCATGGGTACCAGCACACAAAGGAATTGG
AGGGAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCAG
GAAAATACTATTTTTAGATGGAATAGATAAGGCACAAGAAGG
CCATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAGTGG
TTTTAACCTGCCACCTATAGTAGCAAAAGAAATAGTAGCCAG
CTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACA
AGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACACA
TCTAGAAGGAAAAATTATCCTGGTAGCAGTTCATGTAGCCAG
TGGATATATAGAAGCAGAAGTTATTCCAGCAGAGACAGGGCA
GGAAACAGCATACTTTATCTTAAAATTAGCAGGAAGGTGGCC
AGTAAACACAATACATACAGACAATGGCGGCAATTTCATCAG
TACCACGGTTAAGGCCGCCTGTTGGTGGGCAGGGATCAAGCA
GGAATTTGGCATTCCCTACAATCCCCAAAGCCAAGGAGTAGT
GGAATCTATGAATAGAGAATTAAAGAAAATTATAGGACAGGT
AAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGC
AGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGG
ATACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGA
CATACAAACTAAAGAATTACAAAAGCAAATTACAAAAATTCA
AAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTG
GAAAGGACCAGCAAAACTTCTCTGGAAAGGCGAAGGGGCAGT
AGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAG
AAAAGTAAAGATCATTAGGGATTATGGAAAACAGATGGCAGG

BNSDOCID: <WO___9521912A1_I_>

FIGURE 9

TGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACAT
GGAACAGTTTAGTGAAACACCATATGTATGTTTCAAAGAAAG
CTAAGGGATGGATTTATAGACATCACTATGAAAACACTCATC
CAAAAATAAGCTCAGAAGTACACATCCCACTAGGGGAAGCTA
GATTGGTAATAACAACATATTGGGGTCTACATACAGGAGAAA
GAGACTGGCATTTGGGTCAGGGAGTCTCCATAGAATGGAGGG
AAAGGACATATAGAACACAAGTAGACCCCGAACTAGCAGACC
AACTAATTCATATACATTACTTTGATTGTTTTTCAGAATCTG
CCATAAGAAGTGCCATATTAGGATATAGAGTTAGGCATAGGT
GTGAATATCAAGCAGGACATAACAAGGTAGGATCTCTACAGT
ACTTGGCACTAACAGCATTAATAACACCAAAGAAGATAAAGC
CACCTTTGCCTAGTGTTGCGAAACTGACAGAGGATAGATGGA
ACAAGCCCCAGAAGACCAAGGGCCACAGAGGCAGCCATACAA
TGAATGGACACTAGAACTTTTAGAGGAGCTTAAGAATGAAGC
TGTTAGGCATTTTCCTAGGGTATGGCTCCATGGCTTAGGGCA
ACATATCTATGAAACTTATGGGGATACTTGGGAAGGAGTGGA
GGCCATAACAAGAACTCTGCAACAACTGCTGTTTATTCATTT
CAGAATTGGGTGTCAACATAGCAGAATAGGCATTATTCGACA
GAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGC
CCTGGAAGCATCCAGGAAGTCAGCCTAAGACTGCGTGTACCA
CTTGCTATTGTAAAAAGTGCTGCTTTCATTGCCAAGTTTGTT
TTATGACAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGC
GGAGACAGCGACGAAGAGCTCCTCAAGACAGTCAGACTCATC
AAGCTTATCTATCAAAGCAGTAAGTAATATATGTAATGCAAC
CTTTACAAATAGTAGCAATAGTAGCATTAGTAGTAGCAGGAA
TAATAGCAATAGTTGTGTGGACCATAGTATTCATAGAATATA
AGAAAATATTAAGACAAAGAAAAATAGACAGGTTGATTGATA
GAATAAGAGAAAGAGCAGAAGACAGTGGCAATGACAGTGAAG
GGGATCAGGAAGAATTATCGGCACTTGTGGACATGGGGCACC
ATGATCCTTGGGATATTAATGATCTGTAGAGCTGCAAACAAT
TTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAGAGAA
GCAACCACCACTCTATTTTGTGCATCAGATGCCAAGGCATAT
GATGCAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTA
CCCACAGACCCTAACCCACAAGAAGTAGAATTGAAAAATGTG
ACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAACAG
ATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTGAAG
CCATGTGTAAAATTAACCCCACTCTGTGTTTCTTTAAATTGC
ACTGATGCTACTAATACCACTAATAGTAATACCACTAGCAGC
AGCGAGAAACCGAAGGGGACAGGGGAAATAAAAAACTGCTCT

FIGURE 9

TTCAATATCACCACAAGCATAAGAGATAAGGTGCAGAAACAA
TATGCACTTTTTTATAGCCTTGATGTAGTACCAATGGATGAT
AATGATAATAGTACAAGCTATAGGTTAATAAGTTGTAACACC
TCAATCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCA
ATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTA
AAGTGTAAAGATAAAAGGTTCAATGGAAAAGGACCATGTACA
AGTGTCAGCACAGTACAGTGTACACATGGAATTAGGCCAGTA
GTATCAACTCAACTGTTGTTAAATGGCAGTCTAGCAGAAGAA
GAGGTAGTAATTAGATCTGACAATTTTACGAACAATGCTAAA
ACCATAATAGTACAGCTGAGCAAATCTGTAGAAATTACTTGT
GTAAGACCCAACAACAATACAAGAAAAAGTATAAGTATGGGA
CCAGGGAGAGCATTTTATACAACAGAAATAATAGGAGATATA
AGACAAGCATATTGTAACATTAGTAAAGCAAACTGGACTGAC
ACTTTAGAACAGATAGCTAGAAAATTAAGAGAACAATTTGAG
AATAAAACAATAGTCTTTAAGCCATCCTCAGGAGGGGACCCA
GAAATTGTAACACAGTTTTACAGTTTTAATTGTGGAGGGGAA
TTTTTCTACTGTAATTCAACACAACTGTTTAATGGTACTTGG
AATGGTACTTGGGTTAATGGTACTTGGAGTAGTAATAATACG
ACTGATACTGCAAATATCACACTCCCATGCAGAATAAAACAA
TTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCC
CCTCCCATCAAAGGACAAATTAAATGTACATCAAATATTACA
GGGCTGATATTAACAAGAGATGGTGGTAACAATAACACCACG
AACGACAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGAT
ATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTA
GTACAAGTTGAACCATTAGGAGTAGCACCCACCAAGGCAAAG
AGAAGAGTGGTGCAAAGAGAAAAAAGAGCAGTGGGAATAGGA
GCTATGTTCCTTGGGTTCTTAGGAGCAGCAGGAAGCACTATG
GGCGCAGCGTCAGTGACGCTGACGGTACAAGCCAGACAATTA
TTGTCTGGTATAGTGCAGCAGCAGAACAATCTGCTGAGGGCT
ATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGC
ATCAAACAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATAC
CTAAGGGATCAACAGCTCCTGGGACTTTGGGGTTGCTCTGGA
AAACTCATTTGCACCACTACTGTGCCTTGGAACAATAGCTGG
AGTAATAAATCTCTGGAAACAATTTGGGATAACATGACCTGG
ATGCAGTGGGAAAGAGAAATTGACAATTACACAAACATAATA
TACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAAAAT
GAACTAGAATTATTGGAATTGGATAAATGGGCAAATTTGTGG
AATTGGTTTAGTATATCAAACTGGCTATGGTATATAAAATTA
TTCATAATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGTT

BNSDOCID: <WO___9521912A1_I_>

FIGURE 9

TTTACTGTACTTTCTATAGTTAATAGAGTTAGGCAGGGATAC
TCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAAGGGA
CCCGACAGGCCAGAAGGAATCGAAGAAGAAGGTGGAGAGAGA
GACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCTTAGCA
CTTTTCTGGGACGACCTGAGGAGTCTGTGCCTCTTCAGCTAC
CACCACTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTG
GAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATACTGG
TGGAATCTCCTGCAGTATTGGAGGCAGGAACTACAGAAGAGT
GCTGTTAGCTTGTTCAATGGCACGGCCATAGCAGTAGCTGAG
GGGACAGATAGAGTTATAGAAGCTTTACGAAGGGCTTATAGA
GCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAA
AGGGCTTTGCTATAAAATGGGTGGCAAGTGGTCAGAAAGTAG
TGTGGTTAGAAGGCATGTACCTTTAAGACAAGGCAGCTATAG
ATCTTAGCCGCTTTTTAAAAGAAAAGGGGGGACTGGAAGGGC
TAATTCACTCACGGAAAAGACCAGTTGAACCAGAAGAAGATA
GAAGAGGCCATGAAGAAGAAAACAACAGATTGTTCTGCTTGC
TCAGCTGGGGACTTTCCAGAAGGCGCGGCCTGAGTGACTAAG
CCCCGTTGGGGACTTTCCGAAGAGGCATGAAGGGACTTTCCA
AGGCAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCT
CAGATGCTGCATATAAGCAGCTGCTTTCTGCCTGTACTGGGT
CTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCT
AGCTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTT
GAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTG
GTATCTAGAGATCCCTCAGACCATTTTAGTCCGTGTGGAAAA
TCTCTAGCA



FIG 10 (a)

BNSDOCID: <WO___9521912A1_I_>

FIG 10(b)(i)


trends in CD4 count since seroconversion
CD4 counts
2500
1600
900
400
100
0
0
2
4
6
8
10
12
14
years since seroconversion
CD4 counts on square root scale
C54
C64
C98
Donor
C49
C18
D36

FIG 10(b)(ii)



BNSDOCID: <WO___9521912A1_I_>

FIG 10(c)(i)


trends in CD8 since seroconversion
CD8 count
3500
3000
2500
2000
1500
1000
500
0
0
2
4
6
8
10
12
14
years since seroconversion
C18
C54
C64
C98
C49
Donor



FIG 10(c)(ii)

BNSDOCID: <WO___9521912A1_I_>


trends in lymphocyte count since seroconversion
lymphocyte count
8000
6000
4000
2000
0
0
2
4
6
8
10
12
14
years since seroconversion
C54
C64
C18
C49
C98
Donor

FIG 10(d)

FIG 10(e)



BNSDOCID: <WO___9521912A1_I_>

FIG 10 (f)



beta-2 microglobulin plotted on a log scale



FIG 10(g)

BNSDOCID: <WO___9521912A1_I_>

FIG 11

Diagrammatic sequence alignment against HIV NL4-3 showing deletions in HIV-1 asymptomatic cohort.
Deletions shown as gaps in sequence blocks.



INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 95/00063

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.[6] C12N 7/02, 7/04, 15/48; C12Q 1/68, 1/70; A61K 39/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

ELECTRONIC DATABASES AS BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AU IPC C12N 7/02, 7/04

Electronic data base consulted during the international search (name of data base, and where practicable, search terms used)

DERWENT - WPAT, BIOT: CHEMICAL ABSTRACTS - CASM, KEYWORDS: HIV, LAV, ARV, HTLV, AVIRULENT, ATTENUATED, NON PATHOGENIC, DELETION, NEF, LTR

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P, X	WO,A, 94/17825 (UNIVERSITY OF CALIFORNIA) 18 August 1994, see entire document.	1-92
X	WO,A, 91/19795 (IMMUVAX) 26 December 1991, see entire document.	1-92
X	WO,A, 92/00987 (HARVARD COLLEGE) 23 January 1992, see entire document.	1-92
X	WO,A, 92/05864 (CONNAUGHT LABORATORIES LTD) 2 May 1991 see pages 8-9, figures 1-2, claims.	1-92

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 May 1995	3 MAY 1995 (03.05.95)
Name and mailing address of the ISA/AU	Authorized officer
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA	ROSS OSBORNE
Facsimile No. 06 2853929	Telephone No. (06) 2832404

Form PCT/ISA/210 (continuation of first sheet (2)) (July 1992) copkjy

BNSDOCID: <WO___9521912A1_I_>

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
X	WO,A, 90/13641 (SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH) 15 November 1990.	68
Y		70-71
X	The Lancet, Volume 340, issued October 10, 1992, J. Learmont et al, "Long term symptom less HIV-1 infection in recipients of blood products from a single donor". pages 863-867 see entire article.	1-92
Y	Cell, Volume 65, issued May 17, 1991, H.W. Kestler et al "Importance of the nef gene for maintenance of high virus loads and for development of AIDS". pages 651-662. See page 59 column 2 line 54 to page 660 column 1 line 3.	5-19,24-36,40-69,71-92
Y	Science, Volume 258, issued 18 December 1992, M.D. Daniel et al "Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene". pages 1938-1941.	5-19,24-36,40-69,71-92
X	Derwent WPAT Online Abstract Accession Number 93-146253 JP,A, 5078386 (SANYO KOKUSAKU PULP CO) 30 March 1993.	68
X	US 5221610 (INSTITUT PASTEUR) 22 June 1993, see column 5 lines 26-43 and column 16 line 39 to column 20 claim 5.	65-69
X	AU-B-73582/87 (588462) (U.S. DEPARTMENT OF COMMERCE) 9 November 1987	1-4,20-23,37-39,70
Y	whole document.	5-19,24-36,40-69,71-92
Y	Proc. Natl. Acad. Sci. USA. Volume 89 issued November 1992, J.O. Ojwang et al "Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme". pages 10802-10806, see entire article.	68,70-71
P,X	WO,A, 94/29437 (UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY) 22 December 1994.	1-7,20-26,37-39,70

Box I **Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international search report has not established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II **Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims

2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically

claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

BNSDOCID: <WO___9521912A1_I_>

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	9119795	CA	2085897	EP	537247		
WO	9417825	AU	58487/94	WO	9417825		
WO	9200987	EP	491930	JP	5501654		
WO	9205864	AU	86591/91	CA	2092553	EP	478842
		EP	479187	FI	931506	JP	6504941
		NO	930993	PT	99148		
WO	9013641	EP	471796	JP	4505261		
AU	87/73587	CN	87103817	DK	288/88	EP	247002
		FI	880275	FR	2599208	NO	880281
		PT	84927	US	4945289	WO	8707469
		YU	923/87				

END OF ANNEX